Treatment mode selection system and laser catheter system including the treatment mode selection system

By designing a catheter with laser-induced pressure waves and porous attenuation members, the problems of penetration calcification and fibrous occlusion and therapeutic agent delivery in the prior art are solved, and efficient damage to vascular occlusion and effective delivery of therapeutic agents are achieved. .

CN113038898BActive Publication Date: 2024-12-03KONINKLIJKE PHILIPS NV
View PDF 16 Cites 0 Cited by

Patent Information

Application Number
CN201980066439.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-08-09
Filing Date
2019-08-09
Publication Date
2024-12-03
Estimated Expiration
2039-08-09

AI Technical Summary

Technical Problem

The prior art is difficult to effectively penetrate calcified and fibrous vessel occlusion, especially in the case of complete occlusion, and destroy the occlusion portion without hydraulic pressure, making it difficult to deliver therapeutic agents.

Method used

A catheter including an outer sheath, an inner sheath and a transmitter is designed to destroy the vessel occlusion using laser-induced pressure waves and enable the delivery of therapeutic agents through porous attenuation members and liquid media ports.

Benefits of technology

The catheter is able to penetrate calcified and fibrous complete occlusion, destroying the vascular blockage and delivering therapeutic agents without hydraulic pressure, improving therapeutic efficacy and operational flexibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113038898B_ABST
    Figure CN113038898B_ABST
Patent Text Reader

Abstract

The present disclosure generally relates to the use of medical devices in treating vascular conditions. In particular, the present disclosure provides devices and methods for destroying intimal and medial calcium within the vasculature using laser-induced pressure waves generated within a sheath. The present disclosure also provides a treatment mode selection system that can be used with such devices and methods.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] not applicable. Technical Field

[0003] The present disclosure generally relates to the use of medical devices in treating vascular conditions. In particular, the present disclosure provides materials and methods for using laser-induced pressure waves to disrupt vascular obstructions and deliver therapeutic agents to the obstructed area. Background Art

[0004] Arterial disease is a common condition that affects millions of Americans. Coronary artery disease (CAD) is often caused by a condition called atherosclerosis, which is often manifested by the accumulation of a waxy substance inside a subject's coronary arteries. This substance, called plaque, is formed from cholesterol, fatty compounds, calcium, and a blood clotting material called fibrin. Similarly, peripheral arterial disease (PAD) is often caused by the accumulation of plaque inside a subject's peripheral arteries (e.g., arteries in a patient's arms, hands, legs, and / or feet).

[0005] As plaque builds up in the coronary, peripheral, and other arteries, the arteries narrow and / or become stenotic, making it more difficult for blood to flow through the arteries. As the stenosis increases and the blockage worsens, blood flow slows, and when complete vascular occlusion develops, blood flow through the artery stops completely, which in turn can lead to pain in the limbs and, in severe cases, gangrene, which may eventually require amputation.

[0006] Balloon angioplasty and other endoluminal medical treatments are well known and have been shown to be effective in treating stenotic lesions at the core of CAD and / or PAD, as long as the artery is only partially blocked rather than completely blocked. In a typical angioplasty procedure for treating CAD, a catheter is inserted into the subject's groin or arm and advanced through the aorta and into the coronary arteries of the heart. The angioplasty catheter includes a balloon that, when placed within the partial occlusion, is able to expand, thereby dilating the blockage or restriction and increasing the size of the artery diameter to provide more typical blood flow through the artery.

[0007] Over time, vascular occlusions (particularly complete occlusions) may calcify and / or become fibrous, thereby reducing the ability of the balloon to expand the vascular occlusion. Certain types of catheters (e.g., electrically induced shock wave balloon catheters) can be used to destroy calcified tissue. Electrically induced shock wave balloon catheters can include a balloon filled with liquid and one or more pairs of electrodes in the balloon. When a discharge is generated between the electrodes, plasma is generated, causing one or more vapor bubbles to form. The vapor bubbles generated in the balloon expand and contract the balloon. The expansion and contraction of the balloon generates fluid pressure, thereby transferring a certain amount of energy to the vascular occlusion and / or the blood vessel wall, which is sufficient to destroy calcium in the lumen and calcium in the tissue layer of the vascular system (e.g., calcium deposits). In addition to generating vapor bubbles when forming a plasma generated by an electrical reaction in the liquid, a shock wave is also generated. The shock wave is transmitted through the balloon and is transmitted to the calcified vascular occlusion, and the shock wave changes the calcified occlusion.

[0008] In the case of a complete stenotic occlusion, it may be difficult to access the stenosis with a balloon. Additionally, if the complete occlusion becomes calcified and / or fibrous, thereby increasing the stiffness of the occlusion, penetrating the occlusion and inserting the balloon catheter may become more difficult, if not impossible. For example, the proximal and / or distal ends of the occlusion may become calcified to the point where a "cap" or "calcified cap" is formed, such that even an electrically induced shock wave balloon catheter may not be able to penetrate a calcified complete occlusion because the balloon must be within and adjacent to the occlusion in order to operate. Also, because the balloon within an electrically induced shock wave balloon catheter is typically located near the distal end of the electrically induced shock wave balloon catheter, the balloon cannot be inserted or passed through the calcified cap of a complete occlusion. Summary of the invention

[0009] There is a need for a device that can penetrate a calcified and / or fibrous vascular occlusion (particularly a calcified cap(s)) and that can disrupt at least a portion of the vascular occlusion when the device penetrates and traverses the complete occlusion. There is also a need for a device that can deliver laser-induced pressure waves to the vascular occlusion to disrupt the calcified and / or fibrous portion without applying hydraulic pressure to the calcified and / or fibrous portion. These needs and other needs are met by aspects, embodiments, and configurations of the present disclosure.

[0010] The present disclosure provides a catheter, which includes an outer sheath, an inner sheath and one or more emitters. The outer sheath has a proximal end and a distal end, wherein the distal end includes a tip; the inner sheath may include at least one lumen, a proximal end and a distal end, wherein the inner sheath is radially arranged inside the outer sheath, wherein the distal end of the inner sheath may be arranged close to the tip, thereby creating a cavity between the outer sheath and the inner sheath; one or more emitters are arranged inside the inner sheath, extending from a proximal portion of the inner sheath to the distal end of the inner sheath and into the cavity, wherein the proximal end of the one or more emitters is coupled to a laser generator, and at least one emitter is arranged in the cavity.

[0011] The catheter of paragraph

[0009] , wherein the catheter further comprises one or more liquid media ports disposed about the sheath.

[0012] The catheter of any of paragraphs

[0009] -

[0010] , wherein the outer sheath is capable of expanding and contracting in an axial direction.

[0013] A catheter according to any of paragraphs

[0009] -

[0011] , wherein the outer sheath is composed of the group consisting of: a polymer, a polymer with a coil or a polymer with an embedded braid, a polymer with an embedded braid and a fluorinated ethylene propylene or lubricated fluoropolymer liner, a laser cut hypotube, a triple coil or a dual coil, or any combination of the foregoing.

[0014] The catheter of any of paragraphs

[0009] -

[0012] , wherein the catheter further comprises a protective shield axially disposed within the cavity between the distal end and the tip of the inner sheath.

[0015] The catheter of any of paragraphs

[0009] -

[0013] , wherein the shield includes a proximal end and a distal end, wherein the shield tapers from the proximal end to the distal end, or wherein the shield tapers from the distal end to the proximal end.

[0016] The catheter of any of paragraphs

[0009] -

[0014] , wherein the tip comprises a proximal end and a distal end, wherein the tip has a solid configuration along its longitudinal axis from its proximal end to its distal end.

[0017] The catheter of any of paragraphs

[0009] -

[0015] , wherein the tip comprises an open configuration at a distal end of the outer sheath.

[0018] The catheter of any of paragraphs

[0009] -

[0016] , wherein the tip comprises a proximal end and a distal end, wherein the tip has a hollow configuration along its longitudinal axis from its proximal end to its distal end.

[0019] A catheter according to any of paragraphs

[0009] -

[0017] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 300 nanometers and about 360 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0020] A catheter according to any of paragraphs

[0009] -

[0018] , wherein at least one emitter is configured to emit laser energy having a wavelength of approximately 308 nanometers with a pulse duration of approximately 10 nanoseconds to approximately 200 nanoseconds and at a frequency of between approximately 1 pulse per second to approximately 100 pulses per second.

[0021] The catheter of any of paragraphs

[0009] -

[0019] , wherein the total energy output for at least one emitter is between about 1 and 300 mJ / mm2. 2 )between.

[0022] A catheter according to any of paragraphs

[0009] -

[0020] , wherein the liquid medium is a contrast agent or a contrast solution.

[0023] The catheter of any of paragraphs

[0009] -

[0021] , wherein the liquid medium is any one of an iodine-containing contrast agent or a gadolinium contrast agent.

[0024] A catheter according to any of paragraphs

[0009] -

[0022] , wherein the liquid medium is configured to exhibit high absorption of light energy having a wavelength between about 1 nanometer and about 1 millimeter emitted from at least one emitter with a pulse duration between about 1 nanosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0025] The catheter of any of paragraphs

[0009] -

[0023] , wherein at least one emitter is one or more concentric emitters.

[0026] The catheter of any of paragraphs

[0009] -

[0024] , wherein at least one transmitter is two or more single fiber transmitters.

[0027] The catheter of any of paragraphs

[0009] -

[0025] , wherein the at least one transmitter is configured to translate within the outer sheath.

[0028] The catheter of any of paragraphs

[0009] -

[0026] , wherein the tip includes a distal end and a flexible membrane at the distal end thereof.

[0029] The catheter of any of paragraphs

[0009] -

[0027] , wherein the liquid medium is configured to: absorb light energy; generate laser-induced pressure waves and / or vapor bubbles and / or cavitation events to disrupt vascular occlusions; modify the vascular surface to enhance drug absorption, including but not limited to disrupting both intraluminal calcium and calcium deposits within the vasculature; and / or deliver the drug to an area surrounding the vascular occlusion. The liquid medium can include a contrast agent, including, for example, an iodine-containing contrast agent or a gadolinium contrast agent, and a contrast solution containing dye(s) and / or particle(s).

[0030] A catheter according to any of paragraphs

[0009] -

[0028] , wherein the inner sheath further comprises a first guidewire lumen, and further comprises a sealable valve coupled to the outer sheath, the sealable valve having a second guidewire lumen and a seal, based on which a guidewire is introduced into the first guidewire lumen and the second guidewire lumen and a liquid medium is introduced into the cavity, the liquid medium actuates the seal within the valve and closes the opening between the valve and the guidewire.

[0031] The catheter of any of paragraphs

[0009] -

[0029] , wherein the sealable valve further comprises an outer wall and a flange radially disposed therein, wherein a gap exists between the outer wall and the flange.

[0032] The catheter of any of paragraphs

[0009] -

[0030] , wherein the sealable valve includes a proximal portion and a distal portion, and wherein the flange is disposed toward the proximal portion of the sealable valve.

[0033] The catheter of any of paragraphs

[0009] -

[0031] , wherein the proximal portion of the sealable valve is tubular.

[0034] The catheter of any of paragraphs

[0009] -

[0032] , wherein the distal portion of the sealable valve tapers radially inward from the outer wall toward the second guidewire lumen.

[0035] The catheter of any of paragraphs

[0009] -

[0033] , wherein the sealable valve further comprises an opening in the outer wall extending toward the proximal portion.

[0036] The catheter of any of paragraphs

[0009] -

[0034] , wherein the flange tapers radially inward toward the second guidewire lumen as the flange advances from the distal portion to the proximal portion.

[0037] The present disclosure also provides a method for treating an occlusion in a vascular system of a subject, the method comprising: positioning a catheter in the vascular system of the subject, the catheter comprising an outer sheath, an inner sheath, a protective cover, one or more transmitters, and one or more liquid medium ports, the outer sheath having a proximal end and a distal end, wherein the distal end comprises a tip; the inner sheath having at least one lumen, a proximal end, and a distal end, wherein the inner sheath is radially disposed within the outer sheath, wherein the distal end of the inner sheath is disposed proximal to the tip, thereby forming a cavity between the outer sheath, the inner sheath, and the tip; the protective cover is axially disposed in the cavity between the distal end of the inner sheath and the tip; the one or more transmitters is disposed within a distal end of the inner sheath and / or cavity, wherein one or more of the emitters are coupled to a laser generator, wherein one emitter is disposed within the cavity; one or more liquid medium ports are coupled to at least one lumen to position the tip adjacent to an occlusion within the vascular system, a liquid medium is introduced into the cavity through the one or more liquid medium ports, at least one emitter within the cavity is activated to transmit pulses of light energy into the liquid medium, wherein transmitting the pulses of light energy from the emitter into the liquid medium generates at least one propagating laser-induced pressure wave that causes the tip to engage and disrupt at least a portion of the vascular occlusion.

[0038] A method for treating an occlusion within a vasculature of a subject according to any of paragraphs

[0009] -

[0036] , wherein the liquid medium is any of an iodine-containing contrast agent or a gadolinium contrast agent.

[0039] The present disclosure provides a catheter system, which includes: a sheath having a proximal end and a distal end and a lumen therein; a laser catheter, which includes: a proximal end capable of being coupled to a laser generator; a distal end; and at least one emitter coupled to the laser generator; wherein the catheter is arranged in the sheath, based on which the distal end of the laser catheter is arranged close to the distal end of the sheath, and a cavity is formed between the distal end of the laser catheter and the distal end of the sheath; a unit for introducing a liquid medium into the cavity; a handle, which includes: a base coupled to the proximal end of the sheath; and a drive mechanism that is translationally coupled to the base, the drive mechanism being coupled to the laser catheter so that translation of the drive mechanism relative to the base causes translation of the laser catheter in the lumen of the sheath.

[0040] A catheter system according to any of paragraphs

[0009] -

[0038] , wherein the drive mechanism includes: a control element that is movably coupled to a base; and a coupling member that is movably coupled to the base and driven by the control element, the coupling member being coupled to the laser catheter so that movement of the control element relative to the base causes translation of the laser catheter within the lumen of the sheath.

[0041] The catheter system of any of paragraphs

[0009] -

[0039] , wherein the control element is rotatably coupled to the base, and rotation of the control element relative to the base causes translation of the laser catheter within the lumen of the sheath.

[0042] A catheter system according to any of paragraphs

[0009] -

[0040] , wherein the control element includes a first threaded surface, and the drive mechanism also includes a shaft capable of translating within a base and coupled to a coupling member, the shaft including a second threaded surface, and the second threaded surface is coupled to the first threaded surface, so that rotation of the control element relative to the base causes translation of the shaft within the base and translation of the laser catheter within the lumen of the sheath.

[0043] The catheter system of any of paragraphs

[0009] -

[0041] , wherein the handle further comprises a tube coupled to the base that receives the laser catheter, and wherein the shaft comprises an internal lumen that can translationally receive the tube as the shaft translates within the base.

[0044] The catheter system of any of paragraphs

[0009] -

[0042] , wherein the drive mechanism further comprises a seal coupled to the shaft, the seal being capable of translationally engaging the tube.

[0045] The catheter system of any of paragraphs

[0009] -

[0043] , wherein the tube is a hypotube.

[0046] The catheter system of any of paragraphs

[0009] -

[0044] , wherein the base includes a first key feature and the shaft includes a second key feature, the second key feature coupled to the first key feature to inhibit rotation of the shaft relative to the base.

[0047] The catheter system of any of paragraphs

[0009] -

[0044] , wherein the base includes an opening disposed within the control element, and the second threaded surface extends through the opening to couple to the first threaded surface.

[0048] The present disclosure provides a handle for coupling to a sheath and a laser catheter, the handle comprising: a base configured to couple to a proximal end of the sheath; and a drive mechanism movably coupled to the base, the drive mechanism configured to couple to the laser catheter such that translation of the drive mechanism relative to the base causes translation of the laser catheter within the lumen of the sheath.

[0049] A handle according to any of paragraphs

[0009] -

[0047] , wherein the drive mechanism includes: a control element that is movably coupled to a base; and a coupling member that is movably coupled to the base and driven by the control element, the coupling member being configured to couple to a laser catheter so that movement of the control element relative to the base causes translation of the laser catheter within the lumen of the sheath.

[0050] The handle of any of paragraphs

[0009] -

[0048] , wherein the control element is rotatably coupled to the base, and rotation of the control element relative to the base causes translation of the laser catheter within the lumen of the sheath.

[0051] A handle according to any of paragraphs

[0009] -

[0049] , wherein the control element includes a first threaded surface, and the drive mechanism also includes a shaft that can translate within the base and is coupled to the coupling member, the shaft includes a second threaded surface, and the second threaded surface is coupled to the first threaded surface, so that rotation of the control element relative to the base causes translation of the shaft within the base and translation of the laser catheter within the lumen of the sheath.

[0052] The handle of any of paragraphs

[0009] -

[0050] , wherein the handle further comprises a tube coupled to the base, the tube receiving the laser catheter, and wherein the shaft comprises a channel that can translationally receive the tube when the shaft translates within the base.

[0053] The handle of any of paragraphs

[0009] -

[0051] , wherein the drive mechanism further comprises a seal coupled to the shaft, the seal being capable of translatably engaging the tube.

[0054] A handle according to any of paragraphs

[0009] -

[0052] , wherein the tube is a hypotube.

[0055] The handle of any of paragraphs

[0009] -

[0053] , wherein the base includes a first key feature and the shaft includes a second key feature, the second key feature coupled to the first key feature to inhibit rotation of the shaft relative to the base.

[0056] The handle of any of paragraphs

[0009] -

[0054] , wherein the base includes an opening disposed within the control element, and the second threaded surface extends through the opening to couple to the first threaded surface.

[0057] The present disclosure provides a catheter comprising: an outer sheath having a proximal end, a distal end, and a porous attenuation member disposed adjacent to the distal end, wherein the porous attenuation member comprises a plurality of openings; an inner sheath having a proximal end and a distal end, wherein the inner sheath is radially disposed within the outer sheath; and at least one emitter coupled to a laser generator, wherein the at least one emitter is radially disposed within the outer sheath such that the at least one emitter is radially disposed within the attenuation member.

[0058] The catheter of any of paragraphs

[0009] -

[0056] , wherein the porous attenuating member is configured to form a semi-rigid biocompatible structure.

[0059] The catheter of any of paragraphs

[0009] -

[0057] , wherein the porous attenuating member is configured to form a rigid biocompatible structure.

[0060] The catheter of any of paragraphs

[0009] -

[0058] , wherein the outer sheath comprises a non-porous biocompatible layer.

[0061] The catheter of any of paragraphs

[0009] -

[0059] , wherein the porous attenuation member is integrally disposed within the solid biocompatible layer.

[0062] The catheter of any of paragraphs

[0009] -

[0060] , wherein the porous attenuation member is disposed outside of the solid biocompatible layer.

[0063] The catheter of any of paragraphs

[0009] -

[0061] , wherein the porous attenuation member is disposed within the interior of the solid biocompatible layer.

[0064] A catheter according to any of paragraphs

[0009] -

[0062] , wherein the porous attenuation member includes a plurality of openings, wherein the plurality of openings include at least one of the following shapes: circular; elliptical; triangular; square; rectangular; spiral; polygonal; rhombus; pentagon; hexagon; heptagon; octagon; nonagon; and decagon.

[0065] A catheter according to any of paragraphs

[0009] -

[0063] , wherein the liquid medium is a contrast agent or a contrast solution.

[0066] A catheter according to any of paragraphs

[0009] -

[0064] , wherein the liquid medium is any one of an iodine-containing contrast agent or a gadolinium contrast agent.

[0067] A catheter according to any of paragraphs

[0009] -

[0065] , wherein the liquid medium is configured to exhibit high absorption of light energy having a wavelength between about 1 nanometer and about 1 millimeter emitted from at least one emitter with a pulse duration between about 1 nanosecond and about 1 second and at a frequency between about 1 pulse per second and about 500 pulses per second.

[0068] A catheter according to any of paragraphs

[0009] -

[0066] , wherein at least one emitter is two or more concentric emitters.

[0069] A catheter according to any of paragraphs

[0009] -

[0067] , wherein at least one transmitter is two or more single fiber transmitters.

[0070] The catheter of any of paragraphs

[0009] -

[0068] , wherein at least one transmitter is configured to translate within the outer sheath.

[0071] The catheter of any of paragraphs

[0009] -

[0069] , wherein the distal end of the outer sheath comprises an open configuration.

[0072] The catheter of any of paragraphs

[0009] -

[0070] , wherein the distal end of the outer sheath comprises a closed configuration.

[0073] The present disclosure provides a method for treating an occlusion within a vascular system of a subject, the method comprising: introducing a catheter into the vascular system of the subject, the catheter comprising an outer sheath, an inner sheath, at least one emitter, and one or more liquid medium ports, the outer sheath having a proximal end, a distal end, and a porous attenuation member disposed adjacent the distal end, wherein the porous attenuation member comprises a plurality of openings; the inner sheath having a proximal end and a distal end, wherein the inner sheath is radially disposed within the outer sheath; at least one emitter coupled to a laser generator, wherein the at least one emitter is radially disposed within the outer sheath; a or a plurality of liquid medium ports are coupled to at least one lumen; the outer sheath is positioned such that the porous attenuation member is adjacent to an occlusion within the vascular system; at least one emitter is positioned such that the at least one emitter is radially disposed within the porous attenuation member; the liquid medium is introduced into the outer sheath; the at least one emitter is activated to transmit a pulse of light energy into the liquid medium; wherein the transmission of the pulse of light energy from the emitter into the liquid medium generates at least one propagating laser-induced pressure wave that passes through the outer sheath and the porous attenuation member and destroys at least a portion of the occlusion.

[0074] The present disclosure provides a kit, the kit comprising an outer sheath and a laser catheter, the outer sheath having a proximal end, a distal end, and a porous attenuation member disposed adjacent to the distal end, wherein the porous attenuation member comprises a plurality of openings; the laser catheter is configured to be disposed within the porous attenuation member. The laser catheter comprises an inner sheath and at least one emitter, the inner sheath having a proximal end and a distal end, wherein the inner sheath is configured to be disposed radially within the outer sheath; the at least one emitter is coupled to a laser generator, wherein the at least one emitter is configured to be disposed radially within the outer sheath, so that the at least one emitter is disposed radially within the porous attenuation member.

[0075] The present disclosure provides a method for treating an occlusion within a vascular system of a subject, the method comprising: introducing an outer sheath into the vascular system of the subject, wherein the outer sheath comprises a proximal end, a distal end, and a porous attenuation member disposed adjacent the distal end, wherein the porous attenuation member comprises a plurality of openings; introducing a laser catheter into the vascular system of the subject, wherein the laser catheter is configured to be disposed within the porous attenuation member, wherein the laser catheter comprises an inner sheath, at least one emitter, and one or more liquid medium ports, the inner sheath having a proximal end and a distal end, wherein the inner sheath is configured to be disposed radially within the outer sheath; the at least one emitter is coupled to a laser generator, wherein , at least one emitter is radially disposed within the outer sheath; one or more liquid medium ports are coupled to at least one lumen; the outer sheath is positioned so that the porous attenuation member is adjacent to a portion of an occlusion within the vascular system; at least one emitter is positioned so that the at least one emitter is radially disposed within the porous attenuation member; liquid medium is introduced into the outer sheath; at least one emitter is activated to transmit pulses of light energy into the liquid medium; wherein transmitting pulses of light energy from the emitter into the liquid medium generates at least one propagating laser-induced pressure wave that passes through the outer sheath and the porous attenuation member and destroys at least a portion of the occlusion.

[0076] The method of any of paragraphs

[0009] -

[0074] , further comprising the step of repositioning the outer sheath such that the attenuation member is adjacent another portion of the occlusion.

[0077] The method of any of paragraphs

[0009] -

[0075] further comprising the step of repositioning the laser catheter within the outer sheath.

[0078] The method of any of paragraphs

[0009] -

[0076] , wherein the laser catheter is repositioned within the attenuation member.

[0079] The method of any of paragraphs

[0009] -

[0077] further includes the steps of removing the laser catheter from the vascular system and removing the outer sheath from the vascular system.

[0080] The method of any of paragraphs

[0009] -

[0078] , further comprising the step of inserting a drug-coated balloon into the vasculature such that the drug-coated balloon is positioned adjacent the remaining portion of the occlusion.

[0081] The method of any of paragraphs

[0009] -

[0079] further includes the steps of expanding the drug-coated balloon and applying the drug disposed on the drug-coated balloon to the remaining portion of the occlusion.

[0082] The present disclosure provides a catheter comprising: a sheath having a guidewire lumen, a proximal end and a distal end; a plurality of emitters circumferentially arranged around the guidewire lumen or circumferentially arranged adjacent to the guidewire lumen, wherein each emitter emits a laser; and a unit for guiding the laser emitted from the emitter to the guidewire lumen or a guidewire within the guidewire lumen.

[0083] A catheter according to any of paragraphs

[0009] -

[0081] , wherein the unit for guiding laser light emitted from a transmitter into a guidewire lumen or a guidewire within a guidewire lumen comprises an outer band coupled to a distal end of the sheath, wherein the outer band includes a distal end and the transmitter is disposed proximate the distal end of the outer band.

[0084] A catheter according to any of paragraphs

[0009] -

[0082] , wherein the transmitter is directed toward the guidewire lumen or the guidewire within the guidewire lumen.

[0085] A catheter according to any of paragraphs

[0009] -

[0083] , wherein the means for directing laser light emitted from the transmitter into the guidewire lumen or the guidewire comprises a cap coupled to the distal end of the sheath.

[0086] A catheter according to any of paragraphs

[0009] -

[0084] , wherein the cap includes an inner side and an outer side, wherein the inner side is tapered to direct laser-induced pressure waves and / or cavitation events into the guidewire lumen or a guidewire within the guidewire lumen, thereby causing excitation and / or vibration of the guidewire.

[0087] The catheter of any of paragraphs

[0009] -

[0085] , wherein the transmitter is disposed proximate to an inside of the cap.

[0088] The catheter of any of paragraphs

[0009] -

[0086] , wherein the sheath is an inner sheath and further includes an outer sheath that can translationally receive the inner sheath.

[0089] A catheter according to any of paragraphs

[0009] -

[0087] , wherein the outer sheath includes a sleeve, and wherein the means for directing laser light emitted from the transmitter to the guidewire lumen or the guidewire within the guidewire lumen includes an attenuation member of the outer sheath coupled to the sleeve.

[0090] The catheter of any of paragraphs

[0009] -

[0088] , wherein the attenuation member includes an inner surface, an outer surface, and a plurality of openings extending from the inner surface to the outer surface.

[0091] A catheter according to any of paragraphs

[0009] -

[0088] , wherein the attenuation member includes a plurality of openings, the plurality of openings comprising at least one of the following shapes: circular; elliptical; triangular; square; rectangular; spiral; polygonal; rhombus; pentagonal; hexagonal; heptagonal; octagonal; nonagonal; and decagonal.

[0092] The present disclosure provides a method for treating an occlusion within a vascular system of an object, the method comprising: positioning a catheter within the vascular system of the object, the catheter comprising: a sheath having a guidewire lumen, a proximal end, and a distal end; a plurality of emitters arranged circumferentially around the guidewire lumen or circumferentially adjacent to the guidewire lumen, wherein the emitters are capable of emitting laser light; and a unit for guiding the laser light emitted from the emitters into the guidewire lumen or a guidewire within the guidewire lumen; positioning the distal end of the sheath adjacent to the occlusion within the vascular system; delivering a liquid medium to the distal end of the sheath; activating the emitters to send pulses of light energy through the liquid medium; wherein sending the pulses of light energy from the emitters into the liquid medium generates a plurality of propagating laser-induced pressure waves that destroy at least a portion of the occlusion; and wherein the unit for guiding the laser light emitted from the emitters into the guidewire lumen or a guidewire within the guidewire lumen causes vibrations within the guidewire.

[0093] A method according to any of paragraphs

[0009] -

[0091] , wherein the unit for guiding laser light emitted from a transmitter into a guidewire lumen or a guidewire within a guidewire lumen comprises an outer band coupled to a distal end of a sheath, wherein the outer band comprises a distal end and the transmitter is disposed proximate the distal end of the outer band.

[0094] A method according to any of paragraphs

[0009] -

[0092] , wherein the unit for guiding laser light emitted from a transmitter into a guidewire lumen or a guidewire within a guidewire lumen comprises an outer band coupled to a distal end of a sheath, wherein the outer band comprises a distal end and the transmitter is disposed proximate the distal end of the outer band.

[0095] The method of any of paragraphs

[0009] -

[0093] , wherein the transmitter is directed toward the guidewire lumen or the guidewire in the guidewire lumen.

[0096] The method of any of paragraphs

[0009] -

[0094] , wherein the means for directing laser light emitted from the transmitter into the guidewire lumen or guidewire comprises a cap coupled to the distal end of the sheath.

[0097] A method according to any of paragraphs

[0009] -

[0095] , wherein the cap comprises an inner side and an outer side, wherein the inner side is tapered to direct laser-induced pressure waves and / or cavitation events to a guidewire lumen or a guidewire within the guidewire lumen, thereby causing excitation and / or vibration of the guidewire.

[0098] The method of any of paragraphs

[0009] -

[0096] , wherein the transmitter is positioned proximate to the inside of the cap.

[0099] The method of any of paragraphs

[0009] -

[0097] , wherein the sheath is an inner sheath, and wherein the catheter further comprises an outer sheath that can translationally receive the inner sheath.

[0100] A method according to any of paragraphs

[0009] -

[0098] , wherein the outer sheath comprises a sleeve, and wherein the means for directing laser light emitted from the transmitter to the guidewire lumen or the guidewire within the guidewire lumen comprises an attenuation member of the outer sheath coupled to the sleeve.

[0101] A method according to any of paragraphs

[0009] -

[0099] , wherein the attenuation member includes an inner surface, an outer surface, and a plurality of openings extending from the inner surface to the outer surface, and wherein transmitting a pulse of light energy from an emitter into the liquid medium generates a plurality of propagating laser-induced pressure waves that pass through the plurality of openings.

[0102] The method of any of paragraphs

[0009] -

[00100] , wherein the attenuation member comprises a plurality of openings, the plurality of openings comprising at least one of the following shapes: circular; elliptical; triangular; square; rectangular; spiral; polygonal; rhombus; pentagon; hexagon; heptagon; octagon; nonagon; and decagon.

[0103] The present disclosure provides a method for treating an occlusion within a vascular system of an object, the method comprising: positioning a catheter within the vascular system of the object, the catheter comprising a sheath and a plurality of emitters, the sheath having a guidewire lumen, a proximal end, and a distal end; the plurality of emitters being arranged circumferentially around the guidewire lumen or circumferentially adjacent to the guidewire lumen, wherein the emitters are capable of emitting laser light; positioning the distal end of the sheath adjacent to the occlusion within the vascular system; delivering a liquid medium to the distal end of the sheath; activating the emitters to send pulses of light energy through the liquid medium; wherein sending the pulses of light energy from the emitters into the liquid medium generates a plurality of propagating laser-induced pressure waves that destroy at least a portion of the occlusion; and wherein the plurality of propagating laser-induced pressure waves induce vibrations within the guidewire.

[0104] The present disclosure provides a method for treating an occlusion in a vascular system of an object, the method comprising: positioning a catheter in the vascular system of the object, the catheter comprising an outer sheath, a tip, an inner sheath, a sealable valve, and one or more transmitters, the outer sheath having a proximal end and a distal end; the tip being coupled to the distal end of the outer sheath; the inner sheath having a first guidewire lumen, a proximal end, and a distal end, wherein the inner sheath is radially disposed within the outer sheath, wherein the distal end of the inner sheath is disposed proximal to the tip, thereby forming a cavity between the outer sheath, the inner sheath, and the tip; the sealable valve being coupled to the outer sheath, the sealable valve having a second guidewire lumen and a seal; the one or more transmitters being disposed within the inner sheath, extending from the proximal end of the inner sheath to the distal end of the inner sheath and advancing The invention relates to a method of introducing a catheter into a cavity, wherein one or more emitters are coupled to an energy source (e.g., a laser generator); wherein at least one emitter is disposed within the cavity; positioning the tip adjacent to an occlusion within a vascular system by advancing the catheter along a guidewire, wherein the guidewire is received in a first guidewire lumen and a second guidewire lumen; introducing a liquid medium into the cavity, wherein the liquid medium actuates a seal within a valve and closes an opening between the valve and the guidewire; and activating at least one emitter within the cavity to transmit pulses of light energy into the liquid medium; wherein transmitting the pulses of light energy from the emitter into the liquid medium generates at least one propagating laser-induced pressure wave that causes the tip to engage and disrupt at least a portion of the vascular occlusion.

[0105] A method according to any of paragraphs

[0009] -

[0103] , wherein the sealable valve further comprises an outer wall and a flange radially disposed therein, wherein a gap exists between the outer wall and the flange, and wherein introducing the liquid medium into the cavity comprises introducing the liquid medium into the gap to actuate a seal within the valve and close an opening between the valve and the guide wire.

[0106] The method of any of paragraphs

[0009] -

[0104] , wherein the sealable valve further comprises an opening in the outer wall extending into the gap, and wherein introducing the liquid medium into the gap comprises introducing the liquid medium into the gap via the opening.

[0107] The method of any of paragraphs

[0009] -

[0105] , wherein the flange tapers radially inward toward the second guidewire lumen as the flange advances from the distal portion of the valve toward the proximal portion of the valve.

[0108] The present disclosure provides a catheter comprising a sheath, a tip, one or more emitters, and a light-absorbing material, wherein the sheath has a proximal end and a distal end; the tip is coupled to the distal end of the sheath and forms a cavity at the distal end of the sheath; the one or more emitters are carried by the sheath and coupled to an energy source (e.g., a laser generator), wherein at least one emitter is disposed in the cavity; and the light-absorbing material is coupled to at least a portion of the sheath and the tip and is disposed so that light emitted from at least one emitter intersects with the light-absorbing material.

[0109] The catheter of any of paragraphs

[0009] -

[0107] , wherein the light absorbing material is disposed within the cavity.

[0110] The catheter of any of paragraphs

[0009] -

[0108] , wherein the light absorbing material is disposed outside the cavity.

[0111] The catheter of any of paragraphs

[0009] -

[0109] , wherein the light absorbing material is applied as a coating to a support structure located within the cavity.

[0112] The present disclosure provides a method for treating an occlusion within a vascular system of a subject, the method comprising: positioning a catheter within the vascular system of the subject, the catheter comprising a sheath, a tip, one or more emitters, and a light absorbing material, the sheath having a proximal end and a distal end; the tip being coupled to the distal end of the sheath and forming a cavity at the distal end of the sheath; the one or more emitters being carried by the sheath and disposed toward and / or in the cavity, wherein the one or more emitters are coupled to an energy source (e.g., a laser generator); the light absorbing material being coupled to at least a portion of the sheath and the tip; positioning the tip adjacent to the occlusion within the vascular system by advancing the catheter within the vascular system; and activating at least one emitter to emit a pulse of light energy such that the light energy intersects at least a portion of the light absorbing material.

[0113] The method of any of paragraphs

[0009] -

[0111] further comprising delivering a liquid medium to the cavity.

[0114] A method according to any of paragraphs

[0009] -

[0111] , wherein the tip further comprises a flexible membrane carrying a light absorbing material, and activating at least one emitter to transmit a pulse of light energy such that intersection of the light energy with at least a portion of the light absorbing material causes deflection of the flexible membrane.

[0115] The present disclosure provides a method for treating an occlusion within a vascular system of a subject, the method comprising: positioning a catheter within the vascular system of the subject, the catheter comprising a sheath and at least one emitter, the sheath having a proximal end and a distal end; the at least one emitter being carried by the sheath, wherein each emitter is capable of emitting laser light; positioning the distal end of the sheath adjacent to the occlusion within the vascular system; delivering a gas-saturated liquid medium to the distal end of the sheath; activating the emitter to send pulses of light energy through the gas-saturated liquid medium; wherein sending the pulses of light energy from the emitter into the gas-saturated liquid medium generates at least one propagating laser-induced pressure wave that destroys at least a portion of the occlusion.

[0116] The method of any of paragraphs

[0009] -

[0114] , wherein the gas-saturated liquid medium is any one of an iodine-containing contrast agent or a gadolinium contrast agent.

[0117] The method of any of paragraphs

[0009] -

[0115] , wherein the gas-saturated liquid medium comprises a supersaturated liquid medium.

[0118] The present disclosure provides a method for treating an occlusion within a vascular system of a subject, the method comprising: positioning a catheter within the vascular system of the subject, the catheter comprising an outer sheath, an inner sheath, one or more optical fibers, and at least one emitter, the outer sheath having a proximal end, a distal end, and a lumen therein; the inner sheath comprising a proximal end and a distal end opposite the proximal end, the proximal end being capable of coupling to an energy source (e.g., a laser generator); one or more optical fibers extending from the proximal end of the inner sheath to the distal end of the inner sheath; at least one emitter coupled to the one or more optical fibers; positioning the distal end of the outer sheath adjacent to the occlusion within the vascular system; positioning the distal end of the inner sheath adjacent to the distal end of the outer sheath to form a cavity between the distal end of the inner sheath and the distal end of the outer sheath; delivering a liquid medium to the cavity; and activating the emitter to emit a pulse of light energy through the liquid medium; wherein sending the pulse of light energy from the emitter into the liquid medium generates at least one propagating laser-induced pressure wave that destroys at least a portion of the occlusion.

[0119] The method of any of paragraphs

[0009] -

[0117] further includes: repositioning the inner sheath within the outer sheath after activating the transmitter; and subsequently activating the transmitter to send a pulse of light energy through the liquid medium; wherein sending the pulse of light energy from the transmitter into the liquid medium generates at least one propagating laser-induced pressure wave that destroys at least a portion of the occlusion.

[0120] The method of any of paragraphs

[0009] -

[0118] further includes traversing the entire occlusion using the inner sheath and the outer sheath after activating the transmitter.

[0121] The method of any of paragraphs

[0009] -

[0119] , wherein the inner sheath further comprises a guidewire lumen, wherein positioning the catheter within the vasculature of the subject comprises receiving a guidewire in the guidewire lumen and advancing the inner sheath and outer sheath along the guidewire, and further comprising traversing the occlusion using the guidewire.

[0122] The method of any of paragraphs

[0009] -

[0120] further comprising traversing the occlusion using the inner sheath without the outer sheath after activating the transmitter.

[0123] The method of any of paragraphs

[0009] -

[0121] further includes: inserting a drug-coated balloon into the vascular system after activating the transmitter so that the drug-coated balloon is positioned adjacent to the remaining portion of the occlusion; and expanding the drug-coated balloon and applying the drug disposed on the drug-coated balloon to the occlusion.

[0124] The catheter, kit, and / or method of any of paragraphs

[0009] -

[0122] , wherein the total energy output for at least one emitter is between about 20 and about 1000 millijoules per square millimeter (mJ / mm 2 )between.

[0125] The catheter, kit, and / or method of any of paragraphs

[0009] -

[0123] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 150 nanometers and about 400 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0126] A catheter, kit, and / or method according to any of paragraphs

[0009] -

[0124] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 400 nanometers and about 800 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0127] A catheter, kit, and / or method according to any of paragraphs

[0009] -

[0125] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 800 nanometers and about 3000 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0128] The catheter, kit, and / or method of any of paragraphs

[0009] -

[0126] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 3000 nanometers and about 12000 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0129] The catheter, kit, and / or method of any of paragraphs

[0009] -

[0127] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 300 nanometers and about 360 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0130] The catheter, kit, and / or method of any of paragraphs

[0009] -

[0128] , wherein at least one emitter is configured to emit laser energy having a wavelength of approximately 308 nanometers with a pulse duration between approximately 10 nanoseconds and approximately 200 nanoseconds and at a frequency between approximately 1 pulse per second and approximately 100 pulses per second.

[0131] The catheter, kit, and / or method of any of paragraphs

[0009] -

[0129] , wherein the attenuation member is disposed outside of the outer sheath.

[0132] The catheter, kit, and / or method of any of paragraphs

[0009] -

[0130] , wherein the attenuation member is disposed within the interior of the outer sheath.

[0133] The catheter, kit, and / or method of any of paragraphs

[0009] -

[0131] , wherein the attenuation member is integrally formed with the outer sheath.

[0134] A method for increasing compliance of a blood vessel in a subject, the method comprising: locating a calcified portion in the tunica media of a blood vessel of the subject, positioning a laser catheter within the vascular system of the subject, the catheter comprising a proximal end, a distal end, and at least one emitter disposed at the distal end, positioning a sheath on the laser catheter within the vascular system of the subject, wherein the sheath comprises a proximal end, a distal end, and an attenuation member disposed adjacent to the distal end, positioning the sheath within the vascular system such that the attenuation member is disposed adjacent to a portion of the calcified portion, positioning the laser catheter within the vascular system such that the attenuation member is disposed adjacent to a portion of the calcified portion, introducing a liquid medium into the outer sheath and the at least one emitter; activating the at least one emitter to transmit pulses of light energy into the liquid medium; emitting one or more pulses of light energy from the at least one emitter, wherein the one or more pulses of light energy react with the liquid medium and generate a plurality of propagating laser-induced pressure waves, the laser-induced pressure waves disrupting the calcified portion of the tunica media, thereby increasing compliance of the blood vessel.

[0135] The method of paragraph

[0121] further includes the step of repositioning the sheath so that the attenuation member is adjacent to another calcified portion of the media.

[0136] The method of any of paragraphs

[0009] -

[0121] further comprising the step of repositioning the laser catheter within the sheath.

[0137] The method of any of paragraphs

[0009] -

[0121] , wherein the laser catheter is repositioned within the attenuation member.

[0138] The method of any of paragraphs

[0009] -

[0121] further includes the steps of removing the laser catheter from the vascular system and removing the outer sheath from the vascular system.

[0139] The method of any of paragraphs

[0009] -

[0017] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 150 nanometers and about 400 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0140] The method of any of paragraphs

[0009] -

[0017] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 400 nanometers and about 800 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0141] The method of any of paragraphs

[0009] -

[0017] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 800 nanometers and about 3000 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0142] The method of any of paragraphs

[0009] -

[0140] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 3000 nanometers and about 12000 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0143] The method of any of paragraphs

[0009] -

[0141] , wherein at least one emitter is configured to emit laser energy having a wavelength between about 300 nanometers and about 360 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0144] The method of any of paragraphs

[0009] -

[0142] , wherein at least one emitter is configured to emit laser energy having a wavelength of approximately 308 nanometers with a pulse duration between approximately 10 nanoseconds and approximately 200 nanoseconds and at a frequency between approximately 1 pulse per second and approximately 100 pulses per second.

[0145] The method of any of paragraphs

[0009] -

[0143] , wherein the total energy output for at least one emitter is between about 1 and about 100 millijoules per square millimeter (mJ / mm 2 )between.

[0146] The method of any of paragraphs

[0009] -

[0144] , wherein the total energy output for at least one emitter is between about 30 and about 80 millijoules per square millimeter (mJ / mm 2 )between.

[0147] The method of any of paragraphs

[0009] -

[0145] , wherein the liquid medium is a contrast agent or a contrast solution.

[0148] The method of any of paragraphs

[0009] -

[0146] , wherein the liquid medium is any one of an iodine-containing contrast agent or a gadolinium contrast agent.

[0149] A method according to any of paragraphs

[0009] -

[0147] , wherein the liquid medium is configured to exhibit high absorption of light energy having a wavelength between about 1 nanometer and about 1 millimeter emitted from at least one emitter with a pulse duration between about 1 nanosecond and about 1 second and at a frequency between about 1 pulse per second and about 1000 pulses per second.

[0150] The method of any of paragraphs

[0009] -

[0148] , wherein at least one emitter is two or more concentric emitters.

[0151] The method of any of paragraphs

[0009] -

[0149] , wherein at least one transmitter is two or more single fiber transmitters.

[0152] The method of any of paragraphs

[0009] -

[0150] , wherein the attenuation member is configured to form a semi-rigid biocompatible structure.

[0153] The method of any of paragraphs

[0009] -

[0151] , wherein the attenuation member is configured to form a rigid, biocompatible structure.

[0154] The method of any of paragraphs

[0009] -

[0152] , wherein the sheath comprises a non-porous biocompatible layer.

[0155] The method of any of paragraphs

[0009] -

[0153] , wherein the attenuation member includes an inner surface, an outer surface, and a plurality of openings extending from the inner surface to the outer surface.

[0156] A method according to any of paragraphs

[0009] -

[0154] , wherein the attenuation member includes a plurality of openings, the plurality of openings comprising at least one of the following shapes: circular; elliptical; triangular; square; rectangular; spiral; polygonal; rhombus; pentagon; hexagon; heptagon; octagon; nonagon; and decagon.

[0157] The method of any of paragraphs

[0009] -

[0155] , wherein the attenuation member is integrally disposed within the sheath.

[0158] The method of any of paragraphs

[0009] -

[0156] , wherein the attenuation member is disposed outside of the sheath.

[0159] The method of any of paragraphs

[0009] -

[0157] , wherein the attenuation member is disposed within the interior of the sheath.

[0160] The method of any of paragraphs

[0009] -

[0158] , wherein the liquid medium is any one of an iodine-containing contrast agent or a gadolinium contrast agent.

[0161] The method of any of paragraphs

[0009] -

[0159] , wherein the distal end of the sheath comprises an open configuration.

[0162] The method of any of paragraphs

[0009] -

[0160] , wherein the distal end of the sheath comprises a closed configuration.

[0163] According to the present disclosure, after penetrating the calcified and / or fibrous complete occlusion and destroying at least a portion of the occlusion using a catheter sheath that emits laser-induced pressure waves, the method may further include delivering one or more therapeutic agents disposed on the balloon via the balloon catheter, wherein, in the polymer-free drug formulation, the therapeutic agent may include one or more oxidation-insensitive drugs, including one or more of the following: taxanes, thalidomide, statins, corticosteroids, and lipophilic derivatives of corticosteroids. In the polymer-free formulation, the therapeutic agent may also include one or more lipophilic antioxidants, such as nordihydroguaiaretic acid, resveratrol, and propyl gallate. For example, U.S. application US 13 / 628608, which is a continuation of international application PCT / EP2010 / 066754 filed on November 3, 2010, discloses a scoring or cutting balloon catheter that can improve the adhesion of therapeutic agents to the balloon catheter by using a combination of an oxidation-insensitive drug and a lipophilic antioxidant. For its teaching purposes and all other purposes, the entire contents of the above two applications are incorporated herein by reference.

[0164] In addition, U.S. application US 13 / 707401, filed on December 6, 2012 and published on October 21, 2014, discloses a scoring element for a balloon catheter coated with a polymer matrix for delivering hydrophobic and lipophilic drugs to areas within a thrombus or plaque. This U.S. patent application is a divisional application of U.S. patent application US 11 / 411635 filed on April 26, 2006, and this application claims priority to U.S. provisional application US 60 / 680450 filed on May 11, 2005. For their teaching purposes and all other purposes, the entire contents of all of these applications are incorporated herein by reference.

[0165] In addition, U.S. application No. 13 / 310,320, filed on December 2, 2011 and published on October 22, 2013, discloses methods and apparatus for local delivery of water-soluble therapeutic agents and water-insoluble therapeutic agents to the surface of normal and diseased body cavities, U.S. application No. 13 / 310,320 being a divisional application of U.S. application No. 12 / 712,134, filed on February 24, 2010 and published on March 6, 2012, and U.S. application No. 12 / 726,101, filed on March 17, 2010 and published on February 14, 2012, which is a continuation-in-part of U.S. application No. 12 / 712,134, filed on February 24, 2010 and published on March 6, 2012, and U.S. application No. 12 / 726,101, filed on March 17, 2010 and published on February 14, 2012. 12 / 712,134 is a continuation-in-part of U.S. Application No. 12 / 558,420 filed on September 11, 2009, which is a continuation-in-part of U.S. Application No. 12 / 210,344 filed on September 15, 2008 and published on September 4, 2012, and U.S. Application No. 14 / 149,862 filed on January 8, 2014, which is a continuation-in-part of U.S. Application No. 13 / 560,538 filed on June 27, 2012 and published on March 18, 2014, which is a continuation-in-part of U.S. Application No. 13 / 560,538 filed on September 15, 2008 and published on September 4, 2012 Divisional application 12 / 210,344, the entire contents of which are incorporated herein by reference for their teaching purposes and all other purposes.

[0166] In addition, U.S. application US 13 / 926515 filed on June 25, 2013, which claims priority to U.S. provisional application US 61 / 665758 filed on June 28, 2012, discloses methods and apparatus for coating medical devices comprising a therapeutic agent dispersed in a polymer or oligomer matrix, the entire contents of both applications being incorporated herein by reference for their teaching purposes and all other purposes.

[0167] The present disclosure also provides a catheter system, which includes: a sheath having a proximal end and a distal end and a lumen therein; a laser catheter including a proximal end and a distal end capable of being coupled to an energy source (e.g., a laser generator); at least one emitter, which is disposed at the distal end of the laser catheter and coupled to the energy source (e.g., a laser generator), wherein the catheter is configured to be disposed within the sheath, based on which the distal end of the laser catheter is disposed close to the distal end of the sheath, forming a cavity between the distal end of the laser catheter and the distal end of the sheath; and a unit for introducing a liquid medium into the cavity,

[0168] The present disclosure also provides a method for increasing compliance of a blood vessel in a subject, the method comprising: locating a calcified portion in the tunica media of a blood vessel of the subject; positioning a laser catheter in the subject's vascular system, the catheter comprising a proximal end, a distal end, and at least one transmitter disposed adjacent to the distal end; positioning a sheath on the laser catheter in the subject's vascular system, wherein the sheath comprises a proximal end, a distal end, and an attenuation member, the attenuation member being disposed at or adjacent to the distal end of the sheath, wherein the attenuation member comprises an open area between 40% and 60%, wherein the attenuation member is composed of at least one 75 to 100 mm thick layer of attenuation per inch. The invention relates to a method for forming a sheath having 125 turns of a coil; positioning the sheath within the vascular system so that the attenuation member is arranged to be adjacent to the portion of the calcified portion in the tunica media of the blood vessel; positioning the laser catheter within the vascular system so that at least one emitter is positioned within the attenuation member and adjacent to the portion of the calcified portion in the tunica media of the blood vessel; introducing a liquid medium into the sheath and the at least one emitter; and transmitting a plurality of light energy pulses from the at least one emitter into the liquid medium, wherein the plurality of light energy pulses react with the liquid medium and generate a plurality of propagating laser-induced pressure waves, which destroy the calcified portion of the tunica media, thereby increasing the compliance of the blood vessel.

[0169] The method of paragraph

[0167] , wherein at least one coil comprises a flat wire.

[0170] The method of any of paragraphs

[0167] -

[0168] , wherein the height of the flat filament is between 0.0005 and 0.002 inches and the width is between 0.002 and 0.010 inches.

[0171] The method of any of paragraphs

[0167] -

[0169] , wherein the height of the flat filament is approximately 0.001 inches and the width is approximately 0.005 inches.

[0172] The method of any of paragraphs

[0167] -

[0170] , wherein the spacing between turns of the flat wire in the coil is between 0.003 and 0.008 inches.

[0173] The method of any of paragraphs

[0167] -

[0171] , wherein the coil has 90 to 100 turns per inch.

[0174] The method of any of paragraphs

[0167] -

[0172] , wherein the coil has approximately 95 turns per inch.

[0175] The method of any of paragraphs

[0167] -

[0173] , wherein the sheath comprises a tip and a lumen, wherein the lumen comprises a first inner diameter and a second inner diameter proximal to the tip, wherein the first inner diameter is smaller than the second inner diameter.

[0176] A method according to any of paragraphs

[0167] -

[0174] , wherein the outer diameter of the laser catheter is approximately equal to the first inner diameter of the tip.

[0177] The method of any of paragraphs

[0167] -

[0175] , wherein the first difference between the outer diameter of the laser catheter and the first inner diameter of the tip is approximately 0.0005 inches.

[0178] The method of any of paragraphs

[0167] -

[0176] , wherein the second difference between the outer diameter of the laser catheter and the second inner diameter of the sheath is approximately 0.0025 inches.

[0179] The method of any of paragraphs

[0167] -

[0177] , wherein the sheath comprises a tip having a proximal end and a distal end, wherein the tip tapers from the proximal end to the distal end.

[0180] The present disclosure also provides a method for performing plaque removal in a subject having a vascular occlusion in the subject's vascular system, the method comprising: inserting a guidewire into the vascular system and through the vascular occlusion in the vascular system; introducing a laser catheter into the vascular system and onto the guidewire, wherein the laser catheter includes at least one emitter; using the laser catheter to ablate at least a portion of the vascular occlusion; introducing a sheath into the vascular system and onto the laser catheter, wherein the sheath includes a distal portion and an attenuation member, the attenuation member being disposed at the distal portion of the sheath or disposed adjacent to the distal portion of the sheath, wherein the attenuation member includes 40% to 60% of the open area, wherein the attenuation member is formed by at least one coil having 75 to 125 turns per inch; positioning the sheath within the vascular system such that the attenuation member is radially disposed adjacent to the calcified portion within the vascular system; positioning the laser catheter within the vascular system such that at least one emitter is positioned within the attenuation member and radially adjacent to the calcified portion; introducing a liquid medium into the sheath and the at least one emitter; and transmitting a plurality of light energy pulses from the at least one emitter into the liquid medium, wherein the plurality of light energy pulses react with the liquid medium and generate a plurality of propagating laser-induced pressure waves that destroy the calcified portion.

[0181] The method according to paragraph

[0179] also includes: extending the laser catheter distally of the sheath and ablating another portion of the second vascular occlusion; positioning the sheath within the vascular system so that the attenuation member is radially disposed adjacent to a second calcified portion of the second vascular occlusion; positioning the laser catheter within the vascular system so that at least one emitter is positioned within the attenuation member and radially adjacent to the second calcified portion; introducing a liquid medium into the sheath and the at least one emitter; and sending a plurality of light energy pulses from the at least one emitter into the liquid medium, wherein the plurality of light energy pulses react with the liquid medium and generate a plurality of propagating laser-induced pressure waves that destroy the second calcified portion.

[0182] The present disclosure also provides a catheter system, which includes: a laser catheter, which includes a proximal end, a distal end, and at least one transmitter arranged adjacent to the distal end; a sheath, which is configured to be arranged on the laser catheter and is configured to receive a liquid medium, the sheath includes a proximal end, a distal end, and an attenuation member, the attenuation member is arranged at the distal end of the sheath or is arranged adjacent to the distal end of the sheath, wherein the attenuation member includes an open area between 40% and 60%, and wherein the attenuation member is formed by at least one coil with 75 to 125 turns per inch.

[0183] A system according to paragraph

[0181] , wherein at least one coil comprises a flat wire.

[0184] The system of any of paragraphs

[0181] -

[0182] , wherein the height of the flat wire is between 0.0005 and 0.002 inches and the width is between 0.002 and 0.010 inches.

[0185] The system of any of paragraphs

[0181] -

[0183] , wherein the spacing between turns of the flat wire in the coil is between 0.003 and 0.008 inches.

[0186] A system according to any of paragraphs

[0181] -

[0184] , wherein at least one coil has 90 to 100 turns per inch.

[0187] A system according to any of paragraphs

[0181] -

[0185] , wherein the jacket further comprises an inner sleeve, an outer sleeve, and an intermediate layer concentrically disposed between the inner sleeve and the outer sleeve.

[0188] A system according to any of paragraphs

[0181] -

[0186] , wherein the braided structure is integrally disposed within an inner liner or outer sleeve.

[0189] A system according to any of paragraphs

[0181] -

[0187] , wherein the braided structure is integrally disposed within the inner sleeve.

[0190] A system according to any of paragraphs

[0181] -

[0188] , wherein the braided structure is integrally disposed within the outer shell.

[0191] A system according to any of paragraphs

[0181] -

[0188] , wherein the braided structure is integrally disposed within the outer sleeve and the inner liner.

[0192] The present disclosure also provides a catheter system, which includes: a laser catheter, which includes a proximal end, a distal end, and at least one transmitter arranged adjacent to the distal end; a sheath, which is configured to be arranged on the laser catheter and is configured to receive a liquid medium, the sheath includes a proximal end, a distal end, and an attenuation member, the attenuation member is arranged at the distal end of the sheath or is arranged adjacent to the distal end of the sheath, wherein the attenuation member includes a braided structure, and the braiding density of the braided structure is 40 to 80 stitches per inch.

[0193] A system according to paragraph

[0191] , wherein the open area of ​​the woven structure is between 55% and 75%.

[0194] A system according to any of paragraphs

[0191] -

[0192] , wherein the woven structure has 12 to 20 carriers.

[0195] A system according to any of paragraphs

[0191] -

[0193] , wherein the jacket further comprises an inner sleeve, an outer sleeve, and an intermediate layer concentrically disposed between the inner sleeve and the outer sleeve.

[0196] A system according to any of paragraphs

[0191] -

[0194] , wherein the braided structure is integrally disposed within an inner liner or outer sleeve.

[0197] A system according to any of paragraphs

[0191] -

[0195] , wherein the braided structure is integrally disposed within the inner sleeve.

[0198] A system according to any of paragraphs

[0191] -

[0196] , wherein the braided structure is integrally disposed within the outer shell.

[0199] A system according to any of paragraphs

[0191] -

[0197] , wherein the braided structure is integrally disposed within the outer sleeve and the inner liner.

[0200] The present disclosure also provides a system comprising: a sheath having a proximal end and a distal end and a lumen therein, the lumen being configured to translationally receive a device having a distal end; a handle coupled to the sheath; and a treatment mode selection system coupled to the handle, the treatment mode selection system comprising a user input that can be actuated to configure the device from a first configuration to a second configuration, and vice versa, in which the distal end of the device is disposed away from the distal end of the sheath and in the second configuration, the distal end of the device is disposed proximal to the distal end of the sheath and within the lumen.

[0201] A system according to paragraph

[0198] , wherein the user input portion includes a translatable button.

[0202] A system according to paragraph

[0198] , wherein the user input portion includes a rotatable component.

[0203] The present disclosure also provides a laser catheter system, which includes: a sheath having a proximal end and a distal end and a lumen therein; a laser catheter that is translatably disposed within the sheath, the laser catheter including a proximal end configured to be coupled to a laser generator and a distal end; at least one transmitter configured to be coupled to the laser generator; a handle that is coupled to the sheath and translatably coupled to the laser catheter; a treatment mode selection system that is coupled to the sheath, the treatment mode selection system including a user input that can be actuated to configure the laser catheter system from a first configuration to a second configuration, and vice versa, in which the distal end of the laser catheter is disposed away from the distal end of the sheath and in which the distal end of the laser catheter is disposed proximal to the distal end of the sheath and within the lumen, thereby forming a cavity between the distal end of the laser catheter and the distal end of the sheath.

[0204] A system according to paragraph

[0201] , wherein the user input portion can be actuated to configure at least one operating parameter of the laser generator.

[0205] As used herein, "at least one", "one or more", and "and / or" are open-ended expressions of conjunctions and antonymous conjunctions in operation. For example, each of the expressions "at least one of A, B, and C", "at least one of A, B, or C", "one or more of A, B, and C", "one or more of A, B, or C", and "A, B, and / or C" means A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B, and C together. When each of A, B, and C in the above expressions refers to an element (e.g., X, Y, and Z) or a class of elements (e.g., X, Y, and Z), the 1 -X n , Y 1 -Y m and Z 1-Z o ), the phrase is intended to refer to a single element selected from X, Y, and Z, a combination of elements selected from the same category (e.g., X 1 and X 2 ) and combinations of elements selected from two or more categories (e.g., Y 1 and Z o ).

[0206] It should be noted that the term "a" or "an" entity refers to one or more of that entity. As such, the terms "a" (or "an"), "one or more", and "at least one" can be used interchangeably herein. It should also be noted that the terms "includes," "comprising," and "having" can be used interchangeably.

[0207] Unless specifically stated otherwise herein, the term "about," when used in conjunction with a numerical value, shall mean plus and / or minus ten percent (10%) of the numerical value.

[0208] As used herein, the term "attenuation member" is any component that modifies cavitation events and / or vapor bubbles. An example of an attenuation member is an element that has minimal effect on laser-induced pressure waves but modifies cavitation events and / or vapor bubbles. An example of an attenuation member is a porous attenuation member. However, the attenuation member need not be porous and may include a solid configuration.

[0209] The term "catheter" as used herein generally refers to a tube that can be inserted into a body cavity, duct, lumen, or blood vessel (e.g., vasculature). In most uses, a catheter is a relatively thin flexible tube ("soft" catheter), but in some uses, it may also be a larger, non-solid flexible (but still flexible) catheter ("hard" catheter). In some uses, a catheter may include a lumen along part or all of its length to allow the introduction of other catheters or guidewires. An example of a catheter is a sheath.

[0210] The term "balloon catheter" as used herein generally refers to various types of catheters that carry a balloon for accommodating a fluid. Balloon catheters can also have a variety of internal structures (e.g., different lumen designs), wherein there are at least three basic types: three lumens, two lumens, and coaxial lumens. It is intended to include all variations of internal structure and design changes by using the term "balloon catheter" in this article. In some uses, balloon catheters can be used to perform angioplasty.

[0211] The term "cavitation event" as used herein describes a rapid fluid movement that causes a vapor bubble to collapse to its smallest radius. In certain cases, a cavitation event may include the generation of a pressure wave.

[0212] The term "coupler" or "fiber coupler" refers to a fiber optic device having one or more input fibers or one or more input emitters and one or more output fibers or one or more output emitters. A fiber coupler is typically a special fiber optic device having one or more input fibers or one or more input emitters that is used to couple these fibers or emitters to an energy source. The energy source can be another optical fiber or emitter that carries light energy and is coupled to one or more additional fibers or one or more additional emitters.

[0213] The term "emitter" as used herein refers to a fiber or optical component (including any part thereof, for example, the end of a fiber) that emits light from the distal end of a device (e.g., a catheter) toward a desired target. In some applications, the target can be a tissue or an absorptive medium (e.g., a contrast agent). An emitter can be the output end of any device that transmits light from a light energy source to a target or treatment area. These light energy transmission devices can include glass or fused silica optical fibers, plastic optical fibers, air or gas light guides, and liquid light guides. As described herein, one or more emitters can be used to emit light of any wavelength. One or more emitters can emit light, including but not limited to lasers, white light, visible light, infrared light, and ultraviolet light.

[0214] According to the present disclosure, the catheter contains at least one emitter, which may include glass or fused silica optical fibers, plastic optical fibers, air or gas light guides, and liquid light guides. Examples of liquid light guides or catheters containing liquid light guides can be found in U.S. Application No. 11 / 923,488 filed on October 24, 2007 and U.S. Application No. 12 / 254,254 filed on October 20, 2008, both of which are incorporated herein by reference in their entirety for their teaching purposes and for all other purposes.

[0215] As used herein, the term "flexible structure" shall mean a structure that can bend or otherwise conform to the shape of the vasculature when passing through the vasculature. The term "radially flexible structure" shall include flexible structures that can also expand and / or contract in the radial direction when laser-induced pressure waves pass through.

[0216] As used herein, "laser transmitter" refers to the end portion of a fiber or optical component that transmits laser light from the distal end of a catheter toward a desired target. In certain applications, the target can be tissue or an absorptive medium (eg, a contrast agent).

[0217] The term "laser-induced pressure wave" as used herein is a pressure wave caused by the reaction between laser light and an absorbing material. The laser-induced pressure wave may be generated in a gas, a liquid (eg, saline which may or may not include a contrast agent), or a solid.

[0218] Pursuant to 35 U.S.C. Section 112(f), the term "unit" as used herein should be interpreted as broadly as possible. Therefore, a claim containing the term "unit" should cover all structures, materials, or actions described herein and all their equivalents. In addition, the structures, materials, or actions and their equivalents should include all the contents described in the summary of the invention, the brief description of the drawings, the detailed description, the abstract, and the claims.

[0219] The term "optical fiber" (or laser-active fiber) as used herein refers to a flexible, transparent fiber made of an optically transmissive material (e.g., glass (silicon dioxide) or plastic) used as a waveguide or "light pipe" for transmitting light between the two ends of the fiber.

[0220] As used herein, the term "porous attenuation member" shall mean an attenuation member composed of a rigid member or a semi-rigid member having openings therein. Examples of rigid and semi-rigid members include members composed of coils, braids, laser cut tubes, reinforced polymer extrusions, patterned plastics, metals, and ceramics. Specific materials used to construct such rigid and semi-rigid members may include nitinol (nickel-titanium alloy), stainless steel, titanium, silver, aluminum, cobalt, chromium, nylon elastomer (pebax), silicone, polyurethane, polyethylene and its derivatives, nylon, polytetrafluoroethylene and its derivatives, polyethylene terephthalate, polypropylene, polyetheretherketone, hydroxyapatite, alumina, tricalcium phosphate, silicates, or other biocompatible metals, ceramics, or polymers. Possible configurations for porous attenuation members include, but are not limited to, spiral cuts; interrupted spiral cuts; honeycombs; lattice structures commonly found in vascular stents; grooves; offset grooves; spirals; longitudinal, radial, circumferential, or a combination thereof seams; openings shaped as cuts. The scope of the present disclosure also encompasses "porous attenuation members" constructed from flexible structures and / or radially flexible structures, but it may be preferred that the attenuation members be constructed from rigid or semi-rigid members.

[0221] As used herein, the term "rigid structure" shall mean a structure that is able to bend or otherwise conform to the shape of the vasculature as it passes through the vasculature, but is substantially unable to expand and / or contract in a radial direction as laser-induced pressure waves pass therethrough.

[0222] As used herein, the term "semi-rigid structure" shall mean a structure that is partially rigid, has an additional degree of flexibility when traversing vasculature, but is substantially incapable of expanding and / or contracting in a radial direction when laser-induced pressure waves pass therethrough.

[0223] The term "sheath" as used herein generally refers to a tube that can be inserted into a body cavity duct, lumen or blood vessel (e.g., vascular system) to allow the introduction of a catheter and the introduction of a fluid along its length. An example of a catheter that can be introduced into a sheath is a laser catheter. An example of a fluid that can be introduced into a sheath is an absorptive fluid (e.g., a contrast agent). The sheath can have a closed end or an open end. Because the sheath is a tube that can be inserted into a body cavity, duct, lumen or blood vessel (e.g., vascular system), the sheath can also be considered a catheter. Therefore, a catheter (e.g., a laser catheter) can be introduced into another catheter.

[0224] As used herein, the term "therapeutic agent" generally refers to any known or later discovered pharmacologically active agent that provides treatment to a subject by alleviating one or more of the subject's physiological symptoms. The therapeutic agent can be a naturally occurring compound, a chemically modified naturally occurring compound, or a chemically synthesized compound. The agent is generally selected from the recognized classes of pharmacologically active agents, including, but not limited to, the following: analgesics; anesthetics; antiarthritics; respiratory drugs (including antiasthmatics); anticancer drugs (including antineoplastic drugs); anticholinergics; anticonvulsants; antidepressants; antidiabetics; antidiabetics; anthelmintics; antihistamines; antihyperlipidemics; antihypertensives; anti-infectives (e.g., antibiotics and antivirals); anti-inflammatory drugs; anti-migraine preparations; anal medications; anti-Parkinson's disease drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antituberculosis drugs; antiulcer drugs; antivirals; anxiolytics; appetite suppressants; attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) drugs drugs; cardiovascular preparations (including calcium channel blockers, CNS drugs); beta blockers and antiarrhythmics; CNS stimulants; cough and cold preparations (including decongestants); diuretics; genetic material; herbal remedies; hormone blockers; hypnotics; hypoglycemic agents; immunosuppressants; leukotriene inhibitors; mitotic inhibitors; restenosis inhibitors; muscle relaxants; narcotic antagonists; nicotine; nutritional drugs (e.g., vitamins, essential amino acids and fatty acids); ophthalmic drugs (e.g., antiglaucoma drugs); parasympathetic drugs; psychostimulants; sedatives; steroids; sympathomimetics; tranquilizers; and vasodilators (including general coronary, peripheral and cerebral arteries).

[0225] As used herein, the term "vapor bubble" is a gaseous cavity created within a liquid.

[0226] As used herein, the terms "vasculature" and "vessel" refer to any portion of a subject's circulatory system (including peripheral and non-peripheral arteries and veins). The vasculature can be composed of materials such as nucleic acids, amino acids, carbohydrates, polysaccharides, lipid fibrous tissue, calcium deposits, dead cell remnants, cellular debris, etc.

[0227] The term "vascular occlusion" or "occlusion" refers to the accumulation of fat, lipids, fibrin, fibrocalcified plaques, thrombi and other atherosclerotic tissues within the lumen or intima of an artery, which narrows the internal lumen of the artery or completely blocks the internal lumen of the artery, thereby limiting or blocking the normal blood flow through the arterial segment. The occlusion can partially or completely occlude the vascular system. Therefore, the term "vascular occlusion" or "occlusion" should include complete occlusion and partial occlusion. Alternatively, vascular occlusion or occlusion can also be referred to as vascular obstruction (or obstruction) or vascular restriction (or restriction). Therefore, vascular obstruction can refer to complete obstruction or partial obstruction, while vascular restriction can refer to complete restriction or partial restriction.

[0228] It should be understood that each maximum numerical limitation given throughout this disclosure is considered to include each lower numerical limitation as an alternative, just as if such lower numerical limitations were clearly written in this article. Each minimum numerical limitation given throughout this disclosure is considered to include each higher numerical limitation as an alternative, just as if such higher numerical limitations were clearly written in this article. Each numerical range given throughout this disclosure is considered to include each narrower numerical range falling within such a wider numerical range, just as if such a narrower numerical range was clearly written in this article.

[0229] The foregoing is a simplified overview of the present disclosure to provide an understanding of some aspects of the present disclosure. This overview is neither a broad overview of the present disclosure and its various aspects, embodiments, and configurations, nor an exhaustive overview of the present disclosure and its various aspects, embodiments, and configurations. It is neither intended to identify the key or important elements of the present disclosure nor to delineate the scope of the present disclosure, but rather to present the selected concepts of the present disclosure in a simplified form as an introduction to the specific embodiments presented below. It will be appreciated that other aspects, embodiments, and configurations of the present disclosure can utilize one or more of the features set forth above or described in detail below, either individually or in combination. BRIEF DESCRIPTION OF THE DRAWINGS

[0230] The accompanying drawings are incorporated into and form part of the specification to illustrate several examples of the present disclosure. These drawings, together with the description, explain the principles of the present disclosure. The accompanying drawings illustrate only preferred and alternative examples of how the present disclosure can be made and used and should not be interpreted as limiting the present disclosure to only the illustrated and described examples. As shown below with reference to the accompanying drawings, other features and advantages will become apparent from the following more detailed description of various aspects, embodiments and configurations of the present disclosure.

[0231] Figure 1 An exemplary ablation system is illustrated, comprising a laser generator and a catheter sheath that emits laser-induced pressure waves;

[0232] Figure 2A According to one embodiment of the present disclosure Figure 1 Schematic diagram of a distal portion of a catheter sheath emitting a laser-induced pressure wave;

[0233] Figure 2B is a front view of an embodiment of a distal portion of a catheter emitting laser-induced pressure waves according to one embodiment of the present disclosure;

[0234] Figure 2C is a cross-sectional view of the distal portion of the catheter emitting the laser-induced pressure wave (through Figure 2B plane C in the middle);

[0235] Figure 2B ' is a front view of an embodiment of a distal portion of a catheter emitting laser-induced pressure waves according to one embodiment of the present disclosure;

[0236] Figure 2C ' is a cross-sectional view of the distal portion of a catheter emitting laser-induced pressure waves according to one embodiment of the present disclosure (through Figure 2B ' in plane C);

[0237] Figure 2D is a cross-sectional view (through the distal portion of a catheter emitting laser-induced pressure waves) according to one embodiment of the present disclosure. Figure 2C plane D in the middle);

[0238] Figure 3 is a cross-sectional view of a distal portion of a catheter emitting laser-induced pressure waves according to one embodiment of the present disclosure;

[0239] Figure 4 is a cross-sectional view of a distal portion of a catheter emitting laser-induced pressure waves according to one embodiment of the present disclosure;

[0240] Figure 5 is a perspective view of an embodiment of a distal portion of a catheter emitting laser-induced pressure waves according to one embodiment of the present disclosure;

[0241] Figure 5A is a cross-sectional view (through the distal portion of a catheter emitting laser-induced pressure waves) according to one embodiment of the present disclosure. Figure 5 plane A in the middle);

[0242] Figure 5A ' is a cross-sectional view of the distal portion of a catheter emitting laser-induced pressure waves according to one embodiment of the present disclosure (through Figure 5 plane A in the middle);

[0243] Figure 6is a partially transparent front view of a distal portion of a laser catheter disposed at a location within a distal portion of a catheter sheath;

[0244] Fig. 6A is a partially transparent front view of the distal portion of the laser catheter, with Figure 6 The distal portion of the laser catheter is disposed at an alternate position compared to the position of the laser catheter in the embodiment of the present invention;

[0245] Figure 6B is an enlarged perspective view of a portion of a distal portion of an alternative laser catheter including a deflector coupled to the distal end of the laser catheter;

[0246] Figure 7 is a perspective view of a laser catheter including a shield or deflector as a distal end of the laser catheter according to one embodiment of the present disclosure, wherein the laser catheter is disposed at a position within a distal portion of a catheter sheath;

[0247] Figure 8 is a front view of a removable tip for an ablation catheter according to one embodiment of the present disclosure;

[0248] Fig. 8A is a cross-sectional view of a removable tip of an ablation catheter (through Figure 8 plane A in the middle);

[0249] Fig. 9 is a representative flow chart of a method of treating a subject using a catheter according to one embodiment of the present disclosure;

[0250] Fig.10 is a perspective view of a laser catheter and a guidewire according to one embodiment of the present disclosure;

[0251] Fig.11A is a perspective view of a kit within the vasculature of a patient according to one embodiment of the present disclosure, wherein the kit includes a laser catheter radially disposed within a sheath and over a guidewire, wherein the kit and guidewire are positioned proximate a vascular occlusion;

[0252] Fig. 11B is a perspective view of a kit within the vasculature of a patient according to one embodiment of the present disclosure, wherein the kit includes a laser catheter radially disposed within a sheath and over a guidewire, wherein the kit is positioned proximate a vascular occlusion and the guidewire has penetrated the vascular occlusion;

[0253] Fig. 11Cis a perspective view of a kit within the vasculature of a patient according to one embodiment of the present disclosure, wherein the kit includes a laser catheter radially disposed within a sheath and over a guidewire, wherein the sheath is positioned proximate a vascular occlusion and the laser catheter and the guidewire have penetrated the vascular occlusion;

[0254] Fig.11D is a perspective view of a kit within the vasculature of a patient according to one embodiment of the present disclosure, wherein the kit includes a laser catheter radially disposed within a sheath and over a guidewire, wherein the kit and guidewire have penetrated a vascular occlusion;

[0255] Fig.12 is a representative flow chart of a method of treating a subject using a laser catheter and a sheath according to one embodiment of the present disclosure;

[0256] Fig.13 is a front view of a kit according to one embodiment of the present disclosure, the kit comprising a laser catheter radially disposed within a sheath and over a guidewire;

[0257] Fig.14A is a front view of a kit according to one embodiment of the present disclosure, the kit including a laser catheter radially disposed within a handle and a sheath and over a guidewire;

[0258] Fig. 14B yes Fig.14A A detailed front view of the laser catheter and handle at the proximal end of the handle;

[0259] Fig.15A yes Fig.14A A perspective view of a handle of , wherein several exterior components are partially transparent to illustrate interior components, and the shaft of the handle is shown in a proximal position;

[0260] Fig. 15B yes Fig.14A Another perspective view of the handle of , wherein several exterior components are partially transparent to illustrate interior components, and the shaft is shown in a proximal position;

[0261] Fig. 15C yes Fig.14A A front view of a handle of , wherein several exterior components are partially transparent to illustrate interior components, and the shaft is shown in a proximal position;

[0262] Fig.15D yes Fig.14A A front view of a handle of , wherein several exterior components are partially transparent to illustrate interior components, and the shaft is shown in an intermediate position;

[0263] Fig.15E yes Fig.14AA front view of a handle of , wherein several exterior components are partially transparent to illustrate interior components, and the shaft is shown in a distal position;

[0264] Fig.15F yes Fig.14A A cross-sectional view of a handle of , wherein the shaft is shown in a proximal position;

[0265] Figure 15G yes Fig.14A A cross-sectional view of a handle of , wherein the shaft is shown in an intermediate position;

[0266] Fig.15H yes Fig.14A An exploded view of the handle;

[0267] Fig.15I yes Fig.14A Detailed exploded view of the handle;

[0268] Fig.15J yes Fig.14A Another detailed exploded view of the handle;

[0269] Fig.16A yes Fig.14A A perspective view of the frame of the handle;

[0270] Fig. 16B It is along Fig.16A A front cross-sectional view of the frame along line 16B-16B;

[0271] Fig. 16C It is along Fig.16A A perspective cross-sectional view of the frame taken along line 16B-16B;

[0272] Fig.16D It is along Fig.16A A front cross-sectional view of the frame along line 16D-16D;

[0273] Fig.16E It is along Fig.16A A perspective cross-sectional view of the frame taken along line 16D-16D;

[0274] Fig.16F It is along Fig.16A A front cross-sectional view of the frame along line 16F-16F;

[0275] Figure 16G It is along Fig.16A A perspective cross-sectional view of the frame taken along line 16F-16F; and

[0276] Fig.17 yes Fig.14A A front cross-sectional view of a shaft of a handle;

[0277] Fig.18is a perspective view of an outer sheath including an attenuation member according to one embodiment of the present disclosure;

[0278] Fig.18A is a side view of an attenuation member including a plurality of square openings according to one embodiment of the present disclosure;

[0279] Fig.18B is a side view of an attenuation member including a plurality of diamond-shaped openings according to one embodiment of the present disclosure;

[0280] Fig.18C is a side view of an attenuation member according to one embodiment of the present disclosure, the attenuation member including a plurality of openings formed by a spiral structure wound in a specific direction;

[0281] Fig.18D is a side view of an attenuation member according to one embodiment of the present disclosure, the attenuation member including a plurality of openings formed by a spiral structure wound in a specific direction;

[0282] Fig.18E is a side view of an attenuation member according to one embodiment of the present disclosure, the attenuation member including a plurality of openings formed by a helically wound ribbon;

[0283] Fig.18F is a side view of an attenuation member including a plurality of hexagonal openings according to one embodiment of the present disclosure; and

[0284] Fig.19 is a representative flow chart of a method of treating a subject using a laser catheter and a sheath according to one embodiment of the present disclosure;

[0285] Fig. 20 is a representative cross-sectional view of a distal end of a catheter according to one embodiment of the present disclosure;

[0286] Fig. 20 ' is an alternative embodiment according to the present disclosure Fig. 20 A representative cross-sectional view of the distal end of the catheter is shown in FIG.

[0287] Fig. 20 " is another alternative embodiment according to the present disclosure Fig. 20 A representative cross-sectional view of the distal end of the catheter is shown in FIG.

[0288] Fig. 20 ” is another alternative embodiment according to the present disclosure Fig. 20 A representative cross-sectional view of the distal end of the catheter is shown in FIG.

[0289] Fig.21is a representative side view of a catheter system including a laser catheter and a sheath having a sealable valve according to an embodiment of the present disclosure;

[0290] Fig. 22 yes Fig.21 An enlarged representative perspective view of a sealable valve of the catheter system depicted in;

[0291] Fig.22A Is in an unsealed configuration relative to the guidewire Fig.21 an enlarged representative cross-sectional side view of a sealable valve of the catheter system depicted in;

[0292] Fig. 22B Is in a sealed configuration relative to the guidewire Fig.21 an enlarged representative cross-sectional side view of a sealable valve of the catheter system depicted in;

[0293] Fig.23 is a representative side view of a catheter system according to an embodiment of the present disclosure, the catheter system including a laser catheter, a sheath having a sealable valve, and a light absorbing material support structure;

[0294] Fig.24 is a cross-sectional view of a distal portion of a catheter system according to one embodiment of the present disclosure, the distal portion of the catheter system including a light absorbing material support structure;

[0295] Fig.25 is a cross-sectional view of the arterial wall taken along a direction perpendicular to the longitudinal axis of the arterial wall;

[0296] Fig.25A yes Fig.25 A reduced version of the cross-section of the artery wall in ;

[0297] Fig.26A is a longitudinal cross-sectional view of a healthy arterial wall taken along a direction parallel to the longitudinal axis of the arterial wall;

[0298] Fig.26B is a longitudinal cross-sectional view of an arterial wall taken along a direction parallel to a longitudinal axis of the arterial wall, wherein the arterial wall comprises fat and / or lipid;

[0299] Fig.26C is a longitudinal cross-sectional view of an arterial wall taken along a direction parallel to a longitudinal axis of the arterial wall, wherein the arterial wall includes plaque and calcium in the intima;

[0300] Fig.26D is a longitudinal cross-sectional view of an arterial wall taken along a direction parallel to a longitudinal axis of the arterial wall, wherein the arterial wall includes calcified plaque and lipids in the intima;

[0301] Fig.26Eis a longitudinal cross-sectional view of an arterial wall taken along a direction parallel to the longitudinal axis of the arterial wall, wherein the arterial wall has been ruptured;

[0302] Fig.26F is a longitudinal cross-sectional view of a wall of an artery taken along a direction parallel to a longitudinal axis of the wall of the artery, wherein the artery includes an occlusion;

[0303] Figure 26G is a longitudinal cross-sectional view of the arterial wall taken along a direction parallel to the longitudinal axis of the arterial wall, wherein the laser catheter removes Fig.21 The occlusion depicted in F;

[0304] Fig.26H is a longitudinal cross-sectional view of the arterial wall taken along a direction parallel to the longitudinal axis of the arterial wall, wherein the sheath and the laser catheter are positioned adjacent to Figure 26G The remaining portion of the vessel occlusion depicted in , wherein the tip of the laser catheter (particularly the emitter(s) of the laser catheter) is disposed distally from the most distal end of the sheath;

[0305] Fig.26H ' is a longitudinal cross-sectional view of the arterial wall taken along a direction parallel to the longitudinal axis of the arterial wall, wherein the sheath and the laser catheter are positioned adjacent to Figure 26G The remaining portion of the vessel occlusion depicted in , wherein the tip of the laser catheter (particularly the transmitter(s) of the laser catheter) is disposed within and proximate to the distal-most end of the sheath;

[0306] Fig.26I It is taking advantage of Fig.26H and / or Fig.26H ' A longitudinal cross-sectional view of the arterial wall taken along a direction parallel to the longitudinal axis of the arterial wall after the sheath and laser catheter are shown in FIG.

[0307] Fig.27A and Fig.27B It is a method of using a sheath and laser catheter to remove the limited vessel occlusion and treat the remaining portion of the vessel occlusion within the intima;

[0308] Fig.28A is along the line parallel to Fig.26A The arterial wall depicted in FIG. 1 is similar to a longitudinal cross-sectional view of a healthy arterial wall taken in a direction along the longitudinal axis of the arterial wall;

[0309] Fig.28B is a longitudinal cross-sectional view of an arterial wall taken along a direction parallel to the longitudinal axis of the arterial wall, wherein the media portion of the blood vessel is calcified;

[0310] Fig.28Cis a longitudinal cross-sectional view of the arterial wall taken along a direction parallel to a longitudinal axis of the arterial wall, wherein the sheath and the laser catheter are positioned adjacent to a portion of the arterial wall including a calcified tunica media portion of the vessel;

[0311] Fig.29 It is a method of treating the calcified media portion of a blood vessel using a sheath and laser catheter;

[0312] Fig.30 is a kit including a laser catheter assembly and an outer sheath assembly;

[0313] Fig. 30A yes Fig.30 an enlarged view of a distal portion of the laser catheter assembly and the outer sheath assembly within line 30A-30A, wherein the laser catheter assembly extends beyond the distal end of the outer sheath assembly, and wherein, for clarity of illustration of the drawing, portions of the outer sheath assembly are illustrated in a translucent material;

[0314] Fig. 30B It is taken along line BB Fig. 30A an enlarged longitudinal cross-sectional view of a distal portion of a laser catheter assembly and an outer sheath assembly depicted in , wherein the laser catheter assembly is disposed within the outer sheath assembly and extends beyond a distal end of the outer sheath assembly;

[0315] Fig. 30B 'yes Fig. 30A an enlarged longitudinal cross-sectional view of a distal portion of a laser catheter assembly and an outer sheath assembly depicted in , wherein the laser catheter assembly is disposed within the outer sheath and the distal end of the laser catheter assembly is proximate to the distal end of the outer sheath assembly;

[0316] Fig.31 yes Fig.30 The outer jacket assembly depicted in;

[0317] Fig.31A yes Fig.31 an enlarged view of a distal portion of the outer sheath assembly within line 31A-31A of FIG. 1 , wherein portions of the outer sheath assembly are illustrated in translucent material for clarity of the drawings;

[0318] Fig.31B It is taken along line BB Fig.31A an enlarged longitudinal cross-sectional view of a distal portion of the outer sheath assembly depicted in;

[0319] Fig.31C yes Fig.31B an enlarged longitudinal cross-sectional view of a distal portion of the outer sheath assembly within line 31C-31C;

[0320] Fig.31C 'yes Fig.31BAn alternative embodiment of an enlarged longitudinal cross-sectional view of a distal portion of the outer sheath assembly depicted in;

[0321] Fig.32 yes Fig.30 The laser catheter assembly depicted in;

[0322] Fig.32A yes Fig.32 An enlarged view of the distal portion of the laser catheter assembly within line 32A-32A;

[0323] Fig.33 is a flow chart illustrating steps of a method of using a kit including a laser catheter assembly and an outer sheath assembly;

[0324] Fig.34A is an enlarged view of a distal portion of another kit including an alternative embodiment of a laser catheter assembly and an outer sheath assembly, wherein the laser catheter assembly is disposed within the outer sheath assembly and proximate a distal end of the outer sheath assembly;

[0325] Fig.34B yes Fig.34A an enlarged view of a distal portion of the kit in which the laser catheter assembly is disposed within the outer sheath and extends beyond the distal end of the outer sheath assembly;

[0326] Fig.35 is an enlarged view of a distal portion of another kit including an alternative embodiment of a laser catheter assembly and an outer sheath assembly, wherein the laser catheter assembly is disposed within the outer sheath and proximate a distal end of the outer sheath assembly;

[0327] Fig.36A is an enlarged view of a distal portion of another kit including an alternative embodiment of a laser catheter assembly and an outer sheath assembly, wherein the laser catheter assembly is disposed within the outer sheath assembly and proximate a distal end of the outer sheath assembly;

[0328] Fig.36B yes Fig.36A An enlarged view of the distal portion of the kit in FIG. 1, wherein the laser catheter assembly is disposed within the outer sheath assembly at a position greater than that at Fig.36A The middle laser catheter assembly is positioned further within the outer sheath assembly but closer to the distal end of the outer sheath assembly;

[0329] Fig.37A is an enlarged view of a distal portion of another kit including an alternative embodiment of a laser catheter assembly and an outer sheath assembly, wherein the laser catheter assembly is disposed within the outer sheath and proximate a distal end of the outer sheath assembly;

[0330] Fig.37B yes Fig.37Aan enlarged view of a distal portion of the kit in which the laser catheter assembly is disposed within the outer sheath assembly and extends beyond the distal end of the outer sheath assembly;

[0331] Fig.38 is an enlarged view of a flat wire disposed within one or more embodiments of an outer jacket assembly;

[0332] Fig.39 is an outer sheath for a kit that also includes a laser catheter assembly;

[0333] Fig.39A It is along Fig.39 An enlarged longitudinal cross-sectional view of the distal portion of the outer sheath taken along line 39A-39A;

[0334] FIG. 40 is a diagram showing Fig.39 An enlarged partial exploded view of the various layers of the outer jacket;

[0335] Fig.41 is a front view of a laser catheter system or kit according to one embodiment of the present disclosure, the laser catheter system or kit including a laser catheter radially disposed within a handle and a sheath;

[0336] Fig.42 yes Fig.41 A schematic diagram of a treatment mode selection system of a laser catheter system;

[0337] Fig.43 is a front view of a laser catheter system or kit in a first configuration according to one embodiment of the present disclosure, the system comprising a laser catheter radially disposed within a handle and a sheath;

[0338] Fig.44 Is in the first configuration Fig.43 A perspective view of a laser catheter system;

[0339] Fig.45 It is in the second configuration Fig.43 A front view of a laser catheter system;

[0340] Fig.46 It is in the second configuration Fig.43 A perspective view of a laser catheter system. DETAILED DESCRIPTION

[0341] The present disclosure relates generally to the use of medical devices in treating vascular conditions. In particular, the present disclosure provides materials and methods for using laser-induced pressure waves to disrupt vascular obstructions and deliver therapeutic agents to the obstruction area.

[0342] refer to Figure 1, depicting an exemplary ablation system 100 of the present disclosure. The ablation system 100 includes a laser device 130 coupled to a laser controller 175. The controller 175 includes one or more computing devices programmed to control the laser 130. The controller 175 may be internal or external to the laser device 130 (e.g., a laser generator). The laser device 130 may include an excimer laser or another suitable laser. In some embodiments, the laser 130 generates light in the ultraviolet frequency range. In one embodiment, the laser 130 generates light energy in pulsed form.

[0343] The laser 130 is connected to the proximal end of the laser energy delivery system 120 (e.g., a laser catheter 170) via a coupling 140. The laser catheter 170 includes one or more light energy transmission devices that receive laser energy from the laser 130 and transmit the received laser energy from a first proximal end 124 of the laser energy catheter 170 toward a second distal end 126 of the laser catheter 170. The distal end of the catheter 170 can be inserted into a blood vessel or tissue of the human body 110. In some embodiments, the system 100 uses a plurality of light guides as light energy transmission devices (e.g., optical fibers) to guide the laser light from the laser 130 through the catheter 170 to a target area of ​​the human body 110.

[0344] An exemplary laser catheter device or assembly may include a laser catheter and / or a laser sheath. An example of a laser catheter or laser sheath is sold by Spectranetics under the trade name ELCA TM and Turbo Elite TM (they are used in coronary intervention or peripheral intervention, respectively, for example, to recanalize occluded arteries, change lesion morphology, and facilitate stent placement) and SLSII TM and GlideLight TM (It is used to remove surgically implanted leads.) The working (distal) end of the laser catheter typically has multiple laser emitters that emit energy and ablate the target tissue. The opposite (proximal) end of the laser catheter typically has a fiber optic coupling 140 and an optional strain relief member 124. The fiber optic coupling 140 is connected to a laser system or generator 130. An example of one such laser system is the CVX-300 Excimer Laser System, also sold by Spectranetics.

[0345] Figure 1The laser controller 175 includes a non-transitory computer readable medium (e.g., memory 204) that includes instructions that, when executed, cause one or more processors 200 to control the laser 130 and / or other components of the ablation system 100. The controller 175 includes one or more input devices 206 to receive input from an operator. Exemplary input devices include keys, buttons, touch screens, dials, switches, mice, and trackballs that provide user control of the laser 130. The controller 175 also includes one or more output devices to provide feedback or information to the operator. Exemplary output devices include displays, lights, and audio devices that provide user feedback or information.

[0346] The laser source of the laser 130 can be operatively coupled to a laser controller 175. The laser source can be operable to generate a laser signal or laser beam and provide the laser signal to the person through the fiber optic bundle of the catheter 170. The fiber optic bundle serves as a delivery device for delivering the laser signal to a target area of ​​the person 110.

[0347] Figure 1 A catheter 170 is depicted entering a human leg (preferably via the femoral artery). As discussed above, it may be desirable to treat either CAD or PAD. After entering the femoral artery, if CAD is intended to be treated with catheter 170, catheter 170 is guided through the patient's vasculature and to the coronary arteries. Alternatively, if PAD is intended to be treated with catheter 170, catheter 170 is guided through the patient's vasculature and to a peripheral artery (e.g., the vasculature below the knee, particularly in the patient's leg and / or foot). Unlike a balloon catheter, the catheter 170 of the present disclosure is able to more easily navigate and access smaller sized vasculature because the overall diameter of the sheath is smaller than that of a balloon catheter, thereby allowing the catheter 170 of the present disclosure to more easily treat PAD. That is, the increased size of the balloon of an electrically induced shock wave balloon catheter and / or a typical dilation balloon catheter (compared to catheter 170 of the present disclosure) may prevent or increase the difficulty of a balloon-type catheter from entering, penetrating, and / or treating peripheral vasculature (e.g., vasculature in the leg and / or foot below the knee).

[0348] refer to Figure 2A , Figure 2B , Figure 2C and Figure 2D, depicting an embodiment of a catheter 170 of the present disclosure. The catheter 170 of the present disclosure may include an outer sheath 182, an inner sheath 184, one or more optical fibers 186, and a tip 180. The outer sheath 182, the inner sheath 184, and the one or more optical fibers 186 generally span the length of the catheter 170, and each of them has a proximal end and a distal end. The inner sheath 184 is concentrically and / or radially disposed within the outer sheath 182, and the one or more optical fibers 186 are concentrically and / or radially disposed within the inner sheath 184.

[0349] like Figure 2C , at the distal end 126 of the catheter 170, the distal end of the outer sheath 182 is directly coupled to the tip 180. The inner sheath 184 and the one or more optical fibers 186 are not directly coupled to the tip 180. Instead, the inner sheath 184 and the one or more optical fibers 186 are disposed proximate to the tip 180, thereby forming a cavity between the outer sheath 182, the inner sheath 184, the one or more optical fibers 186, and the tip 180.

[0350] The inner sheath 184, which is composed of a biocompatible polymer, has one or more lumens 190 for delivering a liquid medium to the cavity, thereby partially or completely filling the cavity with the liquid medium. The liquid medium is introduced into the catheter 170 through one or more liquid medium ports (not shown) that are fluidly connected to the one or more lumens 190 in the inner sheath 184 and are arranged around the outer sheath 182. The liquid medium port can also be used as a unit for removing the liquid medium from the catheter 170.

[0351] The liquid medium is configured to absorb light energy, thereby generating a laser-induced pressure wave in the liquid medium. The laser-induced pressure wave compresses the fluid around its origin, thereby generating a vapor bubble. As the laser-induced pressure wave propagates away from its origin, the fluid around the vapor bubble is displaced inward, causing the vapor bubble to collapse and a cavitation event to occur. The vapor bubble and subsequent (one or more) cavitation events are byproducts of the laser-induced pressure wave. And the subsequent (one or more) cavitation events generate additional resulting pressure waves, which are sent to the tip 180 and / or the outer sheath 182 to disrupt the vascular occlusion.

[0352] The liquid medium can include a contrast agent (including, for example, an iodine-containing contrast agent or a gadolinium contrast agent) and a contrast solution containing (one or more) dyes and / or (one or more) particles. In addition, any liquid medium can be used as long as the liquid medium is coupled to a light source, such as a transmitter coupled to one or more optical fibers, which emits light of a suitable wavelength so that the liquid absorbs the light and generates laser-induced pressure waves, vapor bubbles, and cavitation events, which generate additional pressure waves generated thereby. In some cases, the liquid medium can be a contrast agent (e.g., an iodine-containing contrast agent or a gadolinium contrast agent) and / or the liquid medium can be a contrast solution containing a biocompatible fluid (e.g., saline) (wherein (one or more) contrast dyes or (one or more) particles are mixed in various concentrations).

[0353] As mentioned above, one or more optical fibers 186 are disposed within the inner sheath 184, extending from the proximal portion of the inner sheath 184 to the distal end of the inner sheath 184 and into the cavity. The proximal end of the one or more optical fibers is coupled to the laser generator 130. The (one or more) distal ends of the one or more optical fibers 186 are proximal to the distal end of the inner sheath 184, at the distal end of the inner sheath 184, or away from the distal end of the inner sheath 184. Again, one or more emitters are disposed at the distal end of the one or more optical fibers 186. The (one or more) emitters are in direct contact with the liquid medium, so that when laser energy is emitted from the (one or more) emitters, the liquid medium absorbs the emitted light, which in turn generates laser-induced pressure waves and generates vapor bubbles and cavitation events, thereby generating additional pressure waves.

[0354] In order to treat an object with a vascular occlusion, the tip 180 of the catheter 170 is positioned adjacent to the vascular occlusion. When the laser system 130 is activated, light energy travels through one or more optical fibers until the light energy is released from the transmitter. When the liquid medium absorbs the light energy, a laser-induced pressure wave is generated. In addition, the liquid medium rapidly shifts outward and inward, thereby generating vapor bubbles. The energy generated by the laser-induced pressure wave is captured in the cavity and converted into mechanical energy via the moving tip 180 and / or transmitted to the vascular occlusion through the tip 180. The energy generated by the laser-induced pressure wave is transmitted to the vascular occlusion sufficient to destroy the vascular occlusion, particularly the calcified and / or fibrous (e.g., calcium deposit) portion of the complete occlusion. It is expected that the mechanical energy generated by the laser-induced pressure wave at the tip 180 and the resulting fluid displacement are transmitted to the occlusion. Thus, when the energy generated by the laser-induced pressure waves is captured within the cavity, the forces generated by the laser-induced pressure waves are expected to propagate longitudinally, including in a forward (i.e., parallel to the vessel) direction, thereby increasing the ability of the tip to disrupt, destroy, and / or penetrate a vascular occlusion. That is, as the laser-induced pressure waves are generated, the tip 180 of the catheter rapidly moves forward and backward (translates) toward and away from the occlusion, respectively. Pressure waves generated in this manner can also be used to increase compliance of a vessel prior to performing another procedure (e.g., conventional balloon angioplasty or drug-eluting balloon treatment).

[0355] In order to facilitate the conversion of the force generated by the laser-induced pressure wave into the direction of movement of the tip 180 in the forward / backward longitudinal direction, the outer sheath 182 is not only flexible, but the outer sheath 182 also has the ability to expand and contract in the longitudinal direction. An example of such an outer sheath 182 includes a slotted or laser-cut hypotube constructed of a biocompatible material (e.g., stainless steel or a biocompatible polymer). The hypotube has spring-like properties that enable it to expand and contract in the longitudinal direction. Specifically, the slotted or laser-cut pattern in the hypotube enables it to expand and contract. Another example of the outer sheath 182 may include one or more spirally wound wires to form a coiled sheath, which also has the ability to expand and contract in the longitudinal direction.

[0356] To further facilitate movement of the tip 180 in the longitudinal direction, it may be desirable to include a shield 188 disposed axially between the distal end of the inner sheath 184 and the proximal end of the tip 180 and radially between the one or more optical fibers 186 and the outer sheath 182. Figure 2CAs shown, the shield 188, which is depicted as a generally cylindrical tube, can increase the resistance of the laser-induced pressure waves in the radial direction, thereby reducing the ability of the laser-induced pressure waves to travel radially toward the outer sheath 182, and can concentrate the energy generated by the laser-induced pressure waves in the longitudinal direction. The configuration of the cylindrical shield 188 can allow for reduced resistance in the longitudinal direction compared to the radial direction, thereby potentially increasing the energy generated by the laser-induced pressure waves in the longitudinal direction and improving the ability of the tip to translate in the forward / backward direction. The cylindrical shield 188 can also be configured such that its diameter is larger at its proximal end than its distal end, thereby potentially concentrating the laser-induced pressure waves toward the center of the tip 180. Alternatively, the cylindrical shield 188 can be configured such that its diameter is smaller at its proximal end than its distal end, thereby potentially concentrating the laser-induced pressure waves toward the center of the tip 180.

[0357] exist Figure 2B and Figure 2C The tip 180 shown in FIG. 1 has a closed configuration. However, the present disclosure contemplates that the tip can also have an open configuration. Figure 2B and Figure 2C The tip 180 is shown as a separate component from the distal end 126 of the laser catheter 170 and is coupled to the distal end 126. However, the present disclosure contemplates that the tip can also be integral with the distal end 126 of the laser catheter 170. As the tip is advanced distally, Figure 2B and Figure 2C The tip 180 shown in FIG. 1 generally tapers from a larger diameter to a smaller diameter. Figure 2B and Figure 2C The shape of the tip 180 shown in FIG. 1 is generally conical. In addition, the tip 180 has a completely solid configuration, but it can also be partially solid. It is desirable that the tip be composed of a biocompatible material (e.g., stainless steel or a biopolymer).

[0358] Similar to Figure 2B and Figure 2C The tip 180 shown in the figure, Figure 2B 'and Figure 2C The tip 180 in ' has a completely solid configuration, but in Figure 2B 'and Figure 2C The tip 180' in the ' may alternatively have a partially solid configuration. Figure 2B and Figure 2C The tip 180 shown in FIG. Figure 2B 'and Figure 2C The tip 180' in the ' can have a generally convex spherical shape. Although the present disclosure only depicts Figure 2B and Figure 2C The generally conical tip 180 and Figure 2B 'and Figure 2C In addition to the generally spherical tip 180' in the ', the tip may also have alternative shapes, such as a flat shape, a concave shape, a triangular shape, a pyramidal shape, a chisel shape, etc.

[0359] refer to Figure 3 , depicting an alternative embodiment of a catheter of the present disclosure. Figure 2B 'and Figure 2C 'Tip 180', Figure 3 The tip 380 in the embodiment has a generally spherical shape. However, unlike the solid configuration Figure 2B 'and Figure 2C The tip of '180' is different, Figure 3 The tip 380 in the embodiment has a hollow or shell-type configuration. Moreover, in this embodiment and other embodiments, the tip 280 can be press-fit and / or welded to the outer sheath 182".

[0360] exist Figure 2B and Figure 2C as well as Figure 2B 'and Figure 2C 'as well as Figure 3 The embodiment of the catheter depicted in FIG. 1 includes a protective shield 188. However, it may not be necessary to include a protective shield within the catheter. For example, Figure 4 An embodiment of the catheter 170 is illustrated in which the distal tip of the catheter omits a protective cover. As depicted in this figure, in the case of omitting the protective cover, it is desirable that the outer sheath 182"' includes a solid portion between the distal end of the inner sheath 184"' and the proximal end of the tip 480, thereby forming a non-porous cavity.

[0361] refer to Figure 5 , Figure 5A and Figure 5A ', the distal end 526 of the catheter may include a tip 580 that includes a non-metallic component instead of a solid or hollow metal (eg, stainless steel) structure. Figure 5A , the catheter includes an outer sheath 582, an inner sheath 584 disposed concentrically and / or radially within the outer sheath 582, and one or more optical fibers 586 disposed concentrically and / or radially within the inner sheath 584. The distal end of the outer sheath 582 is directly coupled (via press fit and / or welding) to the tip 580. The inner sheath 584 and the one or more optical fibers 586 are not directly coupled to the tip 580. Instead, the inner sheath 584 and the one or more optical fibers 586 are disposed proximate to the tip 580, thereby forming a cavity between the outer sheath 582, the inner sheath 584, the one or more optical fibers 586, and the tip 580.

[0362] Continue to refer Figure 5AThe catheter may include a protective cover 588 disposed axially between the distal end of the inner sheath 584 and the proximal end of the tip 580, and radially between the one or more optical fibers 586 and the outer sheath 582. Figure 5A As illustrated in , the shield 588, depicted as a generally cylindrical tube, increases the resistance of the laser-induced pressure wave in the radial direction, thereby reducing the ability of the laser-induced pressure wave to travel radially toward the outer sheath 582. The configuration of the cylindrical shield 588 allows for reduced resistance in the longitudinal direction as compared to the radial direction, thereby improving the ability of the tip to translate in the forward / rearward direction. The cylindrical shield 588 can also be configured such that its diameter is larger (or smaller) at its proximal end than at its distal end, thereby potentially tapering in the proximal or distal direction and concentrating the laser-induced pressure wave toward the center of the tip 580. The shield 588 can also be used to form a sealed cavity at the distal end of the catheter, thereby preventing liquid media from leaking through the outer sheath 582 because portions of the shield overlap portions of the outer sheath 582, which can be porous. Reference Figure 5A ', if the protective cover is omitted, it may be desirable for the outer sheath 582 to include a solid or imperforate sheath portion between the distal end of the inner sheath 584 and the proximal end of the tip 580, thereby forming an imperforate cavity.

[0363] The inner sheath also includes one or more lumens for the passage of liquid medium into the cavity. The (one or more) distal ends of the one or more optical fibers 586 are near the distal end of the inner sheath 584, at the distal end of the inner sheath 584, or away from the distal end of the inner sheath 584. Again, one or more emitters are disposed at the distal end of the one or more optical fibers 586. The (one or more) emitters are in direct contact with the liquid medium, so that when laser energy is emitted from the (one or more) emitters, the liquid medium absorbs the emitted light, which in turn generates laser-induced pressure waves and generates pressure waves and / or vapor bubbles, thereby generating additional pressure waves and / or one or more cavitation events.

[0364] like Figure 5A and Figure 5A ', the tip 580 has a rounded configuration, forming a collar for the distal end of the outer sheath 582. The tip 580 also includes a flexible membrane 585 at its distal end. For example, the membrane 585 can be constructed of polyester film and can be bonded to the distal end of the tip 580 in an orientation perpendicular to the longitudinal axis. In addition, the membrane can be compliant so as to be shaped relative to and engage the shape of the calcified cap, total occlusion, or lesion.

[0365] In order to treat an object with vascular occlusion, the distal end (particularly the tip 580) of the catheter is positioned adjacent to the vascular occlusion and the membrane is adjacent to the vascular occlusion. The liquid medium is delivered to the cavity from one or more lumens in the inner sheath 584 through one or more liquid medium ports or between the outer sheath and the inner sheath or through a laser catheter. When the laser system 130 is activated, light energy travels through one or more optical fibers until the light energy is released from the (one or more) emitters at the ends of the one or more optical fibers. As the liquid medium absorbs the light energy, a laser-induced pressure wave is formed, and the liquid medium rapidly shifts outward and then inward, thereby generating vapor bubbles. The energy generated by the laser-induced pressure wave and the vapor bubble is captured in a closed system provided by the cavity and is transmitted to the vascular occlusion through the flexible membrane 585 of the tip 580. The energy generated by the laser-induced pressure wave is transmitted to the vascular occlusion enough to destroy calcium deposits and / or fibrous tissue in the vascular occlusion. The force generated by the laser-induced pressure wave can propagate forward longitudinally (i.e., parallel to the blood vessel). Laser-induced pressure waves generated in this manner can also be used to increase the compliance of a blood vessel prior to performing another procedure (eg, conventional balloon angioplasty).

[0366] The above article about Figure 1-5 The embodiment of the catheter discussed is a one-piece catheter such that the optical fiber(s) are integrated into the design of a single catheter. However, the present disclosure also encompasses two-piece catheter systems or kits. Figure 6 and Fig. 6A, the catheter system may include a laser catheter 650 and a tubular sheath 682 having a lumen therein and / or through it and configured to surround the laser catheter 650. Depending on whether the tubular sheath 682 has an open or closed distal end, the tubular sheath 682 may be coupled to the tip 680. A conventional laser catheter 650 including one or more optical fibers 686 can be inserted into the lumen, allowing a clinician to translate the laser catheter 650 within the sheath 682 along the longitudinal axis of the sheath in a forward (distal) and backward (proximal) direction. For purposes of the present disclosure, the laser catheter 650 may include one or more lumens 690 to deliver a liquid medium from one or more liquid medium ports. When the laser system 130 is activated, light energy travels through the one or more optical fibers until the light energy is released from the emitter (one or more) at the end of the one or more optical fibers. As the liquid medium absorbs the light energy, a laser-induced pressure wave is formed, and the liquid medium rapidly displaces outward and then inward, thereby forming a vapor bubble. The energy generated by the laser-induced pressure wave and the vapor bubble is captured in the closed system provided by the cavity and transmitted to the vascular occlusion through the walls of the sheath 682 and / or the tip 680. The energy generated by the laser-induced pressure wave is transmitted to the vascular occlusion sufficient to destroy calcium deposits and / or fibrous tissue within the vascular occlusion. Depending on the position of the (one or more) transmitters within the lumen of the sheath 682, a smaller or larger cavity is created between the distal end of the laser catheter 650, the tip 680, and the sheath 682. It is desirable that the distal end of the laser catheter 650 be positioned close to the tip 680 or translated inside the outer sheath to form a cavity with which the force generated by the laser-induced pressure wave can be propagated radially from multiple axial positions along the longitudinal axis of the outer sheath.

[0367] Depending on the location of the transmitter(s) within the lumen of the sheath 682, the force generated by the laser-induced pressure wave can propagate radially, including forward (i.e., parallel to the vessel), upward (i.e., perpendicular to the vessel), and backward (i.e., proximally). Figure 6 As shown, when the laser catheter 650 is positioned near the tip 680, the laser-induced pressure waves can propagate radially from the sheath 650 and forward from the tip (ie, parallel to the blood vessel). Fig. 6A As shown, Figure 6Compared to the position of the laser catheter 650 in the sheath 682, the laser-induced pressure waves can propagate radially from the sheath 650 in a forward (i.e., parallel to the vessel), upward (i.e., perpendicular to the vessel), and / or backward (i.e., proximally) direction as the laser catheter 650 is translated proximally along the longitudinal axis of the lumen within the sheath 682. Thus, after the tip 680 of the sheath 682 destroys calcification and / or fibrous tissue within the vascular occlusion, the sheath 682 can penetrate and traverse the occlusion, and the laser catheter 650 can slide in a proximal and / or distal direction to destroy additional occluded portions.

[0368] refer to Figure 6B , the laser catheter 650' may also include a deflector 692 attached to its distal end via at least one (and possibly multiple) support members 696, 698. The purpose of the deflector is to direct the laser-induced pressure waves generated by the interaction between the liquid medium and the emitters from one or more optical fibers 686' occurring in the liquid medium in a particular direction. In this figure, the deflector 692 is positioned along the longitudinal axis of the laser catheter 650', but the shape of the deflector 692 is oriented in a radial direction perpendicular to the longitudinal axis of the laser catheter 650'. Therefore, since the laser-induced pressure waves are generated by the interaction between the liquid medium and the laser energy emitted from the emitters, the deflector 692 can guide the laser-induced pressure waves in a radial direction (e.g., 360 degrees around the circumference of the laser catheter 650' and / or the sheath 682). The deflector 692 can be constructed of a non-metallic material or a metallic material (e.g., stainless steel). The deflector 692 can also have a solid or porous construction. Regardless of the configuration of the deflector 692 , the deflector 692 should direct the laser-induced pressure waves in a particular direction that is in a favorable direction, such as toward a vessel occlusion that may be located on one side of the sheath 682 .

[0369] Various shapes and configurations of deflectors are contemplated. For example, reference Figure 7 , the laser catheter 750 may include a deflector 792 disposed away from one or more optical fibers 786 of the laser catheter 750, and may be configured to direct the laser-induced pressure waves in a radial direction less than 360 degrees (e.g., 5 degrees, 10 degrees, 15 degrees, ..., 30 degrees, ..., 45 degrees, ..., 60 degrees, ..., 75 degrees, ..., 90 degrees, ..., 105 degrees, ..., 120 degrees, ..., 135 degrees, ..., 150 degrees, ..., 165 degrees, ..., 180 degrees, etc.) around the circumference of the laser catheter 750 and / or the sheath 792. For example, the deflector 792 may have a solid construction with an opening facing a particular direction. Furthermore, the shape and size of the opening within the deflector may determine the direction in which the laser-induced pressure waves may travel. As Figure 7As shown, the laser catheter 750 can be axially translated within the sheath 782 along the longitudinal axis of the laser catheter 750 and / or the sheath 782. The present disclosure also contemplates that the laser catheter 750 can be rotated within the sheath 782 about the longitudinal axis of the laser catheter 750 and / or the sheath 782 to direct the laser-induced pressure waves not only along the longitudinal direction but also about the radial direction.

[0370] The energy delivered to the vascular occlusion and / or the vessel wall by generating laser-induced pressure waves is sufficient to disrupt intraluminal calcium as well as calcium within the vascular tissue, the vascular occlusion (e.g., calcium deposits). The forces generated by the laser-induced pressure waves can propagate in radial directions, including forward (i.e., parallel to the vessel), upward (i.e., perpendicular to the vessel), and backward (i.e., proximally). The laser-induced pressure waves generated in this manner can also be used to increase compliance of the vessel prior to performing another procedure (e.g., conventional balloon angioplasty, drug-eluting balloon angioplasty, and / or stent placement). That is, the disruption of intraluminal calcium and / or calcium within the vascular tissue and / or calcium within the vascular occlusion by laser-induced pressure waves can improve the ability of the vasculature to absorb drugs, particularly when such drugs are used in conjunction with a drug-eluting balloon.

[0371] Reference again Figure 6 and Fig. 6A , the catheter system includes a laser catheter 650 that is disposed within a sheath 682 and proximate to a tip 680, thereby allowing laser-induced pressure waves to propagate radially from the sheath 650 and propagate forwardly (i.e., parallel to the blood vessel) from the tip. To ensure that the laser catheter 650 is proximate to the tip 680 to create a cavity between the distal end of the laser catheter 650, the sheath 682, and the tip 680, the laser catheter 650 and / or the sheath 682 may include a stopper and / or a matingly engageable spring and / or a recess to maintain the laser catheter 650 at a desired distance proximate to the tip 680. The stopper and / or the matingly engageable spring and / or recess should also be configured to allow a clinician to easily separate the laser catheter 650 from the sheath 682 so that the laser catheter 650 can translate in the sheath 682.

[0372] refer to Figure 8 and 8A If it is not desired to slide the laser catheter within the sheath, the laser system may include a laser catheter 850 that can be engaged with and removed from a cap 870. The cap 870 may include a relatively short sheath attached to a tip 880 and an optional protective shield 888. Similar to Figure 6 and Fig. 6A An embodiment of Figure 8 and Fig. 8AEmbodiments may include matingly engageable springs and / or recesses configured to allow a clinician to easily engage and disengage the laser catheter 850 from the cap 870 .

[0373] The laser catheter 850 may include one or more layers of optical fibers 854 arranged at the periphery of an optional internal lumen or near an optional internal lumen, which may be used to insert a guidewire and / or a liquid medium. Alternatively, the laser catheter 850 may include one or more additional lumens for independent purposes. Again, the proximal end of the laser catheter is coupled to a laser generator. One or more layers of optical fibers 854 are contained in a flexible tubular catheter and terminate at a distal emitter at a distal tip 856 of the laser catheter 850. The liquid medium travels through the lumen 852 until it is introduced into the cavity from one or more liquid medium ports (not shown). The emitter is in direct contact with the liquid medium so that when laser energy is emitted from the proximal emitter, the liquid medium absorbs the emitted light, which in turn generates laser-induced pressure waves and / or vapor bubbles to generate additional pressure waves, thereby converting the laser-induced pressure waves into mechanical energy via moving the tip 880 and / or transferring the pressure to the vascular occlusion through the tip 880.

[0374] refer to Fig. 9 The present disclosure includes a method 900 for treating a subject having a vascular occlusion using embodiments of the catheter assemblies and systems described herein. Fig. 9 is not shown, but it is expected that Fig. 9 Prior to the method described in , at least a portion of a vascular occlusion in a blood vessel of a subject is treated. Such treatment may include, for example, mechanically cutting and / or ablating at least a portion of the vascular occlusion (via application of laser energy, microwave energy, radiofrequency energy, etc.). Fig. 9Method 900 in starts from frame 910, wherein, the embodiment of catheter assembly described herein or system is positioned in the vascular system of object.At frame 920, (for example, by making distal tip advance through vascular system) the distal tip of catheter assembly or system is positioned as the occlusion in adjacent vascular system.At frame 930, liquid medium (for example, any liquid medium) such as described herein is introduced into the distal tip of catheter assembly or system and / or the cavity (for example, introducing via the space between the laser catheter carried in outer sheath and sheath) near the distal tip of catheter assembly or system.At frame 940, laser energy is delivered to one or more transmitters (for example, optical fiber) positioned in the cavity, so that the pulse of light energy is sent to the liquid medium.As described herein, light energy pulse is sent to the liquid medium and can produce laser-induced pressure wave and / or steam bubble and extra pressure wave produced thereby to destroy vascular occlusion.At frame 950, when laser energy is delivered to one or more transmitters and liquid medium, catheter (and transmitter) can translate relative to sheath. The catheter (and transmitter) or the entire catheter assembly can be repositioned within the vascular system. Method 900 also includes ending the process when the desired treatment result is achieved, or repeating any of blocks 910 to 960 as may be necessary for treating a subject with a vascular occlusion. Fig. 9 Not shown, but after performing method 900, it may be desirable to use a drug eluting (coated) balloon (DEB or DCB) catheter to deliver the drug to the remnants of the vascular occlusion. Disrupting the vascular occlusion with laser-induced pressure waves prior to utilizing a DEB may increase the effectiveness of the drug applied to the vascular occlusion because the laser-induced pressure waves may disrupt intraluminal calcium as well as calcium within the vascular tissue, calcium within the obstructed or restricted portion of the vessel (e.g., calcium deposits and / or media calcium), thereby creating a pathway for the drug to enter the vasculature and / or the intraluminal and tissue portions of the vascular occlusion.

[0375] refer to Fig.10 , depicting a laser catheter 1010 and a guidewire 1020 extending through the lumen of the catheter 1010. The laser catheter 1010 includes one or more layers of multiple optical fibers 1016 extending through the lumen and surrounding the lumen, and a sheath 1012 surrounding the one or more layers of optical fibers 1016. The distal end of the laser catheter 1010 may include a metal band 1014 that increases the strength of the distal end and provides a radiopaque marker. Examples of laser catheters 1010 or laser sheaths are available from Spectranetics under the trade name ELCA TM and Turbo Elite TM (each of which is used during coronary intervention or catheterization, e.g., to recanalize occluded arteries, change lesion morphology, and facilitate stent placement) and SLSII TM and GlideLightTM (which is used to remove surgically implanted leads) is sold. Again, as Fig.10 As shown, the working (distal) end of the laser catheter typically has multiple laser emitters that emit energy and ablate the target tissue. The opposite (proximal) end of the laser catheter, not shown, typically has a fiber optic coupling connected to a laser system or generator. One such example of a laser system is the CVX-300 excimer laser system, which is also sold by Spectranetics.

[0376] Again, the present disclosure contemplates a two-piece catheter system or kit. Fig.11A , the system 1110 may include a laser catheter 1010 radially disposed within a sheath 1140. The system may optionally include a guidewire 1130 disposed within the lumen of the laser catheter 1010. As described above, a liquid medium is introduced into the sheath 1120 distal to the laser catheter 1010 (particularly distal to the optical fiber / emitter of the laser catheter 1010) such that when the laser is activated, the liquid absorbs the light and generates laser-induced pressure waves and / or vapor bubbles and additional pressure waves and / or cavitation events generated thereby. Although the liquid is not shown in this figure, the liquid may be introduced through a lumen in the laser catheter 1010, a lumen in the sheath 1120, and / or a lumen or space between the laser catheter 1010 and the sheath 1120. Regardless of which of these locations are used, one or more liquid medium ports positioned at or toward the proximal end of the catheter system will be used.

[0377] refer to Fig.12 , depicts a representative flow chart of a method 1200 for removing a limited vascular occlusion using a laser catheter 1010 to ablate a portion of a vascular occlusion and / or using the laser catheter 1010 in combination with a sheath 1120 to generate laser-induced pressure waves in the presence of a liquid medium and disrupt portions of the vascular occlusion. The method 1200 may include a step 1205 of positioning a guidewire 1130 within a subject's vasculature 1140, a step 1210 of positioning the laser catheter 1010 over the guidewire 1130 within the vasculature, a step 1215 of positioning the sheath 1120 over the laser catheter 1010 within the vasculature, and a step 1220 of positioning the sheath 1120 and the laser catheter 1010 (and optionally the guidewire 1130) adjacent to a limited vascular occlusion 1150 within the subject's vasculature 1140. Again referring to Fig.11A , the sheath 1120 and the laser catheter 1010 are positioned to form a cavity adjacent to the vascular occlusion 1150 so as to collect the liquid medium distal to the laser catheter 1010 (particularly distal to the emitter / optical fiber of the laser catheter 1010).

[0378] Fig.11AThe distal end of the laser catheter 1010 is depicted proximate to the distal end of the sheath 1120. However, it is contemplated that the distal end of the laser catheter 1010 may be disposed at or distal to the distal end of the sheath 1120, as long as there is a liquid medium between the emitter / optical fiber of the laser catheter 1010 and the vessel occlusion 1150. The axial position of the laser catheter 1010 and the sheath 1120 is adjusted by translating either or both components relative to each other. In order to visualize the respective positions of the laser catheter 1010 and the sheath 1120 under fluoroscopy, the laser catheter 1010 and the sheath 1120 may include radiopaque markers at any corresponding positions along their lengths.

[0379] Continue to refer Fig.11A Once the sheath 1120 and laser catheter 1010 are positioned adjacent the vessel occlusion 1150, a liquid medium may be introduced into the distal end of the laser catheter, such as Fig.12 As described in step 1225 of . Continue to refer to Fig.12 Step 1230 includes: activating the laser in the presence of a liquid medium to generate a laser-induced pressure wave and destroying a portion of the vascular occlusion, particularly a calcified cap of the vascular occlusion. The laser catheter 1010 and sheath 1120 can be used to traverse the entire vascular occlusion 1150, such as Fig.12 Step 1240 (and optional Fig.12 If the laser catheter 1010 and sheath 1120 are used to destroy only a portion of the vascular occlusion 1150, the guidewire 1130 may penetrate and traverse the vascular occlusion 1150. For example, Fig. 11B A guidewire 1130 is depicted penetrating and traversing a vascular occlusion 1150 .

[0380] refer to Fig. 11C , assuming that the laser catheter 1010 and sheath 1120 are used to destroy only a portion of the vascular occlusion 1150', the laser catheter 1120 can be used to traverse the vascular occlusion 1150 without the sheath 1120. Fig.12 At step 1245 , when the laser catheter 1150 is passed over the guidewire 1130 through the vascular occlusion 1150 ′ while the sheath 1120 remains proximate to the vascular occlusion, the insertion of the liquid medium can be stopped and the laser catheter 1010 can be used to ablate the vascular occlusion.

[0381] Once the laser catheter 1010 has traversed the entire vessel occlusion, the opening created by the laser catheter 1010 should be large enough to translate the sheath 1120 distally and through the vessel occlusion. At this point, both the distal end of the sheath 1120 and the distal end of the laser catheter 1010 should be distal to the vessel occlusion. Fig.11D, the laser catheter 1010 is able to translate proximally while the sheath 1120 remains fixed within the vascular occlusion. When a liquid medium is introduced into the sheath 1120 in front of the laser catheter 1010, the laser can be activated to generate a laser-induced pressure wave in the presence of the liquid medium. At least a portion of the laser-induced pressure wave is directed radially, and as the laser catheter 1010 translates proximally within the sheath 1120, the laser-induced pressure wave is transmitted through the sheath 1120, thereby destroying the remaining portion of the vascular occlusion 1150'".

[0382] To ensure that the majority of the remaining portion of the vessel occlusion 1150'' is destroyed, and if desired, to destroy intraluminal calcium and / or vascular tissue layers (e.g., middle layers) and calcium within the vessel occlusion, the laser catheter 1010 can be repeatedly translated distally and proximally within the sheath 1120. As discussed above, destruction of the luminal layer and / or vascular tissue layers (e.g., middle layers) and the vessel occlusion can increase the ability of the vasculature to absorb drugs, particularly when such drugs are used with a drug eluting balloon. Furthermore, it is contemplated that in Fig.12 Laser catheter 1010 may be used independently to ablate occluded portions of a vessel, or laser catheter 1010 may be used in conjunction with sheath 1120 before, during, and / or after any step in the process outlined herein.

[0383] Figures 11A-11D A catheter system is shown having a sheath 1120 with an open distal end or tip 1124. Fig.13 , the sheath 1120' can have a fully or partially closed tip 1124. For example, if it is desired to pass a guidewire 1130 through the laser catheter 1010 and the sheath 1120', the tip 1124 will only be partially closed, but if it is not necessary to utilize a guidewire, the tip 1124 can be completely closed.

[0384] Similar to Figures 11A-11D , the laser catheter 1010 can translate distally and / or proximally within the sheath 1120'. To ensure that a cavity is maintained between the distal end of the laser catheter 1010 and the proximal end of the tip of the sheath 1120', the sheath 1120' can include one or more internal stops 1160. The shape of the tip 1124 can be configured similar to the tip 180 illustrated and described with respect to Figures 2-6, so that the catheter system 1110' including the tip 1124 of the laser catheter 1010 is configured so that the energy generated by the laser-induced pressure wave is captured within the cavity and the force generated by the laser-induced pressure wave propagates in a longitudinal direction, including in a forward (i.e., parallel to the vessel) direction, thereby improving the ability of the tip to disrupt, destroy and / or penetrate a vascular occlusion.

[0385] refer to Fig.14Aand Fig. 14B , the laser catheter system 1410 generally includes a laser catheter 1412, a guidewire 1414, a sheath 1416, and a handle 1418 that can translationally couple the laser catheter 1412 to the sheath 1416. The laser catheter 1412, the guidewire 1414, and the sheath 1416 can be similar to the components of the two-piece catheter system or kit described herein, for example. As a specific example, the laser catheter 1412, the guidewire 1414, and the sheath 1416 can be similar to the above combined Figures 11A-11D The laser catheter 1412 is disposed within the lumen of the sheath 1416 and the handle 1418, and the laser catheter 1412 includes a proximal coupling 1420 for coupling to the handle 1418. The guidewire 1414 is disposed within the lumen of the laser catheter 1412. The sheath 1416 includes a proximal coupling 1422 for coupling to the handle 1418.

[0386] The liquid medium is introduced into the sheath 1416 at the distal side of the laser catheter 1412 (particularly at the distal side of the optical fiber / emitter of the laser catheter 1412) so that when the laser is activated, the liquid absorbs the light and generates laser-induced pressure waves and / or vapor bubbles and pressure waves generated thereby. The liquid is introduced via the lumen or space between the laser catheter 1412 and the sheath 1416, and then receives the liquid from the proximal port 1424 coupled to the sheath 1416.

[0387] Reference now Fig.14A , Fig. 14B , Figures 15A-15G , the handle 1418 generally includes a base 1426 coupled to the sheath 1416 and a drive mechanism 1428 coupled to the laser catheter 1412. As described in further detail below, a portion of the drive mechanism 1428 is translatably coupled to the base 1426 to facilitate translation of the laser catheter 1412 within the lumen of the sheath 1416 (e.g., translation to Figures 11A-11D The drive mechanism 1428 can be translated to a proximal position relative to the base 1426 (see Figures 15A-15C ), relative to the distal position of the base 1426 (see Fig.15E and Fig.15F ) and countless intermediate positions in between (see Fig.15D and Figure 15G As a result, the laser catheter 1412 can translate to a corresponding position relative to the sheath 1416.

[0388] Reference now Figure 14A-17, the base 1426 includes an elongated hollow frame 1430 that is movably coupled to a drive mechanism 1428. The frame 1430 includes a proximal portion 1432, a middle portion 1434, and a distal portion 1436. The proximal portion 1432 defines a proximal channel 1438 for translatably receiving a shaft 1440 of the drive mechanism 1428 therein. Fig. 16B , Fig. 16C and Fig.17 , the proximal channel 1438 may include a first key feature that inhibits rotation of the shaft 1440 relative to the frame 1430 by coupling to a second key feature of the shaft 1440. For example, the second key feature of the shaft 1440 may be a non-circular cross-sectional area, and the first key feature of the proximal channel 1438 may be a cross-sectional area that is approximately the same as the cross-sectional area of ​​the shaft 1440 (that is, allowing sufficient clearance to allow relative longitudinal translation, but inhibiting relative rotation and lateral translation) or a cross-sectional area that is approximately the same as a portion of the cross-sectional area of ​​the shaft 1440. As a more specific example and as Fig. 16B , Fig. 16C and Fig.17 As shown, the shaft 1440 includes a rectangular cross-sectional shape having two opposing flat side surfaces 1442 and two opposing arcuate side surfaces 1444. The proximal channel 1438 includes a cross-sectional area that is approximately the same as a portion of the cross-sectional area of ​​the shaft 1440. In particular, the proximal channel 1438 is defined by four opposing flat side surfaces 1446 and two opposing arcuate side surfaces 1448. The flat side surfaces 1446 and the arcuate side surfaces 1448 engage the flat side surfaces 1442 and the arcuate side surfaces 1444 of the shaft 1440, respectively, thereby allowing relative longitudinal translation, but inhibiting relative rotation and lateral translation of the shaft 1440 relative to the frame 1430. In this example, the proximal channel 1438 is also defined by two additional opposing arcuate side surfaces 1449 extending between the flat side surfaces 1446. The arcuate side surface 1449 is disposed to be separated from the shaft 1440 to reduce sliding friction between the shaft 1440 and the frame 1430 .

[0389] Specific reference Fig.16A , Fig.16D and Fig.16E, the intermediate portion 1434 of the frame 1430 includes a first bearing portion 1450, a second bearing portion 1452, and an opening 1454 extending between the first bearing portion 1450 and the second bearing portion 1452 and aligned with the proximal channel 1438. Each of the first bearing portion 1450 and the second bearing portion 1452 includes a first bearing surface 1456 and a second bearing surface 1458. The first bearing surface 1456 and the second bearing surface 1458 rotatably support the control element 1460 of the drive mechanism 1428. Each of the first bearing portion 1450 and the second bearing portion 1452 also includes a clearance surface 1462 between the bearing surfaces 1456, 1458. The clearance surface 1462 is also disposed radially inwardly relative to the bearing surfaces 1456, 1458. The clearance surface 1462, together with the opening 1454, facilitates driving engagement of the control element 1460 with the shaft 1440, as described in further detail below. Within the opening 1454, each of the first bearing portion 1450 and the second bearing portion 1452 includes a guide surface 1464. The guide surface 1464 is translationally coupled to the shaft 1440 and inhibits rotation of the shaft 1440 within the frame 1430.

[0390] Brief reference Figures 15H-15J To facilitate assembly of the base 1426, each clearance surface 1462 can be integrally coupled with the first bearing surface 1456, 1458. After positioning the shaft 1440 within the frame 1430 and positioning the control element 1460 on the first bearing surface 1456, 1458 and the clearance surface 1462, each clearance surface 1462 can be coupled to the second bearing surface 1456, 1458 via, for example, a press fit, one or more adhesives, a snap connector (not shown), etc.

[0391] refer to Fig.16A , Fig.16F and Figure 16G , the distal portion 1436 of the frame 1430 can be similar to the proximal portion 1432 of the frame 1430. That is, the distal portion 1436 defines a distal channel 1466 aligned with the opening 1454, which is used to receive the shaft 1440 in a translatable manner. Fig.16F , Figure 16G and Fig.17And in a similar manner to the proximal channel 1438, the distal channel 1466 can include a first key feature that inhibits rotation of the shaft 1440 relative to the frame 1430 by coupling to a second key feature of the shaft 1440. For example, the second key feature of the shaft 1440 can be a non-circular cross-sectional area, and the first key feature of the distal channel 1466 can be a cross-sectional area that is substantially the same as the cross-sectional area of ​​the shaft 1440 or a cross-sectional area that is substantially the same as a portion of the cross-sectional area of ​​the shaft 1440. According to the specific examples described above and as Fig.16F , Figure 16G and Fig.17 As shown, the distal channel 1466 includes a cross-sectional area that is substantially the same as a portion of the cross-sectional area of ​​the shaft 1440. In particular, the distal channel 1466 is defined by four opposing flat side surfaces 1468 and two opposing arcuate side surfaces 1470. The flat side surfaces 1468 and the arcuate side surfaces 1470 are engaged with the flat side surfaces 1442 and the arcuate side surfaces 1444 of the shaft 1440, respectively, to allow relative longitudinal translation, but to inhibit relative rotation and lateral translation of the shaft 1440 relative to the frame 1430. In this example, the distal channel 1466 is also defined by two additional opposing arcuate side surfaces 1472 extending between the flat side surfaces 1468. The arcuate side surfaces 1472 are arranged to be separated from the shaft 1440 to reduce the sliding friction between the shaft 1440 and the frame 1430.

[0392] Reference again Figures 14A-16G , frame 1430 is coupled to a proximal cover 1476 at its proximal end (e.g., via a press fit, one or more adhesives, etc.). Proximal cover 1476 includes a proximal aperture 1478 (see Fig.15F and Figure 15G ), which is used to allow the laser catheter 1412 to extend into the frame 1430. The frame 1430 is coupled to a distal cap 1480 at its distal end (e.g., via a press fit, one or more adhesives, etc.). The distal cap 1480 includes a distal hole 1482 (see Fig.15F and Figure 15G ), which is used to allow the laser catheter 1412 to extend out of the frame 1430 and into the sheath 1416. The distal hole 1482 receives a tube 1484 (e.g., a hypotube 1484) extending into the shaft 1440 in a press-fit manner and receives the laser catheter 1412. The distal hole 1482 also receives a distal coupling 1486 in a press-fit manner, which is removably and sealingly coupled to the proximal coupling 1422 of the sheath 1416.

[0393] Reference now Fig.14A and Figures 15A-15J , the drive mechanism 1428 generally includes a shaft 1440 and a control element 1460. Figures 15F-15J, the shaft 1440 includes a shaft 1440 channel 1488 for allowing the laser catheter 1412 to extend through the shaft 1440 and for receiving the tube 1484. The shaft 1440 channel 1488 receives a proximal coupling 1490 that is removably and sealingly coupled to the proximal coupling 1420 of the laser catheter 1412 in a press-fit manner. In this way, movement of the control element 1460 relative to the base 1426 causes translation of the shaft 1440 within the base 1426, thereby causing translation of the laser catheter 1412 within the lumen of the sheath 1416.

[0394] The shaft 1440 passage 1488 also receives a seal 1492, such as an O-ring that can translationally engage the outer surface of the tube 1484. In this way, the seal 1492 inhibits liquid in the shaft 1440 passage 1488 (liquid received from the sheath 1416 via the distal coupling 1486 and the hypotube 1484) from leaving the shaft 1440 by flowing between the shaft 1440 and the tube 1484.

[0395] As briefly described above, the control element 1460 is rotatably supported by the frame 1430. The control element 1460 includes a first engagement feature that is coupled to a second engagement feature of the shaft 1440 such that rotation of the control element 1460 relative to the base 1426 causes translation of the shaft 1440 relative to the base 1426 (and causes translation of the laser catheter 1412 within the lumen of the sheath 1416). For example and as shown, the first engagement feature can be a first threaded surface 1494 within the control element 1460, while the second engagement feature can be a second threaded surface 1496 formed on the arcuate side surface 1444 of the shaft 1440. In other words, the shaft 1440 can include a second interrupted threaded surface that extends from the opening 1454 in the frame 1430 to engage the first threaded surface 1494 of the control element 1460. In any event, rotation of the control element 1460 and the first threaded surface 1494 and rotationally fixed shaft 1440 within the frame 1430 will cause translation of the second threaded surface 1496 and shaft 1440 relative to the frame 1430 (and translation of the laser catheter 1412 within the lumen of the sheath 1416).

[0396] Laser-induced pressure waves generally have different characteristics compared to ultrasound. Ultrasound generally consists of periodic oscillations with limited bandwidth. Laser-induced pressure waves are single pulses, primarily positive pressure pulses, followed by relatively small tensile wave components. Ultrasound applies an alternating high-frequency load to tissue, with frequencies in the range of several megahertz, and is therefore capable of inducing heating, tissue tearing, and high-amplitude cavitation. However, as described above, in contrast, the effects of laser-induced pressure waves primarily involve radially directed energy, enabling treatment of deep and adjacent tissues with enhanced sensitivity.

[0397] The ability of the catheter of the present disclosure to generate laser-induced pressure waves for treating vascular occlusion in a subject involves appropriate coupling of an optical system to a liquid medium. Any wavelength of light can be used, including but not limited to laser, visible light, ultraviolet light, and infrared light, as long as the emitted light is coupled to a liquid medium that can absorb the light and generate laser-induced pressure waves. In addition, any liquid medium can be used, as long as the liquid medium is coupled to a light source that emits light of an appropriate wavelength so that the liquid absorbs the light and generates laser-induced pressure waves and / or vapor bubbles. In some cases, the liquid medium can be a contrast agent (e.g., an iodine-containing contrast agent or a gadolinium contrast agent) and / or the liquid medium can be a contrast solution (in which (one or more) contrast dyes or (one or more) particles are mixed in various concentrations) containing a biocompatible fluid (e.g., saline).

[0398] The magnitude of the force generated by the laser-induced pressure wave depends in part on the degree of absorption of the light energy by the liquid medium and the total energy deposited by the light source. Generally, the greater the absorption of the light energy by the liquid medium 160, the greater the force generated by the laser-induced pressure wave. Moreover, the greater the amount of light energy delivered to the liquid medium 160, the greater the force generated by the laser-induced pressure wave. For example, an excimer laser typically emits a laser having a wavelength of about 308 nanometers with a pulse duration between about 120 nanoseconds and about 140 nanoseconds, a frequency between about 25 pulses per second and about 80 pulses per second, and a total energy output between about 1 millijoule and about 100 millijoules. However, in some cases, the total energy output of the laser system can range from greater than 0 to about 300 mJ. When emitted in a contrast agent such as an iodine-containing contrast agent or a gadolinium contrast agent, the contrast agent will have a very high absorption, thereby generating a laser-induced pressure wave with sufficient force to treat a vascular occlusion in a subject.

[0399] The light energy can be emitted at any suitable wavelength capable of producing laser-induced pressure waves. Light energy can be emitted from about 1 nanometer to about 1 millimeter. In some cases, light from about 10 nanometers to about 5000 nanometers can be emitted. In some cases, light from about 100 nanometers to about 1000 nanometers can be emitted. In some cases, light from about 250 nanometers to about 750 nanometers can be emitted. In some cases, light from about 300 nanometers to about 600 nanometers can be emitted. In other cases, light from about 300 nanometers to about 350 nanometers can be emitted.

[0400] The light energy can be emitted with any suitable pulse duration capable of producing a laser-induced pressure wave. In some cases, the light can be emitted with a pulse duration of about 1 femtosecond to about 1 second. In some cases, the light can be emitted with a pulse duration of between about 10 nanoseconds and about 500 nanoseconds. In some cases, the light can be emitted with a pulse duration of between about 100 nanoseconds and about 150 nanoseconds. In other cases, the light can be emitted with a pulse duration of between about 120 nanoseconds and about 140 nanoseconds.

[0401] Light energy can be emitted at any suitable pulse repetition frequency (PRF) or number of pulses per second that can generate vapor bubbles and produce pressure waves generated thereby that propagate through the surrounding vascular system. In some cases, light can be generated in pulses at a frequency between about 1 pulse per second and about 5000 pulses per second. In some cases, light can be generated in pulses at a frequency between about 10 pulses per second and about 2500 pulses per second. In some cases, light can be generated in pulses at a frequency between about 10 pulses per second and about 1500 pulses per second. In some cases, light can be generated in pulses at a frequency between about 100 pulses per second and about 1000 pulses per second. In other cases, light can be generated in pulses at a frequency between about 50 pulses per second and about 500 pulses per second. In other cases, light can be generated in pulses at a frequency between about 50 pulses per second and about 150 pulses per second. In other cases, the light can be pulsed at a frequency between about 50 pulses per second and about 100 pulses per second. In other cases, the light can be pulsed at a frequency between about 25 pulses per second and about 80 pulses per second.

[0402] The total number of pulses administered during a particular treatment period depends on a variety of factors, including patient characteristics, the type of condition being treated, and the specific characteristics of the vascular occlusion, as will be readily appreciated by one of ordinary skill in the art based on this disclosure. In some cases, the total number of pulses administered during a treatment period can range from a single pulse to any number of pulses in a 10 second treatment period, a 15 second treatment period, a 20 second treatment period, a 25 second treatment period, a 30 second treatment period, up to a 1 minute treatment period. Depending on the degree of vascular occlusion remaining after the initial treatment, the treatment period can be repeated.

[0403] For example, the generator and / or one or more emitters can be configured to emit laser energy having a wavelength between about 150 nanometers and about 400 nanometers with a pulse duration between about 1 femtosecond and about 1 second at a frequency between about 1 pulse per second and about 5000 pulses per second. In some cases, the generator and / or (one or more) emitters can be configured to emit laser energy having a wavelength between about 400 nanometers and about 800 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second. In other cases, the generator and / or (one or more) emitters can be configured to emit laser energy having a wavelength between about 800 femtoseconds and about 3000 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second. In other cases, the generator and / or the emitter(s) can be configured to emit laser energy having a wavelength between about 3000 nanometers and about 12000 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second. In other cases, the generator and / or the emitter(s) can be configured to emit laser energy having a wavelength between about 300 nanometers and about 360 nanometers with a pulse duration between about 1 femtosecond and about 1 second and at a frequency between about 1 pulse per second and about 5000 pulses per second.

[0404] As can be appreciated by one of ordinary skill in the art based on the present disclosure, the degree of force generated by the laser-induced pressure wave can be modulated by using lasers that generate laser energy of different wavelengths and different pulse durations. For example, a different degree of force may be required to rupture a vascular occlusion than the degree of force required to deliver a therapeutic agent to vascular tissue. In some embodiments, a laser having a holmium source (referred to as a holmium laser) can emit laser energy at a wavelength of approximately 2100 nanometers (nm) and can be coupled to a variety of light absorbing materials (including water or saline based media) for treating vascular occlusions in a subject.

[0405] Several other additional laser energy sources can be paired with corresponding light-absorbing materials to generate laser-induced pressure waves to treat vascular occlusions. For example, a YAG crystal laser can produce wavelengths of infrared light that have a high absorptivity in aqueous solutions. Aqueous solutions can be used as light-absorbing materials or media to generate laser-induced pressure waves. Aqueous solutions include, but are not limited to, saline, dextrose, radiopaque contrast agents, lactated Ringer's solution, and electrolyte solutions. In some cases, the YAG wavelength can be doubled to generate visible spectrum light at a wavelength of 532nm. Materials or media that can absorb light of this wavelength include, but are not limited to, gold nanospheres, nitrite solutions, potassium permanganate solutions, copper salts, aluminum solutions, aluminum, ammonium salts, and dyes (e.g., hematoxylin and propidium iodide). Light-absorbing materials such as these substances can be part of a solution (e.g., an aqueous solution as described above) and / or they can be used as coatings on various surfaces within the device.

[0406] In some embodiments, a holmium YAG laser can emit laser energy at a wavelength of about 2120 nm and can be coupled with various light absorbing materials (including water or saline based media) to treat vascular occlusions in a subject. In some embodiments, a thulium laser (e.g., a thulium YAG laser) can emit laser energy at a wavelength of about 2013 nm and can be coupled with various light absorbing materials (including water or saline based media) to treat vascular occlusions in a subject. In some embodiments, a thulium laser (e.g., a thulium fiber laser) can emit laser energy at a wavelength of about 1908 nm and can be coupled with various light absorbing materials (including water or saline based media) to treat vascular occlusions in a subject. In some embodiments, an Nd-YAG laser can emit laser energy at a wavelength of about 1064 nm and can be coupled with various light absorbing materials to treat vascular occlusions in a subject. In some embodiments, a double YAG laser can emit laser energy at a wavelength of about 532 nm and can be coupled with various light absorbing materials to treat vascular occlusions in a subject. In some embodiments, an alternative ribbon YAG laser can emit laser energy at a wavelength of about 1319 nm and can be coupled with various light absorbing materials to treat vascular occlusions in a subject. In other embodiments, an Er-YAG laser can emit laser energy at a wavelength of about 2940 nm and can be coupled with various light absorbing materials to treat vascular occlusions in a subject.

[0407] Carbon dioxide (CO 2 ) lasers emit infrared light that is highly absorbed in aqueous solutions. 2 The laser is a commonly used surgical laser and is highly absorbent in tissue due to its high water content. It can be used with CO2 lasers that emit infrared light (e.g., light emitted at a wavelength of 10.6 microns). 2Light absorbing materials to which the laser is coupled to generate laser-induced pressure waves include, but are not limited to, aqueous solutions (eg, saline), dextrose, radiopaque contrast agents, lactated Ringer's solution, and electrolyte solutions.

[0408] Nitrogen lasers can be used to generate low frequency, high energy laser pulses. Nitrogen lasers can emit light in the ultraviolet spectrum (which can emit laser energy at a wavelength of approximately 337 nm) and can be coupled with various light absorbing materials (including but not limited to radiopaque contrast agents and metals and oxides (e.g., aluminum, silver, gold, copper, nickel, cerium, zinc, titanium) and dyes (e.g., hydroxycoumarins and aminocoumarins)) to produce laser-induced pressure waves.

[0409] Other medically useful lasers that can be used to generate laser-induced pressure waves to treat vascular occlusions include titanium sapphire lasers, which can emit laser energy at a wavelength of about 800 nm; ruby ​​lasers, which can emit laser energy at a wavelength of about 694 nm; and alexandrite lasers, which can emit laser energy at a wavelength of about 755 nm. These medical lasers emit laser energy in the near-infrared spectrum and can be used to generate laser-induced pressure waves. Absorbing materials or media that can be coupled to these lasers include, but are not limited to, dyes and colorants, which can be used in solutions, suspensions, or in coatings on another material or surface within a device. Various materials that can absorb laser energy at these wavelengths include copper ions in water, copper salts, and copper sulfate, as well as materials such as fluorophores used in fluorescence microscopy (e.g., methylene blue).

[0410] Dye lasers can also be used to generate laser-induced pressure waves to treat vascular occlusions. In some cases, dye lasers can be tuned to output specific wavelengths of light in the visible spectrum, which can allow the laser to be optimized for certain light-absorbing materials as an alternative or in addition to using materials that are highly absorptive to specific wavelengths of light. In this manner, the light-absorbing material can be any of the previously mentioned materials as well as dyes, colorants, and visible light chromophores.

[0411] For certain applications, it may be desirable to increase the amount and / or size of vapor bubbles generated in conjunction with the laser-induced pressure waves generated by emitting laser energy into a corresponding light-absorbing liquid medium. For example, the size of the catheter may be limited when entering a vessel of smaller diameter size. In some cases, the force exerted by the vapor bubbles on the tissue (e.g., a vascular occlusion) may be proportional to the size of the individual vapor bubbles generated because the bubbles expand and contract after the laser energy is emitted into the liquid medium and the pressure waves are generated. That is, the intensity of the initial laser-induced pressure wave and / or the size of the vapor bubbles may be limited by using a non-gas-saturated liquid medium. One way to increase the size of individual vapor bubbles (e.g., to exert a greater amount of force on a particular tissue) is to saturate the liquid medium with a gaseous substance such that the gas within the liquid medium exhibits a higher vapor pressure than a liquid medium without such a gas. Suitable gaseous substances that may be used to generate a gas-saturated liquid medium include, but are not limited to, ambient air, carbon dioxide, iodine gas, oxygen, nitrogen, compressed air, nitrous oxide, and combinations thereof.

[0412] The higher vapor pressure of a gaseous substance added to a liquid medium will cause the gaseous substance to return to the gaseous state faster (under smaller pressure fluctuations) than the liquid medium. In other words, less pressure is required to bring the saturated gaseous substance out of solution, thereby resulting in larger vapor bubbles and, with them, a greater amount of force. In some cases, the use of a gas-saturated liquid medium allows the use of laser energy at reduced intensity or reduced pulses or pulse durations without any concomitant reduction in the overall force generated by the vapor bubbles (because each vapor bubble is larger). This can enhance the safety and effectiveness of performing the procedure.

[0413] The gaseous substance can be administered to the liquid medium by various means, including under pressure, by mechanical agitation, and / or by bubbling the gas into the liquid medium. In some cases, the gas-saturated liquid medium can be prepared prior to the procedure and then delivered to the distal end of the catheter prior to performing the procedure. Additionally or alternatively, the gaseous substance can be delivered to the liquid medium already present in the catheter.

[0414] Gases and / or gaseous substances can be dissolved and quantified by the amount of gas present in 1 kg of a liquid medium. The maximum amount of gas that can be dissolved in a liquid medium depends on the solubility of the particular gas in the liquid medium, the pressure, and the temperature, as described by Henry's law of gas solubility. For example, carbon dioxide can be dissolved in water at atmospheric pressure at 30 degrees Celsius at a concentration of 1.25 g / kg water or less. And when carbon dioxide is dissolved in water or salt water, the resulting total concentration is between 0.25-3.5 g / kg H 2O. The concentrations of other dissolved gases per kilogram of liquid medium range from 1 mg / kg to 1 g / kg for iodine, 5 to 80 mg / kg for oxygen, 5 to 40 mg / kg for nitrogen, 5 to 500 mg / kg for room air, and 0.1 to 4 g / kg for nitrous oxide.

[0415] Gases and / or gaseous substances can be dissolved in an amount above the theoretical limit, which is called supersaturation. The theoretical limit is described by Henry's law mentioned previously. By dissolving the gas at an elevated pressure or reduced temperature and then returning it to normal atmospheric conditions, it is possible to dissolve more gas than can be dissolved under atmospheric conditions. For example, 2.5 g of carbon dioxide can be dissolved in 30 degrees Celsius of water at 2 atmospheres, which is then returned to atmospheric pressure. For any dissolved gas, the saturation percentage is defined by the gas concentration compared to the theoretical maximum concentration. For any previously mentioned gas in a supersaturated solution, the saturation percentage can range from 100% to 300%.

[0416] The use of a gas-saturated liquid medium or a supersaturated liquid medium can also increase the initial laser-induced pressure wave caused by the interaction of the laser with the liquid medium. That is, the gas-saturated liquid medium or the supersaturated liquid medium can contain a larger potential energy, which, when activated by the laser, can produce a larger initial laser-induced pressure wave than the laser-induced pressure wave produced by the interaction of the laser with the non-gas-saturated liquid medium.

[0417] Additionally or alternatively, the method of the present disclosure further comprises activating at least one proximal laser emitter enclosed within the sheath assembly to send pulses of laser energy through the liquid medium and propagate laser-induced pressure waves to assist in stent deployment. The pressure waves generated by the vapor bubbles can assist in securing or expanding the stent to its full diameter as part of a medical procedure.

[0418] As discussed above, activating one or more emitters and sending pulses of light energy into a liquid medium can generate vapor bubbles. When light is emitted from an emitter (e.g., a laser catheter) within a sheath containing an absorptive liquid medium, vapor bubbles can be generated inside the sheath and / or outside the sheath. Assuming that vapor bubbles are generated inside the sheath, it can be expected to limit some or all potential expansion of relevant portions of the sheath caused by the vapor bubbles. That is, it can be expected to reduce or prevent the ability of the sheath to expand and contract when vapor bubbles are generated therein, so as to reduce or prevent the sheath from applying liquid force or pressure to the vascular occlusion and / or the vessel wall. Moreover, assuming that vapor bubbles are generated outside of the sheath within the vessel wall, it can be expected to reduce and / or prevent the formation of such vapor bubbles, so as to reduce or prevent cavitation events and the formation of the vapor bubbles themselves from applying liquid force or pressure to the vascular occlusion and / or the vessel wall.

[0419] refer to Fig.18 , depicting a perspective view of a biocompatible sheath 1120" that can be used in conjunction with a laser catheter or any of the earlier embodiments to perform a method of treating a subject (e.g., removing or treating a vascular occlusion). The sheath 1120" can include a sleeve or jacket 1122" and an attenuation member 1124". Fig.18 The attenuation member 1124" is illustrated as being exposed and coupled to the distal end of the sleeve 1122" via an adhesive. However, the attenuation member 1124" can alternatively be integrally disposed within the sleeve 1122", disposed outside the sleeve 1122", and / or disposed within the sleeve 1122". In addition, if the attenuation member 1124" is coupled to the distal end of the sleeve 1122", or the attenuation member 1124" is integrally disposed within the sleeve 1122", or disposed within the sleeve 1122", the entire attenuation member 1124" may be covered by the sleeve 1122" (unexposed), the entire attenuation member 1124" may be exposed, or a portion (e.g., a distal portion) of the attenuation member 1124" may be exposed and another portion (e.g., a proximal portion) may be covered.

[0420] Fig.18 Also illustrated is an attenuation member 1124" disposed at the distal end of the sheath 1120". However, the attenuation member 1124" may alternatively and / or additionally be disposed at the proximal end of the sheath 1120", at a central portion of the sheath 1120", at any location or multiple locations between the proximal and distal ends of the sheath 1120", or over the entire length or substantially the entire length of the sheath 1120".

[0421] The attenuation member 1124" has two purposes. One purpose is to strengthen the sleeve 1122" and / or the sheath 1120", and the other purpose is to reduce the size or prevent the possibility of vapor bubbles forming on the exterior of the attenuation member 1124", sleeve 1122" and / or sheath 1120". With respect to strengthening the sleeve 1122", coupling the attenuation member 1124" to the sleeve 1122" can reduce or prevent the ability of the sheath to expand and contract when vapor bubbles are generated therein, so as to reduce or prevent the sleeve 1122" from applying fluid force or pressure to the vascular occlusion and / or the vessel wall. Strengthening the sleeve 1122" can minimize and / or prevent the sleeve from bulging, splitting or peeling (in the case where the sleeve includes multiple layers) and minimize and / or prevent the formation of holes in the sleeve. If this occurs once or more times, it will increase the difficulty of subsequently translating the sleeve through the patient's vasculature and / or relative to the laser catheter.

[0422] The attenuation member 1124" and the sleeve 1122" are both made of biocompatible materials. The coupling of the attenuation member 1124" and the sleeve 1122" forms a rigid or semi-rigid structure within the sheath 1120", so that when the vapor bubble is formed therein, it applies little or no hydraulic pressure to the vascular occlusion and / or the blood vessel wall. It can be expected that most or the only force applied to the vascular occlusion and / or the blood vessel wall is the result of the laser-induced pressure wave passing through 1120", thereby allowing more precise control of the laser-induced pressure wave.

[0423] With respect to another purpose of the attenuation member 1124″ (reducing or preventing the formation of vapor bubbles on the exterior of the attenuation member 1124″, sleeve 1122″, and / or sheath 1120″) and continuing with reference to Fig.18, the openings 1126" within the attenuation member 1124" can prevent the formation and propagation of vapor bubbles on the jacket 1120". The openings 1126" not only allow laser-induced pressure waves to pass through, but the number and size of the openings 1126" (particularly the number and size of the remaining portion of the structure of the sleeve 1122" (or its portion 1128")) can also limit the size of the vapor bubbles that can form on the outside of the jacket 1120". The relationship between the opening area and the enclosed area within the attenuation member 1124" (or the ratio of the opening area to the total area) should allow a sufficient amount of laser-induced pressure waves to pass through the attenuation member 1124". Furthermore, the size of the openings 1126" should allow laser-induced pressure waves to pass therethrough while also limiting the size of the vapor bubbles that can form on the outside of the jacket 1120". Thus, it may be desirable for the ratio of the open area to the total area of ​​the attenuation member 1124″ to be between 1%-99%, including any increments therebetween, for example, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, ... , 15% ... 20%, ... , 25%, ... , 30%, ... , 35%, ... , 40%, ... , 45%, ... , 50%, ... , 55%, ... , 60%, ... , 65%, ... , 70%, ... , 75%, ... , 80%, ... , 85%, ... , 90%, ... %, 91%, 92%, 93%, 94%, 95%, 96%, 97% and 98%. It may also be desirable for the ratio between the opening area and the total area of ​​the attenuation member 1124" to be within a specific range, for example, between 5% and 95%, between 10% and 90%, between 15% and 85%, between 20% and 80%, between 25% and 75%, between 30% and 70%, between 35% and 65%, between 40% and 60%, and between 45% and 55%.Additionally, for any of the ratios listed above, it may be desirable for each opening to have a particular size, for example, between 10 microns and 10,000 microns (1 mm), including any increments therebetween, for example, 10 microns, ..., 12.5 microns, ..., 15 microns, 17.5 microns, ..., 20 microns, ..., 30 microns, ..., 40 microns, ..., 50 microns, ..., 75 microns, ..., 100 microns, ..., 125 microns, ..., 150 microns, 175 microns, ..., 200 microns, ..., 300 microns, ..., 400 microns, ..., 500 microns, ..., 600 microns, ... microns, …, 700 microns, …, 800 microns, …, 900 microns, …, 1000 microns, …, 2000 microns, …, 3000 microns, …, 4000 microns, …, 5000 microns, …, 6000 microns, …, 7000 microns, …, 8000 microns, …, 9000 microns, …, 9100 microns, …, 9200 microns, …, 9300 microns, …, 9400 microns, …, 9500 microns, …, 9600 microns, …, 9700 microns, …, 9800 microns, …, 9900 microns, … and 10000 microns. It may also be desirable for the size of the openings 1126" within the attenuation member 1124" to be within a particular range, such as between 1000 and 9000 microns, between 2000 and 8000 microns, between 3000 and 7000 microns, between 4000 and 6000 microns, and between 4500 and 5500 microns.

[0424] The ability of the attenuation member to reduce or prevent the formation of vapor bubbles on the exterior of the attenuation member 1124", sleeve 1122", and / or sheath 1120" potentially reduces the presence and / or size of vapor bubbles formed on the exterior of the attenuation member 1124", sleeve 1122", and / or sheath 1120", which in turn reduces the likelihood that vapor bubbles will be generated and that vapor bubbles will expand and contract between the attenuation member 1124", sleeve 1122", and / or sheath 1120" and the vessel wall. Furthermore, reducing or preventing the expansion and contraction of vapor bubbles between the sleeve 1122", and / or sheath 1120" and the vessel wall can prevent or reduce the likelihood of applying hydraulic forces or pressure to the vessel occlusion and / or vessel wall, thereby preventing and / or minimizing potential damage to the vascular system itself.

[0425] With respect to the ability of the attenuation member to strengthen the sleeve 1122″ and / or the sheath 1120″, the attenuation member 1124″ can reduce or prevent the ability of the sleeve to expand and contract when vapor bubbles are generated therein and / or the ability of the sheath to expand and contract when vapor bubbles are generated therein. Reducing the ability of the sleeve to expand and contract when vapor bubbles are formed therein and / or the ability of the sheath to expand and contract when vapor bubbles are formed therein can reduce or prevent the sleeve 1122″ and / or the sheath 1120″ from applying hydraulic pressure or pressure to the vessel occlusion, restriction and / or blood vessel wall.

[0426] exist Fig.18 The openings 1126″ in the attenuation member 1124″ depicted in FIG. 1 are shown as hexagons that are disposed around the perimeter and along the length of the attenuation member 1124″. Although the openings 1126″ in the attenuation member 1124″ are shown as hexagons, the openings may have alternative shapes, such as circles, ovals, triangles, squares, rectangles, spirals, polygons, diamonds, pentagons, heptagons, octagons, nonagons, and decagons. For example, Fig.18A A side view of an attenuation member 1124" including a plurality of square openings is illustrated; Fig.18B is a side view of an attenuation member 1124″ including a plurality of diamond-shaped openings; Fig.18C is a side view of an attenuation member 1124" including a plurality of openings formed by a helical structure wound in a particular direction (eg, in a clockwise direction or from left to right); and Fig.18D 1 is a side view of an attenuation member 1124" including a plurality of openings formed by a spiral structure wound in alternating directions (eg, in a counterclockwise direction or from right to left). In addition, two attenuation members 1124" formed in a spiral manner may be combined to form Fig.18E Attenuation member 1124" depicted in FIG. Fig.18E The attenuation member 1124" depicted in FIG. 1 is similar to Fig.18B The attenuation member 1124" depicted in FIG. Fig.18B The attenuation member 1124" depicted in FIG. 1 is a braid, while Fig.18E The attenuation member 1124" depicted in FIG. 1 is formed by winding or otherwise wrapping one or two hypotubes. In addition, Fig.18E The structure (or portion thereof) of the attenuation member 1124" depicted in FIG. Fig.18B The structure of the attenuation member 1124″ (or portion 1128″ thereof) depicted in FIG. 1 is because the size of the braided material is generally smaller. Fig.18F , the structure (or portion thereof) of the attenuation member 1124" is quite large compared to the size of the hexagonal opening.

[0427] refer to Fig.19 , depicting the use of a laser catheter 1010 (eg Fig.10As shown) and sheath 1120" (as Fig.18 as shown) and / or as Figures 11A-11D A representative flow chart of a method 1500 for treating a subject using a laser catheter 1010 in combination with a sheath 1120 to ablate a vascular occlusion and / or to generate laser-induced pressure waves in the presence of a liquid medium and disrupt portions of a vascular occlusion is shown. The method 1500 may include a step 1505 of positioning a guidewire 1130 within the subject's vasculature 1140, a step 1510 of positioning the laser catheter 1010 over the guidewire 1130 within the vasculature, a step 1515 of positioning the sheath 1120 over the laser catheter 1010 within the vessel, and a step 1520 of positioning the sheath 1120 and the laser catheter 1010 (and optionally the guidewire 1130) adjacent to the vascular occlusion 1150 within the subject's vasculature 1140. Again, referring to Fig.11A Positioning the sheath 1120 and laser catheter 1010 adjacent the vascular occlusion 1150 may form a cavity for collecting liquid media distal to the laser catheter 1010 (particularly distal to the emitter / optical fiber of the laser catheter 1010 ).

[0428] Fig.11A The distal end of the laser catheter 1010 is depicted proximate to the distal end of the sheath 1120. However, it is contemplated that the distal end of the laser catheter 1010 may be disposed at or distal to the distal end of the sheath 1120, as long as there is a liquid medium between the emitter / optical fiber of the laser catheter 1010 and the vessel occlusion 1150. The axial position of the laser catheter 1010 and the sheath 1120 may be adjusted by translating either or both components relative to each other. In order to visualize the respective positions of the laser catheter 1010 and the sheath 1120 under fluoroscopy, the laser catheter 1010 and the sheath 1120 may include radiopaque markers at any corresponding positions along their lengths.

[0429] Continue to refer Fig.11A Once the sheath 1120 and laser catheter 1010 are positioned adjacent the vessel occlusion 1150, a liquid medium may be introduced into the distal end of the laser catheter, such as Fig.19 As described in step 1525 of . Continue to refer to Fig.19 Step 1530 includes: activating the laser in the presence of a liquid medium to generate a laser-induced pressure wave and destroying portions of the vascular occlusion, particularly the calcified cap of the vascular occlusion. The laser catheter 1010 and sheath 1120 can be used to traverse the entire vascular occlusion 1150, such as Fig.19 Step 1540 (and optionally Fig.191535), or is used to destroy only a portion of the vascular occlusion 1150. If the laser catheter 1010 and sheath 1120 are used to destroy only a portion of the vascular occlusion 1150, the guidewire 1130 can penetrate and traverse the vascular occlusion 1150. For example, Fig. 11B A guidewire 1130 is depicted penetrating and traversing a vascular occlusion 1150 .

[0430] refer to Fig. 11C , assuming that the laser catheter 1010 and sheath 1120 are used to destroy only a portion of the vascular occlusion 1150', the laser catheter 1120 can be used to traverse the vascular occlusion 1150 without the sheath 1120. Fig.19 At step 1545 , when the laser catheter 1150 is passed over the guidewire 1130 through the vascular occlusion 1150 ′ while the sheath 1120 remains proximate to the vascular occlusion, the insertion of the liquid medium can be stopped and the laser catheter 1010 can be used to ablate the vascular occlusion.

[0431] refer to Fig.19 Step 1550, and once the laser catheter 1010 has traversed the entire vessel occlusion, the opening created by the laser catheter 1010 should be large enough to translate the sheath 1120 distally and through the vessel occlusion. At this point, the distal end of the sheath 1120 and the distal end of the laser catheter 1010 should both be distal to the vessel occlusion. At this point, refer to Fig.11D , the laser catheter 1010 is able to translate proximally while the sheath 1120 remains fixed within the vascular occlusion. Upon introduction of a liquid medium into the sheath 1120 ahead of the laser catheter 1010, the laser can be activated, thereby generating a laser-induced pressure wave in the presence of the liquid medium. At least a portion of the laser-induced pressure wave is directed radially, and as the laser catheter 1010 translates proximally within the sheath 1120, the laser-induced pressure wave is transmitted through the sheath 1120 and / or the sheath 1120 itself expands and contracts, thereby disrupting the remaining portion of the vascular occlusion 1150''.

[0432] To ensure that the majority of the remaining portion of the vessel occlusion 1150'' is destroyed, and if necessary, to destroy intraluminal calcium and / or vascular tissue and the vessel occlusion, the laser catheter 1010 can be repeatedly translated distally and proximally within the sheath 1120. As discussed above, destruction of the luminal layer and / or vascular tissue and vessel occlusion can enhance the ability of the vasculature to absorb drugs, particularly when such drugs are used in conjunction with a drug eluting balloon. Furthermore, it is contemplated that in Fig.19 Laser catheter 1010 may be used independently to ablate occluded portions of a vessel, or laser catheter 1010 may be used in conjunction with sheath 1120 before, during, and / or after any step in the process outlined herein.

[0433] As discussed above, sending light energy pulses from the transmitter into the liquid medium can generate laser-induced pressure waves and / or vapor bubbles and cavitation events, thereby obtaining additional pressure waves that destroy at least part of the vascular occlusion. The catheter can include a guidewire lumen, and the guidewire can pass through the guidewire lumen and penetrate the vascular occlusion. It can also be expected to excite and vibrate the guidewire to improve the ability of the guidewire to pierce and penetrate the vascular occlusion. Therefore, the present disclosure also envisions that the laser energy emitted by the transmitter will be directed into the liquid medium in the direction of causing the liquid medium to propagate pressure waves toward the guidewire lumen and / or the guidewire, so that the pressure wave excites and vibrates the guidewire.

[0434] refer to Fig. 20 , depicts a cross-sectional view of the distal end of a system 1610 that includes a laser catheter 1612 radially disposed within a sheath 1614. As shown, the distal end of the catheter 1612 includes one or more layers of optical fibers 1616 disposed circumferentially around an internal guidewire lumen 1618 that receives a guidewire 1620. The inner layer of optical fibers 1616 extends to a distal tip 1626 of the catheter 1612 and terminates at a distal emitter 1622 within the catheter 1612. Liquid media can be introduced into the distal side of the catheter 1612 through a lumen in the catheter 1612 (e.g., a guidewire lumen 1618), a lumen in the sheath 1614 (not shown), and / or a lumen or space between the laser catheter 1612 and the sheath 1614.

[0435] Continue to refer Fig. 20 In addition to having a plurality of optical fibers 1616 and a guidewire lumen 1618, the catheter 1612 may also include an outer band 1624 surrounding a distal tip 1626, thereby increasing the strength and rigidity of the distal tip 1626. As described above, the present disclosure contemplates directing laser energy emitted by the emitter 1622 into the liquid medium in a direction that causes the liquid medium and / or the guidewire 1620 to propagate a pressure wave, such that the pressure wave excites and vibrates the guidewire 1620. Means for directing the laser light emitted from the emitter 1622 toward the guidewire lumen 1618 or the guidewire 1620 include disposing the emitter 1622 proximate to the distal tip 1626 of the catheter 1612 and / or proximate to the distal end of the outer band 1624, such that the emitter 1622 is recessed from the distal tip 1626 of the catheter 1612 and / or proximate to the distal side of the outer band 1624 along the longitudinal axis of the catheter 1612. By recessing the transmitter 1622 from the distal tip 1626 of the catheter 1612 and / or proximal to the distal end of the outer band 1624 , the pressure waves may be directed toward the guidewire lumen 1618 and / or the guidewire 1620 .

[0436] Additional means for directing laser light emitted from emitter 1622 toward guidewire lumen 1618 and / or guidewire 1620 include directing emitter 1622 toward guidewire lumen 1618 or guidewire 1620. For example, as discussed above, the term "emitter" as used herein may refer to an end portion of a fiber or optical component that emits light from its distal end. The emitter 1622 is directed toward the guidewire lumen 1618 and / or guidewire 1620 because the optical fiber is tapered in such a manner that light emitted therefrom is directed radially inward toward the guidewire lumen 1618 and / or guidewire 1620. Fig. 20 As shown, the guidewire lumen 1618 and / or the guidewire 1620 can extend longitudinally distal to the emitter 1622. Thus, when laser light is emitted from the emitter 1622, the light interacts with the liquid medium and the liquid medium absorbs the light energy, thereby generating laser-induced pressure waves and / or vapor bubbles and additional pressure waves generated thereby, which cause excitation and / or vibration of the guidewire lumen 1618 and / or the guidewire 1620.

[0437] refer to Fig. 20 ', depicting an alternative embodiment of the present disclosure, particularly an alternative embodiment of a means for directing laser light emitted from an emitter 1622 toward a guidewire lumen 1618 and / or a guidewire 1620. Similar to the above with respect to Fig. 20 The examples discussed, Fig. 20 The system 1610' in ' includes a catheter 1612' having a plurality of optical fibers 1616, a guidewire lumen 1618, and an outer band 1624 surrounding a distal tip 1626. This embodiment also includes a cap 1628 having a guidewire lumen 1630 extending therethrough.

[0438] Cap 1628 can be removably coupled to conduit 1612', in particular removably coupled to outer band 1624, or cap 1628 can be permanently adhered to conduit 1612', in particular permanently adhered to outer band 1624. Cap 1628 includes a proximal side (e.g., inner side) 1632 and a distal side (e.g., outer side) 1634. The inner side 1632 is tapered so that a cavity 1636 is formed between the distal end of conduit 1612' and the inner side 1632 of cap 1628, thereby allowing liquid media to enter cavity 1636 and accumulate in cavity 1636. Although Fig. 20 ' is depicted as having a conduit 1612' with a flush distal end and a tapered, recessed cap 1628 to create a cavity 1636 between the conduit 1612' and the cap 1628 for collecting the liquid medium, but the present disclosure also contemplates conduits with recessed distal ends (e.g. Fig. 201632 ), which can be used in conjunction with a cap 1628 having a flush or recessed interior 1632 to form a cavity for collecting a liquid medium. Thus, when laser light is emitted from the emitter 1622, the light interacts with the liquid medium in the cavity and the liquid medium absorbs the light energy, thereby generating laser-induced pressure waves and / or vapor bubbles and additional pressure waves generated thereby, which cause excitation and / or vibration of the guidewire lumen 1618 and / or the guidewire 1620.

[0439] Sheath 1614 can be, for example, any of the sheaths described herein. In some embodiments, sheath 1614 can be Figures 11A-11D The sheath 1140 is shown in FIG. 1 , and the catheter 1612 or 1612' may be translatably carried in the sheath. Referring now to FIG. Fig. 20 "and Fig. 20 ” ', systems 1610 ” and 1610 ” ' include laser catheters 1612 and 1612 ', respectively. Systems 1610 ” and 1610 ” ' also include sheaths 1614 ' that can translate and carry catheters 1612 and 1612 ', respectively. Sheath 1614 ' can be Figure 18-18E 1. The sheath 1120' is shown in FIG. 1614. That is, the sheath 1614' includes a sleeve or outer shell 1122' and an attenuation member 1124', which may be any attenuation member described herein.

[0440] The attenuation member 1124" has the following multiple purposes: (1) strengthen the sleeve 1122" and / or the sheath 1614'; (2) reduce or prevent the formation of vapor bubbles outside the attenuation member 1124", sleeve 1122" and / or sheath 1614'; (3) redirect at least a portion of the pressure wave toward the guidewire lumen 1618 and / or the guidewire 1620 to excite and / or vibrate the guidewire 1620. Therefore, the attenuation member 1124" serves as (1) a means for strengthening the sleeve 1122" and / or the sheath 1614'; (2) a means for reducing or preventing the formation of vapor bubbles outside the attenuation member 1124", sleeve 1122" and / or sheath 1614'; (3) a means for redirecting at least a portion of the pressure wave toward the guidewire lumen 1618 and / or the guidewire 1620 to excite and / or vibrate the guidewire 1620.

[0441] Combination Fig.1816. The attenuation member 1124" may be configured to have a plurality of openings 1126" and 1126' of the attenuation member 1124" disposed therein. The attenuation member 1124" may be configured to have a plurality of openings 1126" and 1126' of the attenuation member 1124" disposed therein. The attenuation member 1124" may be configured to have a plurality of openings 1126" and 1126' of the attenuation member 1124" disposed therein. The attenuation member 1124" may be configured to have a plurality of openings 1126" and 1126' of the attenuation member 1124" disposed therein. The attenuation member 1124" may be configured to have a plurality of openings 1126" and 1126' of the attenuation member 1124" disposed therein. Fig.18 ) to control the amplitude or direction of the pressure wave reflected toward the guidewire lumen 1618, the guidewire 1620 and / or the target tissue.

[0442] Again, similar to the above about Fig.18 The discussion included, Fig. 20 "and Fig. 20 The attenuation member 1124" depicted in the "' is shown as being at the distal end of the sheath 1614'. However, the attenuation member 1124" may alternatively and / or additionally be disposed at the proximal end of the sheath 1614', at a central portion of the sheath 1614', at any location or multiple locations between the proximal and distal ends of the sheath 1614', or over the entire length or substantially the entire length of the sheath 1614'. Thus, as the catheter 1612 or 1612' translates within the sheath 1614', the guidewire 1620 will continue to be excited and / or vibrated.

[0443] As described above, for example, reference Fig.13 , the catheter system according to embodiments of the present disclosure may have a completely or partially closed distal tip. In some of these embodiments, it may be desirable to seal the sheath with a guidewire when introducing a liquid medium into the closed distal tip. Figure 21-22B A catheter system 1710 according to such an embodiment is illustrated. That is, the catheter system 1710 includes a sheath 1720 having a partially enclosed tip 1722 (in Fig.21 The sheath 1720 carries a laser catheter (e.g., the laser catheter 1010 described herein), and the laser catheter 1010 can translate distally and / or proximally within the sheath 1720. Fig.21As shown, the sheath 1720 can taper distally toward the tip 1722. Alternatively, the sheath 1720 can include a flat surface that receives the tip 1722. As another alternative, the tip 1722 can have a size similar to the lumen of the sheath 1720 and be received in the lumen in a press-fit manner. In order to ensure that a cavity is maintained between the distal end of the laser catheter 1010 and the proximal end 1724 of the tip 1722 of the sheath 1720, the sheath 1720 may include one or more internal stops 1726. The shape of the tip 1722 can be configured similar to the tip 180 illustrated and described with respect to FIGS. 2-6, so that the catheter system 1710 including the laser catheter tip 1722 is configured so that the energy generated by the pressure wave is captured in the cavity and the force generated by the pressure wave is propagated longitudinally (including propagating in a forward (i.e., parallel to the blood vessel) direction), thereby increasing the ability of the tip to destroy, damage and / or penetrate a vascular occlusion.

[0444] Tip 1722 includes a proximal end 1724, a distal end 1728, and a lumen 1730 extending therethrough from its proximal end 1724 to its distal end 1728. Tip 1722 also includes a valve that seals the intersection of tip 1722 and guidewire 1040 when guidewire 1040 passes through guidewire lumen 1730. An example of a valve is flange 1732, such as Figure 22-22B As shown, a flange 1732 is illustrated, which is disposed at and / or toward the proximal end 1724 of the tip 1722 .

[0445] Back to Figure 21-22B When the guidewire 1040 is introduced through the lumen 1730 of the laser catheter 1010 and into the guidewire lumen 1730 of the tip 1722, the guidewire 1040 and the tip 1722 are slidably coupled so that the tip 1722 can slide on the guidewire 1040 (or the guidewire 1040 can slide through the lumen 1730 of the tip 1722), as shown in FIG. Fig.22AAs shown in the figure, there is a gap (or opening) caused by the guidewire lumen 1730 between the flange 1732 and the guidewire 1040. If the gap is maintained during the introduction of the liquid medium into the distal end of the catheter system 1710 (via, for example, the opening or gap between the laser catheter 1010 and the sheath 1720), the liquid medium will travel through the guidewire lumen 1730 and enter the patient's vascular system, which would be undesirable. The flange 1732 (which may include a tapered portion 1734 that tapers from the distal end 1728 of the tip toward its proximal end 1724) is configured to collapse radially when the liquid medium is introduced into the distal end of the catheter system 1710 due to the increase in fluid pressure on the flange 1732. The increase in fluid pressure on flange 1732 actuates flange 1732 and moves flange 1732 radially inward toward guide wire lumen 1730, closing the gap between flange 1732 and guide wire 1040, thereby forming a seal between flange 1732 and guide wire 1040. Fig. 22B As flange 1732 advances from distal end 1728 toward proximal end 1724, flange 1732 tapers radially inward toward guidewire lumen 1730, and the reduction in thickness of tapered portion 1734 of flange 1732 increases the ability of the flange to flex when exposed to the pressure generated when a liquid medium is introduced. When the liquid medium is removed from the distal end of catheter system 1710, the pressure within catheter system 1710, the pressure on flange 1732, decreases, and flange 1732 naturally retracts to its initial position, as shown. Fig.22A As shown, a gap is re-established between the tip 1722 and the guide wire 1040 so that the two components can slide relative to each other. Therefore, the flange 1732 acts as a sealable valve within the tip 1722 and is actuated by introducing a liquid medium into the distal end of the catheter system 1710 and removing the liquid medium from the distal end of the catheter system 1710.

[0446] Although in Fig.22A and Fig. 22B The tapered portion 1734 illustrated in the figure tapers from the distal end 1728 of the tip toward its proximal end 1724, but the direction of the taper can be reversed so that the tapered portion 1734 tapers from the proximal end 1724 of the tip toward its distal end 1728. In addition, the flange 1732 can taper toward any portion along its length so that the portion of the flange 1732 is thinner at one or more positions along its length than at other positions along its length. Therefore, when the fluid pressure applied on the flange 1732 increases, the thinner portion of the flange 1732 actuates and moves radially inwardly toward the guide wire lumen 1730, so that the gap between the flange 1732 and the guide wire 1040 is closed, thereby forming a seal between the flange 1732 and the guide wire 1040.

[0447] Tip 1722 can be constructed by any type of compressible or compliant biopolymer (e.g., silicone or fluoropolymer), compliant adhesive, etc. The configuration of the tip 1722 depicted in these figures includes an outer wall 1736 and a flange 1732 radially disposed therein, so that a gap is created between them to allow a liquid medium to enter the flange 1732 and to actuate it. Flange 1732 is also depicted as being arranged toward the proximal end 1724 of tip 1722, and tip 1722 itself is depicted as tubular, and its distal end 1728 has an inward taper that tapers from outer wall 1736 toward the guide wire lumen 1730 to the distal side. Although tip 1722 is depicted as including specific parts and shapes, the present disclosure should include other shapes and parts known to those skilled in the art. In addition, tip 1722 can alternatively include a self-sealing tube constructed by any type of compressible or compliant biopolymer (e.g., silicone or fluoropolymer), compliant adhesive, etc. For example, the tip 1722 may include a tube having a lumen 1730 therethrough such that the lumen expands when a guidewire is inserted and contracts when the guidewire is removable, thereby appearing as a slit.

[0448] Continue to refer Figure 21-22B , the tip 1722 may include one or more openings 1738 through its outer wall 1736. The openings 1738 allow the liquid medium to reach the flange 1732 not only from the gap between the flange 1732 and the outer wall 1736 at the proximal end 1724 of the tip 1722, but also to reach the flange 1732 at a location away from the proximal end 1724 of the tip 1722. Allowing the liquid medium to reach the flange 1732 at or toward its distal portion can potentially increase the likelihood and effectiveness of actuating the flange 1732. Although the tip 1722 is illustrated as having a tubular portion 1740 starting from its proximal end 1724 and a tapered portion 1742 from the end of its tubular portion 1740 toward the distal end 1728 of the tip, other shapes of the tip 1722 should be included within the scope of the present disclosure.

[0449] As discussed herein, when laser light is emitted from the emitter(s), the light interacts with the liquid medium and the liquid medium absorbs the light energy, thereby generating vapor bubbles within the catheter system 1710. The openings 1738 in the tip 1722 can reduce the size of the bubbles formed within the catheter system 1710 and / or reduce the likelihood of the bubbles expanding toward the distal end of the catheter system 1710.

[0450] In some embodiments, the apparatus and methods of the present disclosure can also be used to deliver laser-induced pressure waves to ablate vascular occlusions using substantially solid light-absorbing materials instead of liquid media. In some cases, a laser that emits light of a specific wavelength is paired with a light-absorbing material designed to absorb light of that wavelength, which can significantly improve the energy efficiency of the laser-induced pressure waves generated by the reaction. Using such a pairing can ultimately reduce the energy input required to treat the vascular occlusion, which can improve the safety of the procedure and reduce costs. For example, a catheter according to an embodiment of the present disclosure can be filled with air or a substantially inert liquid medium (e.g., saline) instead of a contrast agent, which can significantly reduce the amount and size of vapor bubbles generated with the laser-induced pressure waves. Since the laser-induced pressure waves can propagate outside the catheter to ablate the vascular occlusion, it can be advantageous to reduce (e.g., by filling the catheter with saline) or eliminate (e.g., by filling the catheter with air or an inert gas) the generation of vapor bubbles in some cases. In other cases, the liquid medium delivered to the distal end of the catheter can be pre-treated based on the present disclosure using methods known to those of ordinary skill in the art to remove the amount of gas dissolved in the liquid medium, as this can also reduce the amount of vapor bubbles generated along with the laser-induced pressure waves.

[0451] Suitable light-absorbing materials can be any agent that can absorb light energy and generate laser-induced pressure waves. For example, the light-absorbing material can include an aromatic hydrocarbon bonded with iodine (e.g., an iodinated X-ray contrast agent). Low-osmotic pressure, nonionic, iodinated and radiopaque contrast agents are also suitable light-absorbing materials that can be used to generate laser-induced pressure waves. Other light-absorbing materials include, but are not limited to, iodinated contrast agents (e.g., diatrizoic acid, methyldiatrizoic acid, iodamide, iodalamic acid, oxacetamic acid, ioglitaic acid, acetophenic acid, iocalic acid, iodomethanesulfonate, iodoxone, iodixanol, lohexanol, loxanic acid, lopamidol, lopromide, lotrolan, lovesol, lopentol, lodixacol, lomerol, lobitradol, loxilan, oxamic acid, Lotox, lobamid, apiiodarone, lopadronic acid, lopanoic acid, locanamate, sodium iopodate, parahydroxyvalerate, calcium iopodate, lopidol, propidone, lofenadate, iodized oil), non-iodinated contrast agents (e.g., barium sulfate), MRI contrast agents (e.g., gadobenic acid, gadobutrol, gadodiamide, gadofosvestrant, gadolinium, gadopentetate, gadoteric acid, gadoteridol, gadoversetamide, gadoxetate, citronellol ammonium ferric sulfate, mangafodipir, femosir, and tilistatine iron oxide nanoparticles), perflubromethane, glucose and other carbohydrates, albumin and other proteins, nitroglycerin or other vasodilators, hydrocarbons (e.g., oils, alcohols or other organic functional groups) (amines, alkanes, carboxyls, etc.), blood / tissue products (e.g., platelet-rich plasma (PRP), packed red blood cells, plasma, platelets, fats, charcoal, biocompatible materials (e.g., stainless steel), biopolymers and bioceramics, or other pharmaceutical agents containing a combination of aromatic carbon rings and functional groups (e.g., salicylic acid, acetylsalicylic acid, methyl salicylate, mesalazine, aspirin, acetaminophen, ibuprofen, clopidogrel), or other drugs and / or biological agents that may be compatible with the medical procedures described herein.

[0452] Suitable light absorbing materials can also include those that absorb wavelengths in the UV spectrum. For example, the light absorbing material can include, but is not limited to, PABA, Padimate 0, phenylbenzimidazole sulfonic acid, Cinoxate, benzophenone, oxybenzone, homosalate, menthyl anthranilate, octocrylene, octyl methoxycinnamate, octyl salicylate, sulisophenone, triethanolamine salicylate, avobenzone, ezsud, 4-methylbenzylidene camphor, Tinosorb M, Tinosorb S, Tinosorb A2B, Neo Heliopan AP, Mexoryl XL, benzophenone, Uvinul T 150, Uvinul A Plus, Uvasorb HEB, Parsol SLX) or amiloride, silicon and its various atomic structures, cadmium telluride, copper indium gallium selenide, gallium arsenide, ruthenium metal organic dyes, polyphenylene vinylene, copper phthalocyanine, carbon fullerene and its derivatives, carbon compounds (e.g., graphite, graphene, diamond, charcoal), titanium and oxides, nickel and oxides, gold, silver, zinc and oxides, tin and oxides, aluminum and oxides or alloys or ceramics of the foregoing metals.

[0453] Light absorbing materials can be combined with various other compounds to promote their attachment to substrates. For example, light absorbing materials can be combined with various compounds (e.g., solubilizers) that help produce solutions or mixtures including light absorbing materials that can be used to coat substrates. In some embodiments, biodegradable and biocompatible hydrophobic polymers can be used as light absorbing materials. For example, biodegradable and biocompatible hydrophobic polymers can be poly(glycerol sebacate) (PGSA) or variants and combinations thereof that can be cross-linked using ultraviolet light. Ultraviolet light can be emitted from the distal end of the catheter to activate, for example, PGSA, and the catheter can be disposed within or outside the sheath.

[0454] Other light-absorbing materials can also include reagents with similar adhesive properties, and in some cases, the light-absorbing properties of these reagents can be supplementary uses of their uses as adhesives or other uses independent of their uses as adhesives. For example, light-absorbing materials can include but are not limited to cyanoacrylates, bovine serum albumin (BSA)-glutaraldehyde, fibrin sealants, gelatin matrix thrombin, gelatin sponges, oxidized cellulose, collagen sponges, collagen wool, recombinant factor VIIa, etc. In some embodiments, light-absorbing materials can include hydrophobic functional groups, such as hexanoyl (Hx; C6) functional groups, palmitoyl (Pam; C16) functional groups, stearyl (Ste; C18) functional groups and oleoyl (Ole; C18 unsaturated) functional groups, so that in a primarily aqueous environment (e.g., vascular tissue), the resistance is washed away or detached from its substrate. Such light absorbing materials can include, but are not limited to, 10Ole-disuccinimidyl tartrate, 10Ste-disuccinimidyl, and variations and combinations thereof.

[0455] The light absorbing material can be configured to exhibit high absorption of light energy from the emitter. Light energy can be emitted at any suitable wavelength capable of producing laser induced pressure waves. Light energy can be emitted from about 1 nanometer to about 1 millimeter. In some cases, light from about 10 nanometers to about 5000 nanometers can be emitted. In some cases, light from about 100 nanometers to about 1000 nanometers can be emitted. In some cases, light from about 250 nanometers to about 750 nanometers can be emitted. In some cases, light from about 300 nanometers to about 600 nanometers can be emitted. In other cases, light from about 300 nanometers to about 350 nanometers can be emitted.

[0456] In general, the light absorbing material can be positioned anywhere within the conduit as long as it generally intersects the path of light emitted from the optical fiber. In some embodiments, the light absorbing material can be substantially solid (e.g., stable in a generally solid state, such as metals and metal alloys). Substantially solid light absorbing materials can be used to construct various portions of a component of a conduit, and / or substantially solid light absorbing materials can be used to construct a separate structure independent of another conduit component.

[0457] In some embodiments, the light absorbing material can be applied to a separate support structure (i.e., a support structure that is not primarily made of the light absorbing material, or a support structure that is not used as a light absorbing material) and used to generate laser-induced pressure waves using the apparatus and methods of the present disclosure. In some embodiments, the light absorbing material is stable only in liquid, gel, or semi-liquid form. In these embodiments, the light absorbing material can be included as part of a formulation or coating suitable for application to a support structure (e.g., impregnated in a hydrogel or other solid support matrix). In some embodiments, the light absorbing material can be part of a formulation or coating that contains other agents that help the light absorbing material be placed on and / or adhered to the support structure. For example, the solid absorbing material can be formulated with a coating agent, a thickener, an adhesive, and / or other drugs or biological agents suitable for use with the apparatus and methods of the present disclosure.

[0458] refer to Fig.23 , illustrates a distal end of a catheter system 1810 including a light absorbing material according to an embodiment of the present disclosure. The catheter system 1810 is similar to the catheter system 1710. That is, the catheter system 1810 includes a sheath 1820 having a partially enclosed tip 1822 (which is Fig.23 1810). The sheath 1820 carries a laser catheter (e.g., the laser catheter 1010 described herein), and the laser catheter 1010 can translate distally and / or proximally within the sheath 1820. Fig.23 As shown, the sheath 1820 can taper distally toward the tip 1822. Alternatively, the sheath 1820 can include a flat surface that receives the tip 1822. As another alternative, the tip 1822 can have a size similar to the lumen of the sheath 1820 and be received in the lumen in a press-fit manner. In order to ensure that a cavity is maintained between the distal end of the laser catheter 1010 and the proximal end of the tip 1822 of the sheath 1820, the sheath 1820 can include one or more internal stops 1826. The shape of the tip 1822 can be configured similar to the tip 180 illustrated and described with respect to Figures 2-6, so that the catheter system 1810 including the laser catheter tip 1822 is configured so that the energy generated by the laser-induced pressure wave is captured in the cavity and the force generated by the laser-induced pressure wave is propagated longitudinally (including propagating in a forward (i.e., parallel to the blood vessel) direction), thereby increasing the ability of the tip to destroy, damage and / or penetrate the vascular occlusion.

[0459] Tip 1822 can include the same features and structures as tip 1722. In addition, tip 1822 includes a light absorbing material support structure 1824. Light absorbing material support structure 1824 serves as a substrate for applying a light absorbing material, which can be any light absorbing material described herein. As described herein, the light absorbing material can be applied as a coating on the proximal end of tip 1822 within the lumen of catheter system 1810, and light absorbing material support structure 1824 can be positioned so that it generally intersects the path of light emitted from the distal end of laser catheter 1010.

[0460] In some embodiments, the light absorbing material can be applied to various surfaces within the catheter system 1810 itself, rather than being applied to a support structure. For example, the light absorbing material can be applied as a coating on the inner surface of the catheter system 1810 or a portion thereof (e.g., the inner surface of the sheath 1820). Laser light emitted from the distal end of the laser catheter 1010 can be directed upward and / or outward so that it can react with the light absorbing material to produce laser-induced pressure waves without the need for additional support structures.

[0461] refer to Fig.24 , illustrates the distal end of a catheter 1910 including a light absorbing material according to an embodiment of the present disclosure. The catheter 1910 is similar to Figure 5A . That is, the catheter 1910 includes a distal end having a tip 1912, which includes a non-metallic component instead of a solid or hollow structure of metal (e.g., stainless steel). The catheter 1910 includes an outer sheath 1914, an inner sheath 1916 disposed concentrically and / or radially within the outer sheath 1914, and one or more optical fibers 1918 disposed concentrically and / or radially within the inner sheath 1916. The distal end of the outer sheath 1914 is directly coupled to the tip 1912 (via press fit and / or welding). The inner sheath 1916 and the one or more optical fibers 1918 are not directly coupled to the tip 1912. Instead, the inner sheath 1916 and the one or more optical fibers 1918 are disposed proximate to the tip 1912, thereby forming a cavity between the outer sheath 1914, the inner sheath 1916, the one or more optical fibers 1918, and the tip 1912.

[0462] The catheter 1910 may include a shield 1920 disposed axially between the distal end of the inner sheath 1916 and the proximal end of the tip 1912, and radially between the one or more optical fibers 1918 and the outer sheath 1914. The shield 1920, depicted as a generally cylindrical tube, increases resistance to the laser-induced pressure wave in the radial direction, thereby reducing the ability of the laser-induced pressure wave to travel radially toward the outer sheath 1914. The configuration of the cylindrical shield 1920 allows for reduced resistance in the longitudinal direction as compared to the radial direction, thereby improving the ability of the tip to translate in the forward / rearward direction. The cylindrical shield 1920 may also be configured such that its diameter is larger (or smaller) at its proximal end than at its distal end, thereby potentially tapering in the proximal or distal direction and focusing the laser-induced pressure wave toward the center of the tip 1912. The protective cover 1920 may also be used to form a sealed cavity at the distal end of the catheter 1910, thereby preventing the leakage of liquid media through the outer sheath 1914, because portions of the protective cover overlap portions of the outer sheath 1914, which may be porous.

[0463] The inner sheath also includes one or more lumens for the liquid medium to enter the cavity. The (one or more) distal ends of the one or more optical fibers 1918 are near the distal end of the inner sheath 1916, at the distal end of the inner sheath 1916, or away from the distal end of the inner sheath 1916. Again, one or more emitters are disposed at the distal end of the one or more optical fibers 1918. The (one or more) emitters are in direct contact with the liquid medium, so that when laser energy is emitted from the (one or more) emitters, the liquid medium absorbs the emitted light, which in turn generates laser-induced pressure waves and generates vapor bubbles and / or cavitation events, thereby generating additional pressure waves.

[0464] The tip 1912 has a circular configuration, forming a collar for the distal end of the outer sheath 1914. The tip 1912 also includes a flexible membrane 1922 at its distal end. For example, the membrane 1922 can be constructed of polyester film and can be bonded to the distal end of the tip 1912 in an orientation perpendicular to the longitudinal axis. In addition, the membrane can be compliant so as to deflect and engage the shape of a calcified cap, a complete occlusion, or a lesion. In some embodiments, the membrane 1922 can be constructed of an elastic or superelastic material (e.g., nitinol).

[0465] The membrane 1922 carries a light absorbing material support structure 1924 within the cavity. The light absorbing material support structure 1924 serves as a substrate for applying the light absorbing material, which can be any of the light absorbing materials described herein. In other embodiments, the light absorbing material support structure 1924 can be carried by the membrane 1922 outside the cavity, or the light absorbing material can be applied as a coating on the membrane 1922 (either within the cavity or outside the cavity) as described herein. In any case, the light absorbing material can be positioned so that it substantially intersects the path of light emitted from the distal end of the optical fiber(s) 1918. In some embodiments and as Fig.24 As shown, the light absorbing material support structure 1924 can cover the entire membrane 1922 within the cavity. In other embodiments, the light absorbing material support structure 1924 can partially cover the membrane 1922 within the cavity. In these embodiments, the location and / or size of the light absorbing material support structure 1924 on the membrane 1922 can affect the location where the vapor bubble forms and collapses, which in turn affects the deflected shape of the membrane 1922. In some embodiments, the light absorbing material can be applied to various other surfaces within the conduit 1910 instead of being applied to the support structure. For example, the light absorbing material can be applied as a coating to the inner surface of the protective cover 1920 or a portion thereof.

[0466] In order to treat an object with a vascular occlusion, the distal end (particularly the tip 1912) of the catheter 1910 is positioned adjacent to the vascular occlusion, wherein the membrane 1922 is adjacent to the vascular occlusion. The liquid medium can be delivered to the cavity from one or more lumens within the inner sheath 1916 through one or more liquid medium ports or between the outer sheath and the inner sheath or the laser catheter 1910. When the laser system is activated, light energy travels through one or more optical fibers until the light energy is released from the (one or more) emitters at the ends of the one or more optical fibers. When the light absorbing material and the liquid medium absorb the light energy, a laser-induced pressure wave is formed, and the liquid medium rapidly shifts outward and inward, thereby forming a vapor bubble. The energy generated by the laser-induced pressure wave and the vapor bubble is captured in the closed system provided by the cavity and is transmitted to the vascular occlusion through the flexible membrane 1922. The energy generated by the laser-induced pressure wave is transmitted to the vascular occlusion sufficient to destroy calcium deposits and / or fibrous tissue within the vascular occlusion. The force generated by the laser-induced pressure waves can propagate longitudinally, anteriorly (ie, parallel to the vessel). Pressure waves generated in this manner can also be used to increase the compliance of a vessel prior to performing another procedure (eg, conventional balloon angioplasty).

[0467] As mentioned above about Fig.12 and Fig.19 As discussed, the present disclosure discusses the use of a laser catheter 1010 (eg Fig.10 As shown) and sheath 1120 (as Fig.18A laser catheter is used to ablate 1010 at least a portion of a vascular occlusion or restriction in a blood vessel of a subject before generating a laser-induced pressure wave in the presence of a liquid medium and destroying the occluded portion of the vessel. Figure 25-26F To illustrate the formation of a vascular occlusion within the vasculature of a subject being treated using the laser catheter 1010 and the sheath 1120. Fig.25 , depicts a cross-sectional view of a healthy arterial wall 2000 taken along a direction perpendicular to the longitudinal axis of the arterial wall. A healthy arterial wall 2000 or vessel wall generally includes an outer layer referred to as the "adventitia" or "adventitial layer" Fig.25 2020. There may be additional layers outside the adventitia, for example, layer 2010 of the arterial wall 2000. The healthy arterial wall 2000 also includes an intermediate or central layer, called the tunica media 2030. The tunica media 2030 is positioned radially inwardly of the inner portion of the adventitia 2020 and adjacent to the inner portion of the adventitia 2020. The tunica media 2030 has a smooth muscle cell layer and an elastic fiber layer that allows the artery to expand and contract. The healthy arterial wall 2000 also includes an inner layer, called the tunica intima 2040. The tunica intima 2040 is positioned radially inwardly of the tunica media 2030 and adjacent to the tunica media 2030. The healthy arterial wall 2000 also includes an endothelial layer 2050, which is positioned at the innermost surface of the tunica intima 2040 and creates a boundary for a channel (or inner lumen) 2060.

[0468] As described above, the middle membrane 2030 is positioned radially inward of the inner portion of the outer membrane 2020 and adjacent to the inner portion of the outer membrane 2020. In particular, the outer elastic membrane 2035 (commonly referred to as the outer elastic diaphragm) separates the middle membrane 2030 from the outer membrane 2020. As described above, the inner membrane 2040 is positioned radially inward of the inner portion of the middle membrane 2030 and adjacent to the inner portion of the middle membrane 2030. The inner elastic membrane 2025 (commonly referred to as the inner elastic diaphragm) separates the inner membrane 2040 from the middle membrane 2030.

[0469] refer to Fig.25A , depicting Fig.25 A smaller form of the structure of a healthy arterial wall 2000 is depicted in Figure 2. Also, Fig.26A is a longitudinal cross-sectional view of a healthy arterial wall 2000 taken along a direction parallel to the longitudinal axis of the arterial wall. In particular, Fig.26A It is a healthy artery wall along the 2000 Fig.25A A longitudinal cross-sectional view of the structure taken along line BB.

[0470] refer to Fig.26BOver time, due to the accumulation of fat and lipids in the blood, fat and / or lipids 2070' will begin to accumulate and / or deposit in the intima 2040' of the arterial wall 2000'. This disease process is generally referred to as atherosclerosis and occurs in the arteries of the body, including the coronary arteries and peripheral arteries. It is this accumulation of fat and / or lipids 2070' in the intima 2040' that will lead to the formation of vascular occlusions, which can reduce or completely block blood flow in the channel 2060'. Over time, this accumulation of fat and lipids 2070' becomes a heterogeneous mixture 2065" (commonly referred to as plaque) of many components including, but not limited to, fat, lipids, fibrin, fibro-calcific plaque, calcium crystals, thrombi, etc. For example, portions of the fat and / or lipids 2070' may become plaque 2065" or even become calcified, which is depicted as 2055" in FIG. 26. As the fat and / or lipids 2070" aggregate, become plaque 2065" and / or become calcified 2055", the endothelium 2040" becomes inflamed and expands, thereby reducing the cross-sectional area of ​​the channel 2060".

[0471] refer to Fig.26D As the atherosclerotic condition progresses and the condition of the arterial wall 2000'' is not treated, plaque 2065'' continues to accumulate and the intima 2040'' continues to expand and reduce the cross-sectional area of ​​the channel 2060''. However, when the intima 2040'' of the arterial wall 2000'' reaches its limit of further expansion, the intima 2040'' and endothelium rupture 2058'' and release the plaque contents previously contained in thickened lipids and enlarged intimal leukocytes into the channel 2060'', as shown in FIG. Fig.26E Platelets and fibrin aggregate within the channel 2060ˇ of the arterial wall 2000ˇ to try and repair the rupture and in the process form a vessel occlusion 2080ˇ which may have a calcified portion 2085ˇ, as shown in FIG. Fig.26F The figure also illustrates that the formation of vessel occlusion 2080' further reduces the size of channel 2060' and in some instances completely blocks flow.

[0472] refer to Fig.26D , Figure 26G and 26H , the laser catheter 1010 may be used to debulk or remove plaque buildup contained behind the intima 2065″′ or within a vessel occlusion 2080″′ or a portion thereof from a passageway in the arterial wall 2000″′. After debulking the plaque buildup or occlusive condition, the combination of the laser catheter 1010 and sheath 1120 of the present disclosure may be used to treat the remaining portion of the plaque buildup 2065″′ or vessel occlusion 2080″′, particularly by destroying the Fig.26Hand / or Fig.26H The calcified portion 2085 is treated by generating a laser-induced pressure wave as described above. Fig.26I The condition of the arterial wall 2000ˇ″ is shown.

[0473] Fig.26I An arterial wall 2000"" is illustrated having an enlarged channel 2060"", a majority of the plaque 2065"' or vessel occlusion 2080"" removed, and the calcification of the remaining portion of the vessel occlusion and the calcification of the intima 2040"" disrupted or modified to make it more suitable for expansion at lower atmospheric pressures. Fig.25 , Fig.25A and Figure 26A-21 I uses similar numerical values, but different figures include different indicators for the numerical values ​​(e.g., ' and ˇ and combinations thereof) because changes occur within the arterial wall as a vascular occlusion is formed and treated, which are progressively explained from one figure to the next. For the sake of brevity, certain layers of the arterial wall 2000 are omitted from the discussion of certain figures, and the numerical values ​​of certain items of the arterial wall 2000 are omitted from certain figures. Nevertheless, even from Fig.25 , Fig.25A and Figures 26A-26I These contents are omitted in the figure, and it should be considered that the various layers of the arterial wall 2000 and the formations therein have the same values.

[0474] refer to Fig.27A and Fig.27B There is a method 2700 for performing an atherectomy procedure in conjunction with the use of a laser catheter 1010 (e.g. Fig.10 As shown) and sheath 1120 (as Fig.18 The method 2700 generates laser-induced pressure waves in the presence of a liquid medium and destroys the occluded portion of the vessel to treat the remaining portion of the vascular occlusion within the intima to remove plaque accumulation or occlusive conditions. The method 2700 can be used to treat coronary arteries and / or peripheral arteries, including but not limited to arteries of the vascular system of the leg, renal arteries, subclavian arteries, etc.

[0475] Fig.27A and Fig.27B The method 2700 in step 2705 includes locating a vascular occlusion in a blood vessel of a subject. An optional next step 2710 includes positioning a guidewire at the vascular occlusion and / or inserting the guidewire through the vascular occlusion or through a passage through the vascular occlusion. Step 2715 includes performing an atherectomy procedure to remove the plaque or vascular occlusion or a portion thereof. One type of atherectomy device is an ablation catheter, such as the laser ablation catheter 1010 discussed herein, which is capable of ablating at least a portion of a vascular occlusion, such as Figure 26GOther types of ablation catheters include radiofrequency ablation catheters, microwave ablation catheters, and cryoablation catheters. Other plaque removal devices (eg, mechanical plaque removal devices) besides ablation catheters can also be used to remove vascular occlusions.

[0476] After the vascular occlusion (or portion thereof) is removed from the vasculature, step 2720 may then be performed. Step 2720 includes positioning the sheath 1120 of the present disclosure on the laser catheter 1010 within the vasculature of the subject, such as Fig.26H As shown, step 2725 follows, which includes positioning the sheath 1120 and laser catheter 1010 adjacent the vessel occlusion, such as Fig.26H ' as shown. For example, if the clinician is using a catheter 1010 and sheath 1120 with a guidewire lumen, the catheter 1010 can be slid over the guidewire 1130 and into the vasculature, and the sheath 1120 is then slid over the catheter 1010. The catheter 1010 is then coupled to the sheath 1120. Step 2725 also includes positioning the sheath 1120 and the laser catheter 1010 adjacent to the vascular occlusion (or the remainder thereof). The axial position of the laser catheter 1010 and the sheath 1120 can be adjusted by translating either or both components relative to each other. In particular, the sheath 1120 can be moved from Fig.26H The position depicted in the figure is translated to Fig.26H 'Axial positions of the laser catheter 1010 and the sheath 1120 depicted in FIG. Fig.26H The laser catheter 1010 is illustrated extending beyond the distal end of the sheath 1120, wherein the transmitter of the laser catheter 1010 is within the attenuation element of the sheath 1120 and axially aligned with the attenuation element and the remainder of the vascular occlusion, and corresponding portions of the sheath and attenuation element are adjacent to the vascular occlusion (or the remainder thereof).

[0477] Once the sheath 1120 and laser catheter 1010 are positioned adjacent the vessel occlusion such that the emitter and attenuation member are axially aligned adjacent the vessel occlusion, as shown in FIG. Fig.26H 'As shown, the liquid medium can be introduced into the distal end of the laser catheter, such as in Fig.27A and Fig.27B As described in step 2730 of . Fig.27A and Fig.27B Step 2735 includes: activating an energy source (e.g., a laser) in the presence of a liquid medium to generate a laser-induced pressure wave and disrupt a portion of the vessel occlusion. The laser catheter 1010 and sheath 1120 can be used to traverse the entire vessel occlusion or to disrupt only a portion of the vessel occlusion. That is, the laser catheter 1010 and sheath 1120 can be axially movable relative to each other (in Fig.26H and Fig.26H') and / or axially move together while emitting laser-induced pressure waves to destroy portions of the vascular occlusion. If the laser catheter 1010 and sheath 1120 are used to destroy portions of the vascular occlusion, the guidewire 1130 can penetrate and traverse the vascular occlusion, as described in step 2740.

[0478] At least one energy source coupled to at least one emitter of the laser catheter enclosed by the sheath 1120 is activated to emit and transmit laser energy pulses into the liquid medium and / or react with the liquid medium to generate propagating laser-induced pressure waves and destroy the remaining portion of the vascular occlusion. Destroying the remaining portion of the vascular occlusion (particularly any calcified portion within the vascular occlusion) will create cracks in the calcified portion and / or reduce the size of the calcified portion because the laser-induced pressure waves will destroy the calcified portion, thereby cracking the calcified portion and / or breaking up the size of the calcified particles, resulting in a reduction in the continuous zone. In some cases, the method 2700 may include an additional step (not shown) of activating at least one energy source coupled to at least one emitter enclosed within the sheath to emit and transmit laser energy pulses into the liquid medium and / or react with the liquid medium to generate propagating laser-induced pressure waves to deliver the therapeutic agent from the sheath to the remaining portion of the vascular occlusion and / or vascular tissue near the blocked or restricted portion.

[0479] One of the benefits of this disclosure is that: Fig.26H and Fig.26H The catheter 1010 and sheath 1120 depicted in ' may optionally include an attenuation member (e.g., Fig.18 Attenuation member 1124 or Figures 18A-18F The alternative illustrated in FIG. 1 can reduce or prevent the formation of vapor bubbles on the exterior of the attenuation member and / or sheath 1120 and / or strengthen the sheath to minimize or prevent sheath expansion. Strengthening the sheath and / or reducing or preventing the formation of vapor bubbles on the exterior of the attenuation member (or sheath) can reduce or prevent outward and inward fluid displacements from dilating the arterial wall while allowing the laser-induced pressure waves to penetrate the arterial wall and disrupt vascular occlusions and / or calcified portions in the intima. That is, by incorporating an attenuation member to strengthen the sheath, reducing or preventing the formation of vapor bubbles on the exterior of the attenuation member can potentially inhibit the displacement of soft tissue within the arterial wall and possibly reduce or prevent the peeling of layers of the arterial wall.

[0480] Reference again Fig.27A and Fig.27B, after performing step 2735 (and possibly 2740), step 2745 may be performed. Step 2745 includes continuing to insert a liquid medium into the gap between the combination of the laser catheter 1010 and the sheath 1120, thereby continuing to disrupt the vascular occlusion using the laser-induced pressure wave while the laser catheter 1010 remains within the sheath 1120 near its distal end. Alternatively, as described in step 2750, when the laser catheter 1010 passes through the vascular occlusion while the sheath 1120 remains near the vascular occlusion over the guidewire 1130, the insertion of the liquid medium may be stopped and the laser catheter 1010 may be used to ablate the vascular occlusion. That is, the introduction of the liquid medium between the laser catheter 1010 and the sheath 1120 may be terminated, and the laser catheter 1010 may extend beyond the distal end of the sheath 1120, so that the laser catheter 1010 can perform additional plaque removal. After performing additional plaque removal procedures, the distal end of the laser catheter 1010 can be returned to a position within the distal end of the sheath 1120, and liquid medium can again be supplied to the distal end of the laser catheter 1010 within the sheath 1120, thereby once again generating laser-induced pressure waves to destroy the remaining portions of the vessel occlusion recently ablated by the laser catheter.

[0481] To ensure that the majority of the remaining portion of the vessel occlusion is destroyed, and if necessary, to destroy the luminal lining and / or vascular tissue and the vessel occlusion, the laser catheter 1010 may be repeatedly translated distally and proximally within the sheath 1120, as in steps 2745 and / or 2755. As discussed above, destruction of the luminal lining and / or vascular tissue and the vessel occlusion can enhance the ability of the vasculature to absorb drugs, particularly when such drugs are used in conjunction with a drug eluting balloon. Furthermore, it is contemplated that in Fig.19 Laser catheter 1010 may be used independently to ablate occluded portions of a vessel, or laser catheter 1010 may be used in conjunction with sheath 1120 before, during, and / or after any step in the process outlined herein.

[0482] As discussed above, sending pulses of light energy from the transmitter into the liquid medium can generate laser-induced pressure waves and / or vapor bubbles and additional pressure waves generated thereby, which damage at least a portion of the vascular occlusion. The catheter can include a guidewire lumen, and the guidewire can pass through the guidewire lumen and penetrate the vascular occlusion. It can also be expected to excite and vibrate the guidewire to improve the ability of the guidewire to pierce and penetrate the vascular occlusion. Therefore, the present disclosure also contemplates that the laser energy emitted by the transmitter is directed into the liquid medium in a direction that causes the liquid medium to propagate the laser-induced pressure wave toward the guidewire lumen and / or the guidewire, so that the laser-induced pressure wave excites and vibrates the guidewire.

[0483] Although Fig.27A and Fig.27B The method illustrated in may depict steps 2705 to 2755 of method 2700 as being performed serially, but any or all of the steps within method 2700 may be performed in any order and / or in parallel with any other steps. For example, certain steps can be performed without performing other steps. Upon completion of step 2735 and / or step 2740, the combined laser catheter and sheath can optionally be repositioned within the vascular system and adjacent to another portion thereof. Similarly, upon completion of step 2735 and / or step 2740, the (one or more) transmitters can optionally be repositioned within the sheath. The sheath can be repositioned within the vascular system and / or the (one or more) transmitters can be repositioned within the sheath. Method 2900 also includes ending the process when the desired treatment result is obtained, or repeating any of steps 2905 to 2945 if it would be necessary to treat an object with a vascular occlusion.

[0484] In addition, drug eluting (coated) balloon (DEB or DCB) catheters can be used to deliver drugs to the residual site of the vascular occlusion. Destroying the remaining portion of the vascular occlusion with laser-induced pressure waves prior to using a DEB will increase the effectiveness of the drug applied to the vascular occlusion because the laser-induced pressure waves will destroy calcium formed in the intimal layer and calcium formed in the tissue within the blood vessel, thereby creating a channel for the drug to enter the intima and tissue of the blood vessel and / or the vascular occlusion.

[0485] The present disclosure also contemplates the use of laser-induced sheaths with conventional angioplasty balloons and DEBs. For example, a surgical procedure may include performing an atherectomy with a laser catheter to treat calcified portions of the vasculature by using the sheath in conjunction with the laser catheter, as described above. Fig.27A and Fig.27B As described in , an angioplasty balloon (or DEB) is then inserted into the vasculature adjacent to the relevant portion of the vasculature, and the angioplasty balloon is expanded to dilate the relevant portion of the vasculature.

[0486] As discussed above, the laser-induced pressure waves generated by the laser catheters and sheaths of the present disclosure not only disrupt vascular occlusions and / or calcium in the intimal layer, but the laser-induced pressure waves generated by the catheters of the present disclosure can also disrupt calcification of tissue within the vessel wall(s). That is, regardless of whether the vasculature includes an occlusion, the laser-induced pressure waves can be used to disrupt or modify calcified tissue. For example, patients suffering from medial calcification of arteries (also known as Munkeberg's arteriosclerosis) can potentially benefit from treatment with the catheters of the present disclosure.

[0487] refer to Fig.28A, depicting a healthy arterial wall 2300, which is similar to that in Fig.26A For example, Fig.26A Reference numerals 2010, 2020, 2030, 2040, 2050 and 2060 correspond to Fig.28A The reference numerals 2310, 2320, 2330, 2340, 2350 and 2360 are shown. That is, the reference numerals 2310 and 2320 are the outer membrane, the reference numeral 2330 is the middle membrane, the reference numeral 2340 is the inner membrane, the reference numeral 2350 is the endothelium, and the reference numeral 2360 is the channel.

[0488] refer to Fig.28B , depicting a cross-sectional view of an arterial wall 2300', which includes calcium deposits 2370 formed in the tunica media 2330. The calcium deposits begin as crystal aggregates and are typically aggregated along the elastin fibrin layer within the tunica media. As Munkeberg's arteriosclerosis (commonly referred to as calcification of the arterial media) progresses, multiple layers of calcium are formed that cover the entire periphery of the blood vessel. Calcium can also extend radially to the adventitia and intima layers. Munkeberg's arteriosclerosis (calcification of the arterial media) is caused by the absorption of calcium by smooth muscle cells, and this is attributed to, but not limited to, a common complication in patients with vascular conditions, including diabetics, kidney disease patients, and other metabolic or hormonal imbalances. The tunica media 2330 includes smooth muscle cells and elastin fibers that allow the artery to expand and contract. However, once calcium deposits 2370 are formed, the artery's ability to expand and contract is reduced. That is, the formation of calcium deposits 2370 in the tunica media 2330 reduces the compliance of the artery 2300', thereby potentially reducing blood flow through such arteries and potentially negatively affecting other health conditions (e.g., diabetes). As previously mentioned, this condition can occur in conjunction with atherosclerotic conditions or can be an isolated condition without arterial lumen narrowing.

[0489] The combined catheter 1010 and sheath 1120 of the present disclosure is capable of generating laser-induced pressure waves that rupture or break up calcium deposits 2370 in the tunica media 2330 of the arterial wall 2300″, such as Fig.28C As shown, the compliance of the arterial wall 2300"' and the blood flow therethrough are increased while minimizing or preventing the expansion of the arterial wall. That is, one of the benefits of the present disclosure is Fig.28C The sheath depicted in FIG. 1 may optionally include an attenuation member (e.g., Fig.18 Attenuation member 1124 as depicted in FIG. 1 ). Attenuation member 1124 or Figures 18A-18FThe alternatives depicted in can reduce or prevent the formation of vapor bubbles on the exterior of the attenuation member and / or strengthen the sheath to minimize or prevent its expansion. Strengthening the sheath and / or reducing or preventing the formation of vapor bubbles on the exterior of the attenuation member can reduce or prevent outward and inward fluid displacements from expanding and contracting the arterial wall while allowing the laser-induced pressure waves to penetrate the arterial wall and disrupt calcium deposits in the tissue (e.g., tunica media) and / or tissue layers (e.g., tunica media layer) of the vessel.

[0490] Figures 28A-28D Similar numerical values ​​are used, but different figures include different indicators for the numerical values ​​(e.g., ' and ˇ and combinations thereof) because changes occur within the arterial wall as calcium is formed and disposed of, which are progressively illustrated from one figure to the next. For the sake of brevity, certain layers of the arterial wall 2300 are omitted from the discussion of certain figures, and numerical values ​​for certain items of the arterial wall 2300 are omitted from certain figures. Nevertheless, even from Figures 28A-28D These contents are omitted, and it should be considered that the various layers of the arterial wall 2300 and the formations therein have the same values.

[0491] refer to Fig.29 , depicts a method 2900 of using a catheter to generate laser-induced pressure waves to treat calcium deposits in tissue (e.g., tunica media) and / or tissue layers (e.g., tunica media layer) of a blood vessel by disrupting the calcium deposits, thereby increasing compliance of the vasculature and thereby increasing blood flow through the vasculature. The method 2900 can be used to treat calcium deposits in tissue(s) of coronary arteries and / or peripheral arteries. Fig.29 The method 2900 in includes locating calcification of a tissue (eg, tunica media) and / or a tissue layer (eg, tunica media layer) within the vasculature of the subject at step 2910. The optional next step 2920 includes positioning a guidewire within the vasculature of the subject.

[0492] After locating the calcified portion(s) of the tissue (e.g., media) and / or tissue layer (e.g., media layer) within the vascular system, step 2930 may then be performed. Step 2930 includes introducing the laser catheter of the present disclosure and the sheath on the laser catheter of the present disclosure into the vascular system. Step 2940 includes positioning the sheath and the laser catheter (and optionally the guidewire) within the vascular system such that the attenuation member within the sheath is adjacent to the portion of the vascular system having calcification, and disposing the distal end of the laser catheter within the attenuation member adjacent to the vascular system including the calcified portion(s). For example, if the clinician uses the laser catheter 1010 described herein with a guidewire lumen, the laser catheter may be slid over the guidewire and into the vascular system such that the transmitter(s) of the laser catheter is positioned adjacent to the vascular system having calcification. Then, the sheath 1120 of the present disclosure is slid over the laser catheter 1010 to a position within the vascular system such that the attenuation member is adjacent to the vascular system including the calcified portion(s). Thus, the transmitter will be disposed within the portion of the sheath comprising the attenuation member.

[0493] Method 2900 also includes step 2950, ​​which includes introducing a liquid medium (e.g., a contrast agent) having a light absorbing material into the distal end of the laser catheter, wherein the laser catheter is disposed within a sheath, and preferably disposed within a portion of the sheath that includes the attenuation member. At step 2960, an emitter on the laser catheter is activated to initiate the formation of a laser-induced pressure wave, a portion of which passes through at least the sheath that includes the attenuation member, thereby destroying calcium in the vasculature. That is, the laser-induced pressure wave ruptures and / or breaks into smaller particles the calcified portion(s) of the tissue (e.g., the media) and / or tissue layer (e.g., the media layer). Disrupting the calcified portion(s) within the tissue (s) of the blood vessel ruptures the calcified portion(s) because the laser-induced pressure wave is absorbed by the calcified portion, thereby increasing the compliance of the arterial wall, which in turn improves blood flow and also has a positive impact on other health conditions.

[0494] Step 2970 of method 2900 may include continuing to insert the liquid medium into the distal end of the laser catheter and axially translating the laser catheter and / or sheath to destroy portions of calcified tissue of blood vessels in the same or other portions of the vascular system. Any steps of method 2900 may be repeated until a sufficient amount of calcium is destroyed and the compliance of the arterial wall is satisfactorily increased, as described in step 2980.

[0495] In addition, although not in Fig.29, but in some cases, method 2900 may also include the following steps: activating at least one energy source coupled to at least one emitter enclosed within the sheath to emit and transmit laser energy pulses into the liquid medium and / or react with the liquid medium to produce propagating laser-induced pressure waves, thereby delivering the therapeutic agent from outside the sheath through the cracks in the calcified portion and / or potentially delivering through (or to) the cracks in the calcified portion.

[0496] refer to Fig.30 , depicts a kit 3000 that includes a laser catheter assembly 3008 and a sheath assembly 3004. The sheath assembly 3004 may also be referred to as an outer sheath assembly 3004 due to its placement relative to the laser catheter assembly 3008. Fig.31 Depicted Fig.30 The sheath assembly 3004 shown in FIG. Fig.32 Depicted Fig.30 3008 is shown in FIG. The sheath assembly 3004 may include a proximal portion, a distal portion 3040, and a sheath 3012 having a working length of approximately 50 cm to 200 cm (including 140 cm), and a lumen 3024 extending between the two ends. The sheath 3012 may also be referred to as an outer sheath 3012 due to its arrangement relative to the laser catheter assembly 3008. The distal portion 3040 is Fig.31A 3004 is shown in more detail. The proximal end of the sheath assembly 3004 may include a bifurcated tube 3016 (or Y connector), which is coupled to the sheath 3012 through a Luer connector 3020. The bifurcated tube 3016 may include a tube 3028 extending in one direction (e.g., an axial direction) and another tube 3032 extending in a direction deviating from the tube 3028. The tube 3028 may have an opening 3024, through which a guide wire (not shown) may enter the proximal end of the sheath assembly 3004. The tube 3028 may also include a hemostatic valve at or adjacent to the opening 3024. The guide wire can extend from the proximal end of the sheath assembly 3004 to the distal end of the sheath assembly 3004 through the lumen in the sheath assembly 3004. The tube 3032 may include a stopcock 3036, through which a liquid medium may enter the sheath assembly 3004.

[0497] refer to Fig.31A , Fig.31B , Fig.31C and Fig.31C', depicting an enlarged view of a distal portion 3040 of a sheath assembly 3004 having a lumen 3024 therethrough. The distal portion 3040 of the sheath assembly 3004 may include a sheath 3012 (or outer jacket), an inner liner 3096 disposed radially or concentrically within the sheath 3012, an outer band 3072 disposed around the distal end of the sheath 3012 ( Fig.31C ), and a tapered tip 3076 disposed distally of the outer band 3072. The outer band 3072' may alternatively be integrally disposed within the distal end of the sheath 3012' so that the outer sheath (or jacket) 3012' covers ( Fig.31C ') Outer band 3072'. The distal portion 3040 of the sheath 3012 may also have an attenuation member formed therein. The attenuation member may be included throughout the entire length of the sheath 3012, or only at the distal portion 3040. Assuming the length of the sheath 3012 is 140 cm, the length of the distal portion 3040 including the attenuation member may be between 0.010 cm and 10.0 cm, accounting for 0.05% to 20.0% of the length of the sheath 3012.

[0498] The attenuation member may include one or more coils 3068 formed integrally from a flat wire within the sheath 3012. Fig.38 An example of a flat wire is shown in , where the cross-sectional width (X) of the flat wire is 0.005 inches and the cross-sectional height (Y) of the flat wire is 0.001 inches. The flat wire can be constructed from stainless steel (e.g., 304 stainless steel) or other types of metals or metal alloys. In addition, it may be preferred to construct the flat wire with alternative dimensions, for example, a cross-sectional width (X) between 0.001 inches and 0.010 inches, and a cross-sectional height (Y) between 0.0005 inches and 0.015 inches. Alternatively, it may be preferred to use a round wire with a diameter between 0.0005 inches and 0.015 inches instead of a flat wire.

[0499] As discussed herein, it may be desirable for the ratio of the open area of ​​the attenuation member to the total area of ​​the attenuation member to be within a certain range, for example, between 30% and 70%, and possibly between 40% and 60%, and more likely between 45% and 55%, for example, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, or 55%. While round wire may be used to form the coil(s) 3068, using flat wire to construct the coil(s) 3068 may provide the attenuation member with an overall thinner longitudinal cross-sectional profile while reducing the amount of open area per turn of the wire because the height of the flat wire may be less than the width of the flat wire. The width of the flat wire provides a desired ratio of the open area of ​​the attenuation member to the total area of ​​the attenuation member, while the height of the material increases the strength of the coil(s) to withstand the laser-induced pressure waves without breakage. In other words, the smaller longitudinal cross-sectional profile reduces the overall diameter of the sheath assembly, thereby allowing the kit to enter smaller vasculatures while maintaining sufficient strength and rigidity to absorb and attenuate laser-induced pressure waves.

[0500] There are three factors that determine the percentage of open area in the attenuation member: (1) the width of the flat wire (or the diameter of a round wire); (2) the number of turns of the wire; and (3) the gap between each turn of the wire. Once two of these factors are determined for the desired percentage of open area in the attenuation member, the third factor can be addressed. In order to maintain a certain percentage of open area in the attenuation member, there is an inverse relationship between the number of turns and the width of the flat wire (or the diameter of a round wire). That is, for a certain percentage of open area in the attenuation member, the necessary number of turns per inch decreases for wires with larger widths, while the necessary number of turns per inch increases for wires with smaller widths. In addition, there is also an inverse relationship between the number of turns per inch and the gaps between the wire turns. That is, for a certain percentage of open area in the attenuation member using a predetermined wire size, the number of turns per inch increases for smaller gaps between the wire (or wires). Furthermore, there is a direct relationship between the size of the gaps between the wires and the amount of open area in the attenuation member. That is, for a given wire width, the larger the gap between the individual windings, the larger the open area in the attenuation component, and the smaller the gap between the individual windings, the smaller the open area in the attenuation component.

[0501] For example, assuming that the attenuation member is constructed from a flat wire that is 0.005 inches wide by 0.001 inches high, where the desired open area is between 30% and 70%, the attenuation member may include approximately 75 to 125 turns (or revolutions) per inch. In particular, a gap of approximately 0.008 inches between turns of a 0.005 inch wide flat wire produces an open area of ​​approximately 61.5%, while a gap of approximately 0.003 inches between turns of a 0.005 inch wide flat wire produces an open area of ​​approximately 37.5%. In addition, a gap of approximately 0.005 inches between turns of a 0.005 inch wide flat wire produces an open area of ​​approximately 50%. Thus, the attenuation member can be constructed of a flat wire such that the attenuation member includes 75 to 125 turns (or revolutions) per inch of the flat wire, 80 to 120 turns per inch of the flat wire, 85 to 115 turns per inch of the flat wire, or 90 to 110 turns per inch of the flat wire, depending on the amount of open area within the attenuation member, the size (i.e., width) of the wire, and the gaps between the turns of the wire. Thus, it may also be preferred that the attenuation member includes approximately 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, or 125 turns per inch of the flat wire, wherein the flat wire is wound such that the width (X) of the flat wire is parallel to the longitudinal axis of the sheath 3012, and the height (Y) of the flat wire is perpendicular to the longitudinal axis of the sheath 3012. Additionally, if it is desired to have a desired open area of ​​between 30% and 70% for the attenuation member using a 0.004 inch wide flat wire, the gap between the windings may be correspondingly between 0.0017 inches and 0.0093 inches. These are examples, which should not limit the scope of the present disclosure, as it may be desirable to have flat wires with dimensions of 0.0002 to 0.010 inches wide and 0.0005 to 0.002 inches high, as well as round wires with diameters between 0.0005 and 0.010 inches. For these ranges of wire sizes, the gap between the wire winding(s) and the number of turns per length (inch) can be adjusted accordingly to produce the desired open area in the attenuation member.

[0502] In forming the sheath 3012 with the attenuation member disposed therein, the sheath 3012 can have an inner diameter between 0.010 and 0.200 inches and an outer diameter of approximately 0.014 inches, such that the wall thickness of the sheath 3012 is between 0.002 and 0.015 inches. The sheath 3012 can be constructed of a polymeric material (e.g., nylon 12). As mentioned above, the distal portion 3040 can also include an inner liner 3096 disposed radially or concentrically within the sheath 3012. The inner sleeve 3096 can be constructed of a polymer (e.g., polyimide) having a thickness between 0.0005 and 0.010 inches, for example, 0.0005 inches, 0.0006 inches, 0.0007 inches, 0.0008 inches, 0.0009 inches, 0.001 inches, 0.0015 inches, 0.002 inches, 0.0025 inches, 0.003 inches, 0.0035 inches, 0.004 inches, 0.0045 inches, 0.005 inches, 0.0055 inches, 0.006 inches, 0.0065 inches, 0.007 inches, 0.0075 inches, 0.008 inches, 0.0085 inches, 0.0090 inches, 0.0095 inches, and 0.010 inches.

[0503] Again, the distal portion 3040 of the sheath assembly 3004 can include an outer band 3072 (also referred to as a marker band) disposed around the distal end of the sheath 3012 and a tapered tip 3076 disposed distal to the outer band 3072. The outer band 3072 can be constructed of a highly radiopaque material, such as a platinum-iridium alloy or a polymer doped with a radiopaque material, such as barium sulfate, bismuth subcarbonate, bismuth trioxide, or tungsten. The tapered tip 3076 can be constructed of the same material as the sheath 3012 or an alternative material, such as nylon elastomer (pebax), polysulfone, HDPE, LDPE, UHMWPE, polypropylene, polyolefin, cabotene, polyurethane, Suralyn, ionomer, Estane, EPTFE, PTFE, or FEP. Thus, the tapered tip 3076 can be integrally formed with the sheath 3012 or formed as a separate component. The outer circumference of the tapered tip 3076 can taper radially inwardly between 1 and 10 degrees (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 degrees) from its proximal end to its distal end.

[0504] It may also be preferred that the inner diameter of the tapered tip 3076 is slightly smaller than the inner diameter of the inner sleeve 3096 of the sheath 3012, particularly if the inner sleeve 3096 is omitted from the distal end 3040 of the sheath assembly 3004. For example, it may be preferred that the tapered tip 3076 seals the interface between the sheath assembly 3004 and the laser catheter assembly 3008, minimizing or reducing the escape of liquid media at the distal end of the assembly 3000. If a 5 French size laser catheter 3080 of the laser catheter assembly 3008 has an outer diameter of approximately 0.056 inches, it may be preferred that the inner diameter of the tapered tip 3076 is approximately 0.057 inches, thereby leaving a radial distance or gap of approximately 0.0005 inches between the laser catheter 3080 and the tapered tip 3076. For purposes of this disclosure, approximately 0.0005 inches means 0.0001 to 0.001 inches. Additionally, if the outer diameter of the 6 French size laser catheter 3080 of the laser catheter assembly 3008 is approximately 0.069 inches, it may be preferred that the inner diameter of the tapered tip 3076 is approximately 0.070 inches, thereby leaving a distance or gap of approximately 0.0005 inches between the laser catheter 3080 and the tapered tip 3076. While the above-described embodiment includes a gap of approximately 0.0005 inches between the laser catheter 3080 and the tapered tip 3076, such a gap may be between 0 and 0.002 inches and still provide an adequate seal.

[0505] The gap between the laser catheter 3080 and the inner sleeve 3096 (of the sheath 3012) will preferably be larger than the gap between the laser catheter 3080 and the tapered tip 3076, thereby allowing the liquid medium to enter such gap between the laser catheter 3080 and the inner sleeve 3096. For example, for a 5 French size laser catheter 3080 of the laser catheter assembly 3008 having an outer diameter of approximately 0.056 inches, it may be preferred that the inner diameter of the inner sleeve 3096 be approximately 0.0615 inches, thereby leaving a radial distance or gap between the laser catheter 3080 and the inner sleeve 3096 of approximately 0.00275 inches, which is a gap that is approximately five times greater than the gap between the laser catheter 3080 and the tapered tip 3076. For a 6 French size laser catheter 3080 of the laser catheter assembly 3008 having an outer diameter of approximately 0.069 inches, it may be preferred that the inner diameter of the inner sleeve 3096 be approximately 0.0745 inches, thereby leaving a distance or gap of approximately 0.00275 inches between the laser catheter 3080 and the inner sleeve 3096, which is approximately five times the gap between the laser catheter 3080 and the tapered tip 3076. Thus, the diameter of the lumen in the inner sleeve 3096 is greater than the diameter of the lumen in the tapered tip 3076. While the above-described embodiment includes a radial gap of approximately 0.00275 inches between the laser catheter 3080 and the inner sleeve 3096, such a radial gap may be between approximately 0.001 and 0.010 inches and still provide a sufficient amount of liquid medium to enter the radial gap and generate the desired pressure wave when exposed to laser energy.

[0506] refer to Fig.32 and Fig.32A , depicting Fig.30 3008 is shown in FIG. An example of a laser catheter assembly 3008 is the Turbo-Elite 3000 manufactured by Spectranetics. TMLaser atherectomy catheter. The laser catheter assembly 3008 can include a laser catheter 3080, a bifurcated tube 3044, a Luer connector 3048, another sheath 3052, and a coupling 3056. The coupling 3056 is coupled to a laser system, for example, a CVX-300 excimer laser system, which is also produced by Spectranetics. The sheath 3052 is coupled to the coupling 3056, and the sheath 3052 encapsulates a fiber optic bundle that passes through the bifurcated tube 3044 and the laser catheter 3080. The coupling 3056 is configured to encapsulate or incorporate the fiber optic bundle. The bifurcated tube 3044 can be coupled to the proximal end of the sheath 3080. In addition, the Luer connector 3048 can also be coupled to the proximal end of the bifurcated tube 3044, thereby providing an entry point for a guidewire to enter and pass through the laser catheter assembly 3008. The distal portion 3060 of the laser catheter assembly 3008 may include a radiopaque outer band 3084 and a transmitter 3088 disposed distally of the radiopaque outer band 3084, wherein the transmitter 3088 is a distal end of an optical fiber or is coupled to the optical fiber.

[0507] refer to Fig.33 , depicts the following flowchart, which illustrates the use of, for example, a laser catheter assembly 3008 (such as Fig.32 As shown) and sheath assembly 3004 (as Fig.31 Kit 3000 (as shown) Fig.30 ), steps of a method 3300 for removing plaque accumulation or occlusive conditions by performing an atherectomy procedure and treating the remaining portion of the vascular occlusion within the intima using a laser catheter assembly 3008 in combination with a sheath assembly 3004 to generate laser-induced pressure waves in the presence of a liquid medium and destroy the portion of the vascular occlusion. The method 3300 can be used to treat coronary arteries and / or peripheral arteries, including but not limited to arteries of the vasculature of the legs, renal arteries, subclavian arteries, etc. Fig.33The method 3300 in includes positioning a vascular occlusion in the vasculature (or blood vessel) of a subject at step 3305. The optional next step 3310 includes positioning a guidewire 3092 at the vascular occlusion and / or inserting a guidewire 3082 through the vascular occlusion or through a passage through the vascular occlusion. Step 3315 includes inserting an atherectomy device over the guidewire 3092 and into the vascular system of the patient. One type of atherectomy device is an ablation catheter, such as the laser catheter assembly 3008 discussed herein, which is capable of ablating at least a portion of the vascular occlusion. Other types of ablation catheters include radiofrequency ablation catheters, microwave ablation catheters, and cryoablation catheters. Other atherectomy devices (e.g., mechanical atherectomy devices) other than ablation catheters may also be used to remove vascular occlusions. Assuming that laser catheter assembly 3008 is used as an atherectomy device, sheath assembly 3004 may also be introduced into the patient's vasculature simultaneously or sequentially with laser catheter assembly 3008 (e.g., before or after laser catheter assembly 3008 is introduced into the patient's vasculature).

[0508] At step 3320, once the laser catheter assembly 3008 and sheath assembly 3004 (particularly the laser catheter 3080 and sheath 3012), respectively, are positioned within the patient's vasculature, the laser catheter 3080 is positioned beyond the distal end of the sheath 3012 and adjacent to the vascular occlusion. A clinician using kit 3000 will be able to determine that the laser catheter assembly 3008 (particularly the emitter 3088) is positioned beyond the distal end 3040 of the sheath assembly 3004 and adjacent to the vascular occlusion because the radiopaque outer band 3084 of the laser catheter 3080 will be shown under fluoroscopy to be distal to the outer band 3072 of the sheath assembly 3004, as shown in FIG. Fig. 30A At this point, step 3325 may be initiated by activating emitter 3088 (e.g., supplying laser energy thereto) and ablating the vascular occlusion (or a portion thereof), as shown. Figure 26G , Fig.26H and / or Fig.26H ', wherein the laser catheter assembly 3008 and the sheath assembly 3004 respectively replace Figure 26G , Fig.26H and / or Fig.26H 'The sheath 1120 and the catheter 1010.

[0509] After the vascular occlusion (or portion thereof) has been removed from the vasculature, step 3330 may then be performed. Step 3330 includes performing a Fig.26HThe sheath assembly 3004 on the laser catheter assembly 3008 (particularly the sheath 3012 on the laser catheter 3080) is positioned within the vascular system of the subject and adjacent to the vascular occlusion in a manner that positions the sheath 1120 and the catheter 1010. Fig.26H and Fig.26H ' or any (one or more) positions therebetween to adjust the axial position of the laser catheter 3080 and the sheath 3012. For clarity, if Fig.26H The catheter 1010 and the sheath 1120, then Fig. 30A and Fig. 30B Corresponding to how the laser catheter assembly 3040 and sheath assembly 3004 (particularly the laser catheter 3080 and sheath 3012) in those figures would be oriented in the vasculature; and if Fig.26H The catheter 1010 and the sheath 1120 are replaced with the laser catheter 3080 and the sheath 3012. Fig. 30B ' corresponds to how the laser catheter 3080 and sheath 3012 in those figures would be oriented within the vasculature. In particular, the axial positions of the laser catheter 3080 and outer sheath 3008 can be axially aligned such that the emitter 3088 is within the attenuation member 3068 of the sheath 3012, and corresponding portions of the sheath 3012 and attenuation member 3068 are adjacent to the vascular occlusion (or the remainder thereof). That is, step 3330 includes positioning the sheath 3012 on the laser catheter 3080 within the vasculature of the subject and adjacent to the vascular occlusion such that the distal end 3060 of the laser catheter assembly 3008 (including its emitter 3088) is within the distal end 3040 of the sheath assembly 3008, such that the emitter 3088 is within the attenuation member 3068 of the sheath assembly 3004, and the outer band 3084 of the laser catheter assembly 3008 is adjacent to the radiopaque outer band 3072 of the sheath assembly 3004, as shown in FIG. Fig. 30B '(and Fig.26H ').

[0510] Once the sheath assembly 3004 and distal portions 3040, 3060 of the laser catheter assembly 3008 are positioned adjacent the vessel occlusion such that the emitter 3088 and the attenuation member 3068 are axially aligned adjacent the vessel occlusion, a liquid medium may be introduced into the distal end 3060 of the laser catheter assembly 3008, such as Fig.33 The liquid medium may be introduced into the kit 3000 via the tube 3032 and / or the stopcock 3036 at the proximal end of the sheath assembly 3004. Fig.33, step 3340 includes: activating an energy source (e.g., a laser) in the presence of a liquid medium to generate a laser-induced pressure wave and disrupt a portion of the vessel occlusion. The distal ends 3040, 3060 of the laser catheter assembly 3008 and the sheath assembly 3004 can be used to traverse the entire vessel occlusion or to disrupt only a portion of the vessel occlusion. That is, the laser catheter assembly 3008 and the sheath assembly 3004 (particularly their respective distal portions 3040, 3060) can be axially moved relative to each other and / or together while emitting a laser-induced pressure wave to disrupt a portion of the vessel occlusion. While activating the emitter 3088, it can be expected to translate the laser catheter assembly 3008 within the sheath assembly 3004 while the sheath assembly 3004 remains fixed as the liquid medium continues to be introduced into the distal end 3010 of the kit 3000. For example, it may be desirable to retract the laser catheter assembly 3008 within the sheath assembly 3004 by moving the laser catheter assembly 3008 axially in the proximal direction at a rate between 0.5 mm / sec and 5 mm / sec, and particularly at a rate less than or equal to 4.5 mm / sec, 4.0 mm / sec, 3.5 mm / sec, 3.0 mm / sec, 2.5 mm / sec, 2.0 mm / sec, 1.5 mm / sec, or 1 mm / sec within the sheath assembly 3004. In addition to moving the laser catheter assembly 3008 in the proximal direction within the sheath assembly 3004, the laser catheter assembly 3008 may also be moved in the distal direction within the sheath assembly 3004 while maintaining the emitter 3088 proximate the distal end 3040 of the sheath assembly 3008. For clarity, during transmitter activation and proximal and distal movement of the sheath assembly 3008 to destroy calcium, the transmitter 3088 is within the distal end 3040 of the sheath assembly 3008 such that the transmitter 3088 is within the attenuation member 3068 of the sheath assembly 3004 and the outer band 3084 of the laser catheter assembly 3008 is proximal to the radiopaque outer band 3072 of the sheath assembly 3004.

[0511] During calcium destruction, it may be desirable to adjust the settings of the laser system coupled to the laser catheter assembly 3008 so that the emitter 3088 produces 30 to 80 mJ / mm 2 The injection rate is between 40 and 70 mJ / mm 2 The injection rate is between 45, 50, 55, 60 mJ / mm 2The repetition rate of the laser is also expected to be between 25 Hz and 80 Hz, including 25 Hz, 30 Hz, 35 Hz, 40 Hz, 45 Hz, 50 Hz, 55 Hz, 60 Hz, 65 Hz, 70 Hz, 75 Hz and 80 Hz. The pulse width of the laser is also expected to be between 125 nanoseconds and 200 nanoseconds, including 125 nanoseconds, 130 nanoseconds, 135 nanoseconds, 140 nanoseconds, 145 nanoseconds, 150 nanoseconds, 155 nanoseconds, 160 nanoseconds, 165 nanoseconds, 170 nanoseconds, 175 nanoseconds, 180 nanoseconds, 185 nanoseconds, 190 nanoseconds, 195 nanoseconds and 200 nanoseconds. As also discussed herein, the wavelength of the laser energy emitted by the emitter can include various wavelengths, including wavelengths between about 150 nanometers and about 400 nanometers, for example, 308 nanometers.

[0512] If the laser catheter assembly 3008 and sheath assembly 3004 are to be used to disrupt the occluded portion of the vessel, the laser catheter assembly 3008 and sheath assembly 3004 are used as described in step 2740. However, if the clinician wishes to cease using the laser catheter assembly 3008 and sheath assembly 3004 to disrupt the occluded portion of the vessel and use the laser catheter assembly 3008 to perform additional ablations, the clinician would repeat step 3320 (and additional subsequent steps), as described in step 2740. Fig.33 As depicted, the distal portion 3060 of the laser catheter assembly 3008 again extends beyond the distal portion 3040 of the sheath assembly 3004, as shown in FIG. Fig. 30A and Fig. 30B (as well as Figure 26G , Fig.26H and / or Fig.26H After satisfactory ablation is achieved and the vascular occlusion is destroyed by repeating steps 3320 to 3340 or 3345, activation of the transmitter and introduction of the liquid medium into the kit 3000 are stopped, and the kit is removed from the patient's vascular system.

[0513] As discussed above, sending pulses of light energy from the transmitter into the liquid medium can generate laser-induced pressure waves and / or vapor bubbles and additional pressure waves generated thereby, which can destroy at least a portion of the vascular occlusion. The catheter can include a guidewire lumen through which the guidewire can pass and penetrate the vascular occlusion. It can also be expected to excite and vibrate the guidewire to increase the ability of the guidewire to pierce and penetrate the vascular occlusion. Therefore, the present disclosure also contemplates that the laser energy emitted by the transmitter is directed into the liquid medium in a direction that causes the liquid medium to propagate the laser-induced pressure wave toward the guidewire lumen and / or the guidewire, so that the laser-induced pressure wave excites and vibrates the guidewire.

[0514] Although Fig.33The method illustrated in 3300 depicts steps 3305 to 3350 of method 3300 as being performed serially, but any or all of the steps within method 3300 may be performed in any order and / or in parallel with any other steps. For example, certain steps can be performed without performing other steps. Upon completion of step 3335 and / or step 3340, the combined laser catheter and sheath can optionally be repositioned within the vasculature and adjacent to another portion thereof. Similarly, upon completion of step 3335 and / or step 3340, the transmitter(s) can optionally be repositioned within the sheath. The sheath can be repositioned within the vasculature and / or the transmitter(s) can be repositioned within the sheath.

[0515] Similar to Figure 30-32 How can the laser catheter assembly 3008 and the sheath assembly 3004 replace Figure 26G , Fig.26H and Fig.26H ' The catheter 1010 and sheath 1120 shown in the figure are used to perform a similar Fig.27A and Fig.27B Method Fig.33 methods to perform atherectomy and then destroy the remaining occluded portion of the vasculature, Figure 30-32 The laser catheter assembly 3008 and the sheath assembly 3004 (particularly the laser catheter 3080 and the sheath 3012) can replace Fig.28C The catheter 1010 and sheath 1120 shown in FIG. 1 are used to perform a procedure similar to Fig.27A and Fig.27B Method Fig.33 method to execute Fig.29 As described above, Fig.29 Illustrated is a method of using kit 3000 to generate laser-induced pressure waves to treat calcium deposits in tissue (e.g., tunica media) and / or tissue layers (e.g., tunica media layer) of a blood vessel by disrupting the calcium deposits to increase compliance of the vasculature and thereby increase blood flow through the vasculature.

[0516] refer to Fig.34A and Fig.34B , depicting an enlarged view of a distal portion of another kit including a distal portion of a laser catheter assembly 3008 and a Figure 30-31 An alternative embodiment of the distal portion sheath assembly 3004 compared to the sheath assembly 3004 in FIG. Figure 30-31The distal portion of the sheath assembly 3004 in (which includes a sheath 3012 (or outer sleeve) having an attenuation member formed therein, an inner liner 3096 radially or concentrically disposed within the sheath 3012, an outer band 3072 disposed around the distal end of the sheath 3012, and a tapered tip 3076 disposed distal to the outer band 3072), Fig.34A and Fig.34B The distal portion of the sheath assembly depicted in can also have a sheath 3412 (or outer sleeve) having an attenuation member (not shown) formed therein, an inner liner (not shown) disposed radially or concentrically within the sheath 3412, an outer band 3472 disposed about the distal end of the sheath 3412, and a tapered tip 3476 disposed distal to the outer band 3472. The tapered tip 3476 can have multiple sections, for example, a proximal section 3480, an intermediate section 3484, and a distal section 3488. The lengths of some or all of the sections can be the same or different. For example, in Fig.34A and Fig.34B In the embodiment, the length of the proximal portion 3480 is longer than the lengths of the middle portion 3484 and the distal portion 3488, but the middle portion 3484 is shorter than the distal portion 3488. In addition, some or all portions may be tapered. For example, in Fig.34A and Fig.34B , the proximal portion 3480 tapers radially inward from its proximal end to its distal end, the intermediate portion 3484 tapers, and the distal portion 3488 does not taper. These portions may taper between 1 and 10 degrees (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 degrees). The inner diameters of the cross sections may be the same or different, but preferably, the inner diameter of the distal portion 3488 of the tapered tip 3476 is the smallest and is similar to Fig.30 and Fig.31 The size of the inner diameter of the tapered tip 3076 in FIG. Fig.34A and Fig.34B In the embodiment, the proximal portion 3480 has the largest inner diameter, the middle portion 3484 has the next largest diameter, and the inner diameter of the distal portion 3488 is equal to or smaller than the inner diameter of the middle portion 3484.

[0517] Depending on the length of the tapered tip 3476, it may be preferred that the distal end of the distal portion 3488 also include a radiopaque marker 3478, similar to the outer band 3472. The inclusion of the radiopaque outer band 3472 at or near the proximal portion 3480 of the tapered tip 3476 and the radiopaque marker at the distal end of the distal portion 3488 allows the clinician to know whether the distal end of the laser catheter assembly 3008 (particularly the outer band 3084 and the emitter 3088) is near the tapered tip 3476, within the tapered tip 3476, or away from the tapered tip 3476. This may be particularly useful when the clinician is alternating between translating the laser catheter outside of the outer sheath and translating the laser catheter inside the outer sheath (e.g., switching between performing an atherectomy procedure and activating the emitter to destroy an occluded or calcium portion within the vasculature).

[0518] As mentioned above, some or all portions of the tapered tip may be the same or different in length. Fig.35 FIG. 3 is an enlarged view of a distal portion of another kit including an alternative embodiment of a laser catheter assembly 3008 and a sheath assembly, wherein the sheath assembly has an outer sheath 3512 and a tapered tip 3576 including a proximal portion 3580, a middle portion 3584, and a distal portion 3588 of approximately equal lengths, thereby Fig.34A and Fig.34B The total length of the tapered tip 3476 in FIG. 3 is increased compared to the total length of the tapered tip 3576 in FIG. Fig.34A and Fig.34B The outer sheath in Fig.35 The outer sheath also includes a radiopaque outer band 3572 at or near the proximal portion 3580 of the tapered tip 3576 and a radiopaque marker 3578 at the distal end of the distal portion 3588 of the tapered tip 3576.

[0519] refer to Fig.36A and Fig.36B , depicts an enlarged view of the distal portion of a kit of an alternative embodiment of the distal portion of the laser catheter assem...

Claims

1. A laser catheter system, comprising: a sheath having a proximal end and a distal end and a lumen therein, the lumen being configured to translatably receive a device having a distal end, wherein the device comprises a laser catheter translatably disposed within the sheath; a handle coupled to the sheath; and A treatment mode selection system coupled to the handle, the treatment mode selection system comprising a user input that can be actuated to configure the device from a first configuration to a second configuration, and vice versa, wherein the distal end of the device is configured to be away from the distal end of the sheath, and in the second configuration, the distal end of the device is configured to be proximate to the distal end of the sheath and within the lumen, thereby forming a cavity between the distal end of the device and the distal end of the sheath, wherein in the first configuration, the system is configured for use in a first type of treatment, and in the second configuration, the system is configured for use in a second type of treatment, and wherein the first type of treatment includes a plaque resection procedure and the second type of treatment includes a procedure in which the system generates laser-induced pressure waves in the presence of a liquid medium to destroy an occluded portion of a vessel.

2. The system according to claim 1, wherein: The user input includes a translatable button that is actuatable to translate the device within the sheath.

3. The system according to claim 1 or 2, wherein: The user input comprises a rotatable member actuatable to rotate the device relative to the sheath.

4. The system according to claim 1 or 2, further comprising: a controller in operative communication with the user input; Wherein the controller is configured to: receive a signal from the user input and configure the system for use in different types of procedures.

5. The system according to claim 4, wherein: The user input is in operative communication with a prime mover via the controller; and Wherein the user input is configured to be actuated to cause the prime mover to translate the device relative to the sheath.

6. The system according to claim 4, wherein: The controller is mechanically coupled to the device.

7. The system according to claim 1 or 2, in, The laser catheter comprises: a proximal end configured to be coupled to a laser generator; remote; at least one emitter configured to be coupled to the laser generator, wherein the handle is coupled to the sheath and is translationally coupled to the laser catheter; wherein the treatment mode selection system is coupled to the handle, the treatment mode selection system comprising a user input that can be actuated to configure the laser catheter system from a first configuration in which the distal end of the laser catheter system is disposed away from the distal end of the sheath to a second configuration, and vice versa, in which the distal end of the laser catheter system is disposed proximate to the distal end of the sheath and within the lumen, thereby creating a cavity between the distal end of the laser catheter and the distal end of the sheath.

8. The system according to claim 7, wherein: The user input portion is actuatable to configure at least one operating parameter of the laser generator.

9. The system according to claim 8, wherein: The system further includes a controller in operative communication with the laser generator; and Wherein, the controller is configured to be actuated by the user input to send a signal to the laser generator to configure one or more operating parameters of the laser generator to appropriate values ​​for a particular type of procedure.

10. The system according to claim 9, wherein: the controller being in operative communication with the laser generator, the laser generator being coupled to one or more sensors, the one or more sensors being coupled to the laser catheter; and Wherein, the one or more sensors are configured to identify the operating parameters of the laser generator.

11. The system according to claim 9 or 10, wherein: The lumen is configured to allow a liquid medium to be introduced into the cavity between the distal end of the laser catheter and the distal end of the sheath so that when the laser generator is activated, the liquid medium absorbs light and generates laser-induced pressure waves and / or vapor bubbles and pressure waves generated thereby.

12. The system according to claim 11, wherein: The controller is in operative communication with one or more valves; and Wherein the controller is configured to be actuated by the user input to actuate the valve to deliver one or more liquid media to the lumen of the sheath.

13. The system according to claim 12, wherein: The user input comprises a further translatable button, the further translatable button being actuatable to: configuring one or more operating parameters of the laser generator to appropriate values ​​for a particular type of procedure; and / or The valve is actuated to deliver one or more liquid media to the lumen of the sheath.

Citation Information

Patent Citations

  • Methods and systems for delivering substances into luminal walls

    US20060259005A1

  • Liquid light guide catheter having biocompatible liquid light guide medium

    US20090112198A1

  • Liquid light-guide catheter with optically diverging tip

    US20090254074A1

  • Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens

    US20100068170A1

  • Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens

    US20140221976A1